var title_f34_29_35280="Regional odontodysplagia";
var content_f34_29_35280=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Panoramic radiograph: Regional odontodysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 248px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD4AZ0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3J9V8hyTIAOgA7Vn33iDavySBuPSuUurti+WbgnpWVf6hiNtrfLjAwelUSdHP4gBOJHB9qpPq5mTCuM+mcVws+oYLc5GOMnrVVb58qwbvzjoKBHem7LNlm5xnFNkvBsI3D6ntXJw6grkB3wcEjPGavJOCq7WBGOnrQBcvbogEcdOcjrVSW8aW18slRhwOnamufNToef1pYYV8lnI/jzg0AcR4inYtJgfKOBjrXHXGAMsw9x9a9J8RaM/lSSoyhHHU9q4fUNNkVRjAIB7Y/LNJjMZ5PkGOg7Y/nSCYq5AII5zleaWSN49m8gHoAe5qInIZtxBBxsOOR6/hUgKW3AvGRkN17fWkUuuw7lGMuCcdfagqxgDDaQBtBB5OajBIIC4PBBIwaAHF2dCWBYk5GPpTBvD8Djr7GgPlCCTjPA7Uk7EL3HzDORzQA8SFRnJI9cdgOtIZADk7sZ7cZPc+1RsV2KSSSvbqCKElKpJsZwSMOOxHpQBMGySCc9hk8fWpMqPTtkfT0qHcxwxjJ+UZyMcf5NIGUKz7mA9DwaBlqOXzmwHyXGeo6Yq1HlgN5zjjjkVnRsMgbiCxwAKs52KccqODQIklUcqcknnAXn3pY2I3MGAGcE5wRkVT8wk4Z2GeOBTRJ1b5vLU+nPvQBc8wlQJGG3gcdvSl3Es5cFUUY67R9KqO53btp25zgDFNnn+ZUyVGclgentQMfM5IKqM4GdpPP41PAdnBPHJ2/wBDVSFsjeSDgcDp+NSCRVAyw5HOOcUCLDNn5ScqTlu1VnlZ4BjJ3Nn05/rSvJgOQNwxnk9Py61EuSoHy5bnvQMN7eeyuzZzgAN2psg8veoIwTnOf501spKVPzMB0PSkdwSCE3MzfWkBKJdyBVLcDJxwCajkmJBfedoByPcCmgmUMFO3jvxUM7ny352/KcD0oA6nxd4V1HwqmlnU5bZ11KzF5CYWJ2occNkDnkVz0jNjBGOnB6kV6r8el32Hw7kUEZ0RcEHkfcryvaCWaMseBux/XNMB7SHIZgfXn+tRxzHaSQ2MDPYetNZAqK3RsdGHv0zTI3ByuQAMnrjn6UgLaXLIqAE44IUHvSebuKYKsF7de/rUayIu3ehZQxO096aJQoO6PGTnK84H0oAvIxVcbtxDcp6V0OibQss7hcJkKF4zn+tYdiEIYDjcuMnuf6VvWsYjEMZOA3559apCFgt2upXYsQRyD/TPpSzxsgO5u/3c5/M1vWtsscJAPAPXFZ16jRozZBGeh6mnYCKzSVAVUkBugBzn2ras5ZcYfg8CucjnIbK53dsVq2F5wgkQg9ge9AHX6bI3IZmUtjnGa6/RNqOjSMQF4PavPoNSit+SSGHUVo2mvuHUIBhhj8KYj2Y623lJGjFUAFV31koSd2QOME1wEWt5C+x6g1KNQ3MxZ8A80Bc7iDVHYht31zWgmqbRhmIHUcVxdnc5hHPPbvUsl0MjaX/Ch26hc47ULkox5G33PFYmp3uVJLBcHg9hU19PvOc8jPB7fhXLazdDyXUMF3fkaQxsmplg5ZgCOhI6nP6U9brfH8pwO49Pwrm/N3J6nPPqaninYZJ9ORikB0Sz5IxnJ4znFX7O5cFFXjIwR2zWDakllwrHjJ4zg/Wtmwi2OSxJx6dqYHURFvLUEhjjnFaVgv8AozAgH5uAK57T2bztjtknJAz0rqdGTM0cZPDHOMd6YFPUrCY2gaRcq3QY6VxOq25YsgGGzjJr6DbSYtRskSMDKr+frXnviLwwy3DkpgjsB+VAHiPiKxe1iVmK8knI7+9Ye6EWkaIpW6VyWYnjHpj0r07xdoN3FYGRUJAzwB14rzNwwLKV4A6envUsCvvKFwp6cjBz25qMElSN2XAOcD9amKLknaxY4HJ4/CgqpUNjaAMDvSAgBcj+HJ5457dTTirg5QEuCAPc1IibxlfujOABgCpCioV+8QO5OOCKAK8iMIEwJAzNkkHKkd/xzTwhUzCTHmgBhjncPw71YeABFwcg8DHrQ0BEme/fn8MUAUhIREWDgNtI4Awef881I4+QkYxkHBqytoFRGZFBPIU9No96f9iO0Yxkr8v+BoAropVmZT8oPHNLcyEIeuM84Gfwrd0zQzOygAKvXkdqs6poAt5sRldpGeOtOwHIs7/L8zHHp60Rb/unjjqeMmtSSyVWC57+p5qMWyRCQvycnJxmkBR+ZGBBHB5xTC7mXLAkLkgZyRx/KtB7cfZw4B2r14x9KoiFQw5YnbuB9PrQAIz+TuKL93PzduaXLgg4O3BIwOBUuQFG4k5wGwOevWlKLtAVTnkmgZA+8of4sjJHb6UwPJsUdycDJ61ZQ/KwYHaO2Ov/ANanLFGyEqycD1xj/E0CKcgOQpKvkZIJz+AqEl+GIHoMHjgVYeMOcrnOcehPvSEEHZgq5YA7eQKBkSEN8pxkDr05z6UNkpLJ0wpAHfp1pRuU8gKRxuPrmvUP2eLLRdU8eNpniDTbW/gurV/JW5QMEkUg8D1K7vyoAt/HFC3hv4ZTbdv/ABJQM56fLFXlDMSSxzv9ema+6/Fnhvwwnh9rnVNF0+4ttItH8hZoQywxqudqjsPlHHtXwwxMgViiZySFBwF3c/pQAssx8sBDtZMcZHJ9SPWoG3fN5q/MEJGByT0pZRlVLjLDAOenNOt0bkfMvAzxjigQ7J5b5UP3SDyfrjtTTvDhFYcdWTjP+fSriQFkViDkjnpileBmMYGANvYYyR65oAtaQSt7FxkH5T+VdMsmyTYOCFxyevtWLokDxl7poyVjHVu5x3rTVwbgMy57YxxTQGxDeAQBQoAPWm3QWRTjA3d81ShcOrbOFBzkDqKsuyqHfocZ6ZI9MUxGW8ciMWIzg9Bx+NQvdCM5Gd3oTn/9VP1G5MoVQfl6kE4IrMcFVxw2elAzTtLrk7uCR1Y9f84rbsryLeUBXf65ri1eRXbLFtxPGO9X7SdkaPLYJOB7UAdyt4OgOF3fjWhY3RZ1yeB71ykEzuo3NxnIA9TW5pkgCpzg+gNMR3VjcjYMcg/5xUxm6ckHrwawra5yFyR9MVO8wB65HalJXVgOHurg+ZgHGenpmub1eXzGI64Y9u9T3UplUbSB6+lY9yPnbLMe454+hpDEKvksoyTgcCr9rGThQDluMfSs5QSSQ4PGevI9q1tOjYSoBgg880AbFoiKABk4wPatW1QgdzxyR3qrbqMgY4+tadtGzYVSCO5zn8qYE9spLjA5rodPcwPGSCcjP0qlYWQHOw56etdHbWQAVmBwR6UxHS+HdXaQhM8Djp1rsZNHh1CJWmyG7kdxXn+k20lvMrxx5APevSNOv0aHaSu8dBmgaOY8Y+G4W05UtYd7LlmzzkV4vrXgKC7lLxQ+W7c4Xj86+n1UOmXUcjkVja5o9vLbPLGoSRRxgUgsfIGseD7iymaNOSM5JHrXN3OnXFuG3RvlCSWIP6Gvo3WtMljkbK5xwQRXn2r3Mds8iXEaPtPQDOPb60WEeUFGjHzhgGz1GMDtTWkHzZ9Rzjt0rptbu7W5/wBVbFBjk45rnpII5HIDGPd19BSGNidCfnzjoMVOHJchVUNyMHtxUw0tzGrKQ3AIwRxjtURjlgfPIIbOTjg0AKGZdq5PJzyM81at9ySbWUkccen+NMSZWkLuVL54PH+c043iqoPcHOD2HtQB1MUgQRtHHtOBjuKqahcyTKc4DYyCD/KqUOq7FyinHBOG5qheajvLbgCxPAHY+tO4BdzmWePzNibUC/IoHA/r6mqu7dG25js5+92qPzjJcLt5HrwP17VLC6sxVgAFOT9f60gHyB1smXDIw5ZT79MisZXILAc4HQ/4V7pH4m8MfEPTodM8beTpGsKgjttYt0CoT0CyDoB7Hj0IrzT4h+BNX8F3kK6lBvsZRmC/gy8Evfg/w+uDzzxmkM50OMZPVcEDsfamtJkZUbcHnnHFRxs4Ug4zjntnFMeYvy/zE5HTmgB7yH94VIxjOfSlDbFDlMgnJyelQlAq7ieCeCRjOD29aTO5Cu59vK4zyBQAqsVlyRxk9eAPr9KViS4x8oOM8YBqNJcMjIcZBw2On4VYBUKC5c7SMKCAPrQBEMuRuP8As8jPWuh8DX76H4w0PVIyQlpdxu5AxuTO1h/3yxrBDKCVVlPr6U8uzowZvlK/McgflQB9lftB6mLD4W6nGjfvL4x2seD13MM/+Og18fMhVSNxwfftXqHxY8ZDxF8OvAdsswacW7zXaBgTvj/dcgHIOdx+leZ28LTHCn/ZGaYA0SuoVV3EDIH9a0tM8Pz3cyrEpUsBk46GtvRPC0lw0TFgoZegPX/69emaBp9tp1s5KZ2/e3c5p2Juc5YeAj5KqxLYGSQOpplx4JRJCGICDnj29a9ItxHPH5kO5FOPlHpWffNImRIQY3zgjvTsBw0/h4QwxpbAhO+T+tYt7pMtsG2KCD6D9a9OhhRokC84X+KqV3bRnsACO3eiwHnEMDhgCGPrkUlwrBGB4OB1rvG0iO5PCgAdKz7zw+VQhRgDsB2oA4GePdGdwPJ6dcVQlQjC4/Lr+Vdde6UUjXCcYJx2IrnbyHEx8xQMDA4Oc9qQzMZWaVSnXB5HpUkIIkGSQuc+p/GmSR4OPvgDoCcZ+tOQbpUK8Y7Hk59OKQG2tyRH6EAfN2+tWtLu/mw5yyn5ec5rGjEh3AHaAM49KsW2FKbTn36YNMDuIZ9wRugwKsyXLDALds9a5a3v9mADgZ5z0FWLjUFBGChB/vGmIwWJAAOAM5yeKq3qYz67cdO/0piTtvXOMDjOM0syqUzzjJPAz27VIyCNC+4hSACPoK07FZBKCMle+B61mQrndtUh8duCa39D06WaaMqCFxkZ5oQGvZBi65UHpjA68V1OkWjMB8h9ywpmkaGV++uAfSuy0zThsCAEBaoBmmaeRt6cnknit3yAu3gYAOMioWVbdCcYz/Oq8t0xZAA3pQI1rG3mvLxbe06tyWzwB7129hpUFqqEjzJV53N6+wrn/AQDfaZf4iQoz2FdhSZSQU2TkbduQetOopDOP8ZWcVvYFkRS7cH3rwrxBoqzTliMKD8wNeyeM9S829aJThIhjr3rz/ULOW5hdy2NwJxVEnjevW0cMjvGwbbkY7iuc3BZuVZlz0zya9Q1vwtK0DSZ5HIxziuLm0K5V8kpjGOOePxqWBjCZlRvKLjDdznA9PrUkN4THiYF0HUdKsT6e8ChQrHJPJHU1Qmh2gsVweQTt6fSgCxcSWrHZCTGT/ePWqsyNtkCtuUjb8p6GoyiebhFxheec/jU5jKRZXls444yaQEHOADg9vl/LFG5l3Eg789cH+VWlmUOpaMMc8A+3rV+aC2uo99u534BdMYyepxQBkKNr/NhX65Hb0pqliTukBPORjqfarr2+wDCgqAce9QLG3mru6nnPf8AGgBZCViRiQwJ6f412fgf4m6p4fibSNWtotb8MyEibTbpQxjQ9fLJ4HrtPH061yF1GNoOdufbJ+tZ8cG92KkbsdM4Bx6mgZ6rrPw10nxJpc2u/Cu6OoWQObjR5src23soPJA9D+BNeXtbMhlR98cqMVKuuGQjqGB5BrZ8OaxqOgXi6ho95La3cfRkOMD0YHhl9jXvPgW00T4y7dT8SeH2t9V02SMXF5bfJBfd9jdz2JHbjnBxQB8ytEVGQ2cDBBHTPWo0VxCduQSSQSeSex9q+p/j58KV1m1k8QeGrVBqUMf+k2sa4+0oB95R/fUDgdxx1xXy5JGhZNh+RsfMOx7ZzQBAxUMp53DqN3BpZSQxdiOQTxxj3p58suBn5RxnGKUx8EljwRjtnt+HpQBHGQXU5yVHJxwP8TTg+5yxPQ8cdfapLaMb1yrc8DHWpFjj3ER84xuBAP1/nQAwSYVlbjHcHpk5+gq5HORgxNtIJ98Gq6LkrwwGMEjvTWUh22rkc4J7/WgR6J4a8T/Z7crdKrsPmVunFdXb62+oKibcKy7uDwBXl2hThLuONsFXAGT/AAmu+0vS5o5oXEiiH+LnggelUhHbaL5iLud28sjGPX8az9b1KVfkZUC5yOeaoa/4os9PtVghc7VHz47+1cFqGvS3lyCrbV7Ac4pgek2OqxCLfK2Aozg1DPqsc+DGRsHQ964K2ui6bASe/X0rZsJlMZ6ELjHqe2aLgddZXgduc49a31jDxDIJIXniuS08jcME89a7HTvntwvbHXNAGXe6aroCq89K5XXfD3m5McZB6n3NeiSxgAnB564GagmgDx7gM9sUAeEajo08LFGXCg4GO341TS1cS4kXLE444wa9uv8AR4Z1PyDP86wH0BASQmOc+lKwHBxWLKoYx5AGPXJqrKnleYIgQvY16HdaJiHKqC3TOOa5PULFoEKbVI5yB0//AF0AZtsX2MMhjwCG7CllSQkDfyPUkcfhTrdduQwGcY64PNLcjEnzEjj+E0DMaFmMyYUdeM8Z960ktmcpwNo5PHBqvZReddDhlzx7+9ejaTpStCjhFK454pIDndH8OtLh3JCseB3xXoGk6NHbqpJBBXIyM1safZQqkeEXHUL7VsQ2qKwGFUfSmBVtrMBUO0jJ7VtWNvsyzYxgECpIoIwRkDPUD1q86KIGK44GKYjmr+bB2ngDoe1ZhkwR68jJ6cVf1EhmK9QM4Pp7Vk3PKkZBbrQB1PhDWoLGZkuXKoWzk816NZ3kF5Hvt5A6+orwJpAh5Axx3rv/AANr0UNqYpmRSPU0MaPRqgv7lLSzlnkOFRSfrVeDV7KYMUnTC9STXFeLdej1XFrZyZtVb5mH8Tf4UkO5yFzcvf307scNK5PXp7VOYzKVji4/HtTre0MDMxzgnr3rT0uDcxlKkgnp60yTnPENsLe2aJsn5cjHeuGuolAkZiQxGF6dfeu48XSlpyi9+ABxXOS6eXRwMbyQuSO3egDk3gDIytg8kg45rAvtPZncjnncVJ6+9eiS2EaW5LAHAKqfWuWurIvcSCME4I49aQzihGySA/dY8+hOfUVoy2+y5CyqMEZJPQ+//wCqrklqq6nGjoARzg9fwrW1KzH22D5cKwAz2pAcPIqxDOWG5uc8ke4HalhYgoSMHngHvVzVrTyLqRirhVOD2zVYAnacYJJPXAA9v60gLPDAMH5JGfXFTC3BckA4Y9M8A01EYL8zgYOD7nNWFkCuSqKwxv4JyaYENzb5YAEgdskDNULuEoNqt8gB3ADocdK6Fik8gdVbk44BwBWTqqLHJNgc7sD2oAowlypVgMnkknAFdz4B+KeveCrVbWwNtdae0hc2s6dGJySrDkE++a4WB32H5QX2k4Ixx65/Cm3Ln7OVOQCdx7YJ9KQz6m8J/tAeGNV8uLW459FuCOWl/eQ5z/fXp+IFcL8cvh9Y38EvjfwRNDd2Mp8zUIbVhIgPeZcdP9ofj614UAS6hgRxtAU461f0XUdR0W4S40q8nsLhSQWt5CmfUMOjDtgg0wM9V+b5XTnkEDsacfv4MnAwOmeR0pk5Ml0wB4LbjhdvJ/pT9p3sC4IJzwOTSAWKM5425A4IODnP1qaOJvtAdgNudpGMZ7dKRLdmG1RGy5O0881q6Zab7q3imZeueOlAiNrXY4AwV43Z4/yKgvbd0mXa2VPOF47+tdPrQhjQfZBgAFSfWqllGt/p84dRvj5BDcYpgYUU7RTRkHpyVHJ/E+tb0fiOSK3ERyQVGcnk+1YN3G8crA5bPc981WTG0ZYYB4ycdPagC3cXrXFwGcsQTliDnP8Anii3lCYYsd2f4SR9TVMbmVWAXPcHjFTRsUZFIK8cg80AdX4VXSLu/EWu6lcadAwws0VsJhnvuGQQPpmvcvDfwo0DUrKO6sPE0t/ARgSW6xgfQ4zg181wSB5GIKqc9D2HpXUeHdWu9JnS40y4ls7jk+ZE5XcPcd6EB9MWnwt0S3jVTcX7le/mgZ/Jaoa/ocOjXtvBpsN00RjLySPucZzgDPQd6wPB3xbvGKwa7brdIq8zwgJJ9SvQ/hitqfxpd3fiOZtKunGnFEEaPGACcfNwRnqf0pg7FGUbSingnp7VG/DYUHpXRyeJJZji60+zuB/tLgn+dJ9t0K4VftOkywOO8DcD9R/KmI5xEDYAB5JFQy2SuRx0P0rqFsPD9wALbUp7Zh0WZc4/T+tTp4caZf8AQ9QtLhfrg/pmi4WOIvIQYyAME4wM1xevWRZCFBOfTvXr2reGtQSNdlsz4HPlkN/9euE17S7iFStxbyxP0xIpGaAPOjY8nYSzZ6jiqt7YMzKGLjH511KacRkOpyTx6Ustku4bl3ADAPrQBh6dYRib7hz2Hpz1r0jQ7YLp6hVxnpmsbSrJSPu4z69PwrtLOER2ifdC9c46cUAFsMhOF49BWjBkqAPu9MH0qkoHAGfT0rStVdjhSMkZoAtwqQCzdc8egqxdBv7PkKkAnnilRN2F/gCZ5HWpH2T2TxrtA2njHWgDibyUCUkAdTis2WRkXK4yefar9yn7xgSDzWbcY28nODjINAGZcXQRyf4gOcjoaqJfTRSl0Zk9xxTL9Cpfa4B61nTXAIJBJGOufzoA1JtdvvKdFmYI3XHpXTeBUe+jxIG2oSST7VwmlW8l/dLBGQpf+I9FHvXsfhqOw0TTNjyeY+DkjqaALGoJFO0aJt3sccDpWnaWX2OyPy4HXj6VyK6lJDePKvIY8A11V3eND4eDykM8iHG3jk0AeeX8JvNX45UZzgdeanNnvdgVHtntWnpGmXE8El3INqtzgVLFbsA+QQB2xzQBx2vW7oI1UY69O9ZX9ngFsxgHGPrXXX8HnTurAZXBBz1rNu4yADt55/CgDzRrPy9dUzM2BwOOAa6bVNPZmgcRhe4I/wA8VWhsJLrxLDGFJiRt7YHT8a7yaxjeJQDzj8P/ANdIDxTxfB9nv1aRfkdMgYHNYVun7z1A5B65r2Pxr4cF9pbNFjzoRuXA5NedaPpn2q4eNBsxkcjGCKVhmWVY4UMQSMg45/WgoTCDklS2SDxwK6hdE2MGIJG0jnj8az9Stlt9PcOoJzkDt9aAM2xuGDhyenbOao6kxMsw6t1A9T6UyNlR2wc46c4A9qfPGJMsR0GQTnkUAZysQgBD+Yv3cUSgttVgfvdCM4NS3ETKpOQDnOO9OaMCL5cnIwPf196QymV8tGyMLggkN1HpUiKu1FQ7gnU9ODUjQlVG5DgDqG5OaBGgTaxPcgjpQIhUoZicEoPT0pSoVwd/3c89jTg6RMQFz93PPP5f0qRirtIMDaCxJA5/H2oAI2IIyxI6Adq2fCkYbX4A3C/3T3rLaIbYyzZwPw9vpVnw+/kalE5P0OM55poDpvE0UYu5EDNsIwTn+lVdHWO0dG4ZWyCeg9qua5PYEbmQyyHuO2aw73UjIAiIiKuMAdvrTESeIHt1lkCMTkYC9cZHrWEij5iwPygYwf8AOanupUJbI3AjndyPbiq4UOrAnbgcAHr+NIY0DaAWYqVbp6VKrJ8yvz0w2Oh7UjbedqkqvVWOKYi5fIU7s9M5pAWbZsk7iNy5PC962LR224BBz1FZQbC/MQCMnIHX2rQtm3PkKq9qaA7HRV6OSenTGOe34V33hsL55ZTwB+VeeaKzrEpHPbOfvGvQ/DgYQhn6NjB71QjpYpCz4xkfTmrZthgHIwOev9azIiVxt6rnknrV+MNIEXHX07UAQbME4b5hnoM0sfysM/ePAqzcafLHGWiyTjNVlJkKg/Ky9wOtMDVa7uoLMeTdTR7eOGNYWsXt3qBh+33DT+VkJwFwD16degrSkRvs5JPGecc1nSQgtk4HWkBzksAGc8nOcmqs6YxkbifQkVv3UKgEdc56VlyhRtUqDtGOazqxcoNIaL2m2yqpAIPODmtp5AsAQHkAjnp+FVUjBCBVOevSrUUHEg5IznntWgiK3R2kRR16ewrdtFWMIx+ZyMEAVTt4GyEjQl244PT2rqdN0fyrZGblj1xQBXiIaNgMBiM5x0qtCpV33bSpB/GtbUICjoFByBxjjmsiXdEfJI5J7UDOP1NfLuJUfjDduK52+nWOEdOCR7Zrq/EWPMaUcjox9MVw2osGVgM46/WgRn3l0h3Lnn3HTiuf1K5ET5HOexHBq1fSHcxJGe3PasG+Cu6uCSRk45wP8KQzofDWoJEZ5twDqfu468VC/iC8S5MvnO24nIycVgWN+lt5iMCzHpz/ACqtPqCyXGdpAJ7ikB3OneI7iRgS24bgDz2r6C8MWcOp6XavON6KoYj1NfLnh9lkmXA79M/nX1L8ObhZdIaMffjIHXqMUwRqz6aqxlIlAjHQAYAFZuo6WqWpKjBIwcV1CsGzUN8EFpIzkKFUnNFx2PIb6PbqEscWDtOM4qpJauBlhnPr2rsrHQ3aCW9YEmRtwGOg7Zpkum/L8yc/SmScJY2iwXMs7gA/dPHatKMgnnGAcgCm+JV/sywnnI+4Ceep965rS/ElvdqGWQAjrzgikB014R5RDbAME89OlefaPbxjUbp1X5CSSB0Jrb1zxBGkPkwsNzLzTfDtrus3kbksd3/1qYGfcgmVEHRhjPqK5zXIGMFwq/MR2rrruApeQ/xemP5VnaksfmuCuARyR3oA8qmgYy42qVzg7u1akNs6xAuDgjuPu0uphFvZUUHkkYJrVjlzp+6JACOAAMjj+dSMwby28uIKeTg4xyR9KpFXEY5Gc8A8GtrUi3lmRgQcZBxjLVmxKJIH+YEA4IHYGgCsytuZmOCDk47HvVLpGOFxjnn9K1JbUgZwACDkg81myIYtoTC7j97aelIZA52sclgdwG3vxipoigdmkB2nPT61ApJuMLluR97jPSnb/mcEcBjjPQc/yoAm84B8IAMHrjPNIJgOVIVl4z0qFXJk7bSM5bgHvTfMLHf5eQc9BQBprdvLtAJP8OKhkIbjksBkdqrq/wAnJPbv0/wp0kw+Ty2Hykfw9PT60CJnkCc4J3YBGOPWoRLkkAqAe2c4FKzEx4PyHIIU84PP51YstPllRgACoHT/AD2oGQI53EYEinGPlzx7e9SgY6k7unSus03weL3SZLmGUfayDiM9GrnDH5Ujq6sjISrr1OR1+lOwiNcj1xnjPYelW7UbCC555AqBXVlUgckcZHQVYsyFK9gOvy7s++KAOx0OVJFChz8oAwRjNekadJ+4jCjIx1Fef+D9Fu723MsSYiY5Hqa9U0XwzqsMCSCHjb8vaqES2R87CsOAeW9K6dWitrVGcAP3Hqap6ZbxpG63KbJk42n+Kop5GuCRgqo5BI6c0AXY5y8jyM4VAOmOtZt48ZuUlXaM9QKq3M4gDKWzkdzjFUYrxWk29h7ZoA253CxfLjGM8Gs5nB+Y4zjj6Ussozx8y+npVR5cEc8Y7igCK6l2r8wyc1jXEuZMblGOxOa0LiTJJzx6E1lXBHy8gelAHYWeCnIKnHr1q63C7VJAzzWZBKFHBPANOnvFRRJuAC9aBmvp8nl3u5iVJBxXcaXcq1sp65Gc9M15QNRQTbgxI4wc9q6nR9WTCqZBtbsaAudrMySA4UGuX1WJzcblH3euR/L1rft5fMI8o8VDqEuY3VEDOTtBxmgDhNdgK2mXGCx3A96821p1gcgKMHPU17Je+F768UM0ijjoefwrzbxd4ZvLW3lkIYlOqkdaAPONQuVAJ5Bz0BrHmkLD5lB9T3+gq7ej5WUrhhySetZhcBcuQCOg/wDr1IEEi/McYzgk5PWqzRocDODnjPQ/jWtawPfTxW8KF55DtUDvnnivUNP+Ds02meZNcEXjAEKo4+lFgPOvCRIv4w3Kg4bJx9K9y8NeI4NMdIreRWlmIQLuz+NcJefDPUdHt/tMvmh0ONyr3+tcbpt5LpWtJNKzBkfPzHqKaA+u7S8kuIlaBlPYjIyDWZ4jj1O5gWPOIWbGFGc/WvMdA8XQK8c/2ry4+MgHjFe16Rqljq1ss2n3Mc8eBnaeR9RQxktun2bT0V8fInP4CsAaxaOGS4ZUYfkaPH3ibT/D2jyC8nRbidSkUe75jnvj0FfOPivx68zPDp7ll+6HU/54oQM7z4tavaPYS2VpMhkkG0DdmvEZY7q1Y+WzBscEcGq0N89xqKySOzNuzuY5x9a6LzEnnJYgL/eA4oEYQupmuN0ztnOODnJr1DRLiRdLtgO4ySRivN0sWm1xYlXCs3TsPc167HaiOzSNVAKAChAY17f5v4wGPBHU1Fqtu8zeaCSxHQdc9qwtZjc+JYo0/iwcV28sISJFIAYDPTBNAjx3WYpYdTdH3A5xnPr6Vt+HYS8BR0b5cjnjFaHjKwWWFZkGJU5z6DNZ2i3S2tq6s53d+5OaQzUvLKOa0eNz05+lcVH/AKLNIoPKnuMYro7jVgFAXHIzjnNcjqdwXuWlVVz1yBjv+tDA1XnRlwq43cYB6/Wuf1AgSjLYI9s/hUizYCMeFB9Ov1qpcMJXG0ncDx6d6TGV5CGxnH+8OMAe39aUlSGcrwRk5pNrk5GR8uQWPJ7YxShkKlWKgEe55NICSCTDg4JcHJ56cYxUrKvmkRsECgcA9emefXvTGc+aM4DleSRxxTG3oSeZByd2c0wJmB3thtzcMMHIH+Naml6JNqbSeSCDnLEnI/8A11lmVSdyk7jwf6fyr0jwJewNo8kUQjFypyyt1YeuaFqBzN94YutPKFx5qN1dFOV9qgZPJHlLuG35cHge9dXq8d/Jct94QkYODxVGx0KSVA8hABPLEYp2EXvC9xcmSLys5QjYSe3esbxrZm01y5dRiKc7xjnJ711+iG0tv3SMpdcgn/Gs7x3YebZLdjdhG+bHvx1pgcRp1nJeyrFGFZ+AvOD9K9c8JfCK+v4o57qUInBKLzuFch8NLSK71sqxGUwwDdf/AK9fWOjSxwafCqFTgZ49KLAUvDPg+z0m2iUoGKdBjGK6nAAxgY9KrC8RmCr360kt2o7jGKLDOf8AFkEAKOCsbk4J9a5TUrjyIlQDLYzz1q540vjNaGPOMMDleoriNU1KRFKM8bYUYLH5ulMki1LUiztzjocDnNQ2FyQzyM3TkZNc3qF/FHMXlkDN6Drmo4NYZgoHyAjAGaAO7gvPMY/3RyTUV1eHHynJBrHs5HaEFio75AqO9uikTKpAGKAI73UXTzMOMjIyT1rLm1oKQPNXjjmuc1u+la4KDKjkbh+lYb3POTKDn+9kUhnucd8qqFDZYnvVW6vPMikU8/zrLinzzu46ZxmnSyjZwRu5XPbFMQ22ui64JyUFbWl6k5UKX5zjpXKrMyOSCMHgrnr71p2UsUu11f5+cruxQB6/4Y1Au4UnlQM89QK39JuILzUJjFg+WM8epryew1Boowpn2564Oa7PwTd7LqYDPzbc5PUUDPQAMZx3qjqml22pQtHcL1/iHWrqsGHFLUlHk3iL4Q2V08txbTuHbJ29AK8K8XeHp9Fu/KYZ5wpxX2dXjXx0sLNNOaVUVZWI5980xM8x+EFkk3iXz5xuW3TdntuPpX0xochwu4/gewrwr4bWRt7Pz2GJJGzn1Ar0Sw18W8zxggkHg+tMR6WwDAhgCDwQe9eXeN/hDY69em7065+wOVIaMJlSfUeld5Y6tHJBGWIORzjtVpNRt2/ix9aVh3PmbxT8Nrzw3a7pTIQR95SCrEdga47S/Fms6Ddq+nXkkEqHbx0+hz1FfVnjUWmo6WIJHVlzvH1rxRPg/d6vdTXGnToYgSSZTjn+7096BHlviTXNQ1m+lvNRupbi5dsl3OOPb0HYAViuxeQEnle9d94y+H2paBk3Vq0afwkfMDjuDXBPAVDA8k9c0gH2I2ygLnch9ePeulsLiOMEFxtI+6ea5AHypGLZ2A7sdTipXvJEMmC2Bx7EfSgDtI9Ut4r6KRQu5TjJJzXb2uqRTRBywUEdzivD/PdmLLJwrY5Oa2bPWJIl2CQ7SRz7AU7gd5fvbSa/DJv5Q8c7q2NTvFSEhX+bGBkV5DJqUkl20yuCy8kZ6jNaF54ikkG1ZDtwBux1ouFjd8QakDDtVs7hhvSuV85i0qlug5PUY9ahmvi7YLcDnA7fjVJ7rK/M6kgnIHHPrSuBdaSQcknsBk8+1Z96wYqN2AxAJz/M1G8n7sEybtxwRjn61G7kqclk74PGD0z+VIYkxKfKx4BIyD0+lMQh0Db2wDjIHJPPBpkv3Qz4UjB9yKCqLtRSQcZyO/oRSAkDfaGJLEH+FQDkDqelKnzOzhwDgfw9fwppeM5ZQQ6jHoR/9ep4pUSZT8xkORnOeo64oAhCsc/wuDwoOauW1tJPcqqk84HHarNvaAyho2bb1BPBGa0xdwWClEQs54DMBTAzbjThaEyTlVJUYU8moLS9e2vTNa5UjBwDxj0NPuBPqLOwUyE9cD3py6RfST+XDBNuYfKqoSG/GmI7Cw1VdQtTDJL945GD0qvMb60LK0r+Se5PX2rm4o5NLnXzlML8Lt9q6pZ11fQ5WVQWVc8dQR2oAi05pVkyinOckDmuwgkh1axktbgFHK4KnjI9q5CW4Gl6ZbvGBl8cY6nrUuleJre6xBqCheo8zv8A/WpgNtoJ/CuuxTTKzQ78eYvcZzj619A+H9WW4tE2SAxOuQRyea8tCpNbpDfkS2rjCSkZIz/e/wAaueFLqXRZ206Vt0O7dC7HqPT8KEI9d/th7aQKwJAzjHBJrO1DXZZcEbl78Gsq/ufMQShs8c56VRQPcws6lVCjgHrmqAvanMLy0cliHK4PtXlfiF3E5/fBcZU7vau1k1L7Mdkp7cntXE+KxDK5kixtk5BB6GkBy5ZmmwHPPXH+eK1LDCvGrEYIABXnB/rWKGEZIOQ4JOc9T/Sr9hOyuHLbiTwD6+tIZ18dyfs4C9QOg9fSqOrzkRKc4J5xntTLedfJDF+nOOnNY+oXYZpPmIXGOOcUxGJfqDMz7t2RnNZjJJL8w+b1xwB9KnvZyZOMLgnpzxVTz8nJGDgZ56+9SM9WsrhJLcSRNxnOfapXl3oc8DmvPdH1WWzJCE+WeNma7O1vYbq3LpgZHI9D6U7iGSysU4PT+VOgm2nPPHb1qMuA7KBhc/xdaiZiG+XBjHT2NAzodPldjGEyT35r0/w3MtvaF34cjP415PoK5uF3NhM5Oewrt49SVwI4WIXv9fWmI7201xllZiTs9M9K0U115ygjAXPWuJhKrZs/mgsf4SMGrekTfMHIJ2ccmgZ21zqQiTcTx1PPavHPHV1N4u1tILNSLC3fDyHox78V0HiS+nu5TBayMiH5XbuB7VmxGK3gSG12oF6vxigCJvK063SCDgouFA61krdlX3SKck9aZqviCz09ikJWZ26nd0NSW8w1SxMigr1I4xigRrWd5dXAAilOxfftW3J4gt9KsS95OscSAZLnqPaufilj0/TfMdsKgyeOteW+KtSGo3LmSV3ZSQqgfIB2/GgD0NfG66/qsscYMdtEAEDdW969H8MeJY7S3WCaKMRADJj4JP8AePrmvnLw3dx2U3nuzE9hnt6V1en+J98wKnC7uhoGfSiz2Oow7WMMyN/BIAf0NYGp/DzwtqMLJNo9rGWOd8K7G/MV5lD4l3PFDDlmc4yK9L0TxdpUGg+Zqd/BatbITJ5zgEqO49ePSlYdz55+O/gfTvB+r2J0cOtpeRM7Ru2TGynBIPocivJ7gsJCGbcBweeo+td78XvGzeMfEjXcQeOyjHk20bdVTuxHYsecfSvPZ3+9juOeOAKlgI7H5cDeVwSB0K1JIWdWfKqnbB6Y7VXRWbbtxnt7896sJGcnKBnzgMOeaAI1bbI4ZSrAbTzx706WTzSzbghHVAM8dOKVsJK7bWOOCG4/HNRlSUJIYYJHHb3pAMlyHYHaeRjaTnp/n6UKg3lYxuODlT0Xtj3qTZ5jfLhiccr1qUQkRsGGWJz06j60wIHDeVAufl3ZyOv40wlsnHTC8ev4VK5bKDG7YOCw/l9Ka8LBBIyAYHbkgev40gGrEzIuIwVwVDdB9KZhSDtAYEYJAx+lSoVaNlZSrc/Pkt9OO3/16REYqcd+ozg49aAIoXbbsz1GCe9XLe0muSBEjsVxyg6ex/GoYoi0w2cZGGOOnbvXoPhuKPToQigNKx3Nu5z6CmkBzEWmaiASsD4U5JxgCq1pA91fiA4yxwPr3+gr1GS68xNoQBDyTjr7V55fv9g8R74mGRJvHp6kGm0I9m8H+H7TR9MSN1SSRvmdyOcn0rWu57SCLCKobGOBg1zljrKTWMUqPlXXJyay9U1wxttkK9MjntVCOf8AiOkc0UdwFVZAdpx6GsDwnera3JhkYGOcYx/dNW/E1295F8jEqec5rm0cg7j8rA+vUCpbGdRrkDPpMilTugcLxzwelcttKsrZOSO/Tj0rp7a+W7svMkYg48uTHPXoa5y5j8i6kUqMqe4457mhgdFoHiRrT9zeHdbdPmOcV3cVxFPbR4YNGTuSTOSPavIH5kBycZwe+a3dG1eW0JVyXhPUN0ppgew22pEQCOUkkggEd6q/2iizNH5gwwyMHpXMRauJbZfKYhsFk9j6GuWv9XlEzvE5Vd+c9h607iO11u+RoJY9zcHGSckGuGuNQkkDxOSUJztz1P1pw1LcjPI75K4/H1+lVwYyDhT05JHIpXHYilcs5AJGKuW7H5QvOMcDr/8AqqipQsAATjPPStGErwSPm6j6etIDbjQrCFPX1B5rG1MhA4QYVPTue9aEl2lvblpGyexPBNcjqGpNLPIoI2k8nsabAgu51Unksx9T3qh5jsNxOCevNLhgu9N3PHXA9+KciAjBLZHuCKncZoxZVBliOvB6Vo2d7JASYsjGMgdD+FZURQmPBbG3r6epqzEd3lDAzy2e7AetAjq7G/W6xnbke9XpmYJuRvmB7fxVxttOYCGV8NySMcHH9a6nSL1bxMBwZB1APAqkwLKXDLlVZl5wcHofrW9pV6UjBYsVHzNjqa59y4J25DdcY61IbueNWzjpjpjHtTA79NZhKKxIBAyeetaVvf7IlMZILgYGa8jluLk3CMwYxnA//VXUWepzRwZLZY9ARxQI6qe7UCVQ2ARl2z+lcT4q8TmBPs1ln0wF+9Wdr/iBo0EETYbHJXvnrXIteSJcLMkri4D5R8nch+tK4yaa9a5ny3Un16V6t4ajMeiwp3kPPbivJdJg+16hEinG89/WvVVvIrK13u3yxJsQkdT3NCAreM7+SaaLT7RtzswXB9fSnad8LtQuQJJZ4zCSM7RyM1z3h2+W88V2dzORtMnGT+te7WGsNF8oAK5Hyn+dMRzdn8L7SC0ZZxukbuT0rhtc8E32ktI8OWiySAa9x/thGj52k+npXP8AizUI20qaaTGEUnPpxQB5D4enkbciK7yMMAAc0y48L6zrV4GnLCMN9wnG36Ctn4Vxr/a93JcD5ljDKPbPNejvcBVyFTDZG6gD528UeE7/AEOVXmBkgbo68nB7GuPkgLKIxnJ7etfTeqsJkKTRiRG5G4V4prGjI3iC4SzBEYbOM4APoDUtDOSihByMkLjPHGT6ZrofD+gz6ru8ooNpwck8ZrYt/DKRRKuQGIzuNbfhW0bRr0GV/wB242nI6H1oSAxpfAt6cEYBHOSMjFYTeH7oEq0J8wEhiDnvXuoZGU7TgPXJWpWbUr1ZVA2vkADtinYDzN9DuojloTtxjd0xzWhNoUrWKsFGHGcBsfSuv8SoI9FmkTDDuSOnNU9Pc3ejRl26fKeP5UWA8/awf7RDEdsbZ4yfvd61/wCxYPLLGV2cdhxg96XxNG9vfQmMEgfP0qwIJ3aNlyQy5BY9fbNIDnZrGIzlIwwAwf8AaI70gspAcrxxkfSrUz+XfyAOBjg8cH/Cp5CY7YOCuM+5PWgDKe1KxyMwxjmtrR9RVjGTwQBuAORVK/ceRgdSuDx071mW7G3nd1Py+nr3oA721vgsphc/N27jH+Ncv4jBbVi5HyE8DPU4pz3RdopQCDjPTOar38qylJWGQ3GcdD9KbAtaVqM1mWjDBoicqCcf5/8ArVd1G6+0xq6kk4x8prnWkTzW+YgeoXv2qVZwzMmd2OuKVwLbzDaA7MNxBHFUnHDFl68HHFOcqpjAchcHn/8AVUTP+5w4HBHagB1lc7bldi8YweeD7f8A16tXRW4jDc57GsrJ2gleOgx0BHapIpRGilThDx82fypASScHOMAHrTS5aMqRj+Lp29KcWU5OQFz1HSnOMxdRnOc5oAtafeyQkgEknBqWWRGjLMuWDZyTxWemV6fePXkYFWMhEYoiqoxnAz/kUwF835tzEDnJGKuLhVGwnacsNxFU4xtwxbAY54qUSoFAw2B+tADjlZCOn97JzUj3ywock7gMkVmz3Kx7irbuoGeKpNL5jFhzlTwcDjPai4F651BpiS+49hnvWajqTJJuOVIB9+KZu+UqcFgeD6H09qIGBkOAMEnJI6e9IY9STEMlevIB705duxNxD8YBXmmsi+X5gyf4Sc8inpIwGUV1z12nFC3Aek3zeWxUA/KcH9KuRTDcWHJ6cDkDuKyZGLyghNoC85z83v8AWrEcwUbVOEJ4xzgUkBovLukVSAF+8cDp7VcsLr7KdyAlmO3A65znFUYpA24r/F2YY4pGm2eUrIMY4zx9KYj0XTJ7S+sJGaSQXasuxAuVI/iy3YggcY5qKc+SG3L06VxljqJtJVkUn5hkj/PNdzbzw6nabocFyM9elUBly3LAbYgU7Kc/zqKXU38oYbBAA69B3qO73RF42JBDZ9M/SseZjvXOSvYk9aAFnlaSYggbjyDVZnARt6gZHG3tUhLAgMu44DEDjPXvUOCjgMMYHftSA3fCirFO9y7cr8qbvWrviXW2ZUghdSFHJ9aw4L3yIjFGw98dMVR3lvMYneRwVFFwNjRLorNbOGIdHGADjqeK9htNXaCyVpG6jdn1rxXSsLcwqSyKzDGPau7vbwC0RA5HGDzTQHZ2estIGkdsjP5CsHxNrcl5LHYQNlM7nKnPHpWbp175djKzMSp+6TxnH8q5GLVc6lK5bGTyaYjsNN1FdO8QQogwkgaM+hrsLzU/Ktst16jmvH7S683WYvO/eHzMryQoP4f54rsdQvl8yBDv4546UrjNzXNXW2tfOYjCJu9z7VyvhZDfWBuHxvkkZmI+veqvjW5Z7NI1H38c57DmnfDqYCKSNSDtlznsRj/GgR2i2ka4UtliBxjrWf4pEdro00y48xXXb69a1YSZL0oMAgd/pWB45MkrQWqMqhm8w5pgbFncbtItZVbIwD+FZfmCDVS+BiYdfTiptEkU6cYAwO3HGMdqraowESszAsp5NAFLXJVazvIcDGcgCsrRLtBpl3AEIKMWAzVq/dBLcYJAeLIwK5vS5UUXKHA3xk4POCMj86Qx/iWZbm4tWxx5ePTPNPS6MTwLKSAqcg1l6pJ/x7AlZFQYLLyOlRq5eRcY5U5zxj3FICvq0wudUnlhijiEjErGhLKg9Bk5x9aW3keS0C4PAwMjiqU8pLkghckEfL3H+TUtuzbzuY/l6+1ICZjuRt6k/LnGevv9KzSNrIHJYNngetXolZ5docDII9M/jVe6UiYknainByO+PSgCxbuZIdo64/HjpUZm3RgEZZW+v6moIMR4XIK/5/SgsolZiMr06cZ9DQBE0g/vA44PU5/Ckt3ZDyTx90djz3pWJEmFDAt29BigHeWKqBuOMDtx2oGWFbKnqFJIHPXjNRQMGwFHygZPqQOvNKpwn3iAp5weg/rQoCxuHI4Gflzg/WgQ1wu3fjAJOeOnoaRn+WNSy+uRjinqSUw67gFBHHX8fSoHUhgCcc5xjA/E0DJzKJGIJAYnnjHepY5VC5PzY56fh1qn86KC2VOeP/10igk4XdnbnbgcigRfLIVznBxnBPT6UqgiNs8A9h+mKgiDBmYnODgg/wAquQxh+DznoMcD3oAaxYBSGzjpkVHLKUfIOWYYNPnISAsQ2QepPJrLcl7jc7EgHkH8+ooAc5eSbaQu4ArzwSKY0RGQFVuCeO1OiYCQk8kZIA7570j8ogDA4HJ29MnqaQyNmjDNtByG5OePbFCOuCwAYdQoJ/WnqDG7lNwUYKnqRz1pwK7Wbd3/AIDjP50AOZygQghjgghhkD86I8hAxUOG6E9MCnoGeBSF3uGLcDJzT0VfJXhmwSOvTn6UbbgUpXBLDcSwYKOP19qmV9qgxkhxg/jmoyWBcsucgEcdPelUAclc8DkHsaAJ4GKFgCNw45HIqSVi3lAklcDkY4/z6VWBOTuQDOMEHIP408n5VUgEDBJH9aYF1CPKUMRjBw2P84rT0a+e0myj4QjnHtWIHJVdrMQPUY6c1IkxTJULubPbB596AO4vZItQtRJDgyD7xXrj6VzU7MowcED+E8j8ahsL+WBx8qnnDAng1eukWdTLEoUs3AB/OmIplj5j5PBA6cHHtTCAMkqWQjgD+H8aaCACqsfuge4+lMI2N85OSoGAeBSAlkfKLtGcNwT06VF5juxwDjsehprpnB5Kjr82c/4Um3fMNpwT2xnt6d6ANGzkyVYn92vOBitO61PzbcKTyuOQRz9K55WYYbjb2BGKGf5zyMMelMDqrrVFGmop+UtwSa5WaRWuHI5z0IPFOlnZyoPeq7gqzHqfbv8AjQwNSyJWeJy6ht2eR15rrdQvY/7VihGD8oBOfWuOsVAMZfIK4J496sT3xm1DzEYcn71AGt4pvc3Qjj2sBGN2PU1p/DwjzrlduMFTw2OPpXLaiwlmdj/qxgDJ9q7TwPDsspnPJYcYHWjqB02n3QfUZjnaqg8+n/165HxPqhbVJ5AciPEQYt3/AKV0WiWz7LiZwO/avPtcWX7dIxyAW6duaYGroGqGK8+Yna4xyc1u6ldeaXGeo7dfeuN0uzZ5t2SvHHPAreusm1RmY78cjqM/1oAXzVljVigyF2+pNc5IyR30uF7nKnrirPmOrtliOevtWfKpLMwUHcSCFzzz60gG3EeNhUZVTkbjUEgUJxkrg/e6ntVwKhQpIVBX1BOeKpzuAuNo65yKAM25k+dhjbjjA4//AFUq/KoJAAUkfU9adKc+YTEWcYIPcD6VFIdqhW5Uknr1pDLbEMyt14wQOM/Wob5VMud5wxBz6Hvmk81sFVX5QMg9sU2TEkSKRz1OMHP4j+VAEEGAw2su9RjI+p4qSSR1JyGHsBj9KTA8xcgEDH3Tn8qA4xgIA3XnjP0oAVyC2HwFC8gDFNKrtK5TcGOMZ+aiUEyEHkZA5NMV26YU85APANAhWAYE4LYHQdj/AIVNbXDQukiP8yHzAVAzkdM54I9qYQ0ceUDYPylcdT7GmoGXCBlRcjIJzt/z60AOSVS27IVT1A9/bsM0pD7EEmTuO7P4U1FDoSEBwDzk/nRgZwpIU5yQOKBkUmA2MHbkdBnmlRAPvMoXIJyDUg5RNrbueeuafCpbggbVbPA/SgQ+1j3MQzAdOfXNXJnECgE8Nzye3pUK/uYfmGATkg+tV5nD8c55IHp/jQBGw8xlJYHeeDTfIwoZSWIHIwBz7Uin5WUNk5/Mf57U+NmC7kPAwMYzk/5zQMrYCu6nZjJOVPXj9acoCJ82Py4/+vUrffAGBIBx+XekVQ2do6Lxk4yaAGj5Xyr5wM8jnGevpTlVSobAVdvQ9M+tSlSgZdxUHHPYjHf1qJgwTGAcAgkf4UATQBSwXcc9ivQHnpV6IRmMcSMe4Bxis9GXGf7vBPrU8E+2BcCRuTz7VMtUBTa4Zn3KoyFC9MDHvSKw3qSjEFuQOh+lVmYZZS5zkDb/AI1IBsIww64IGTTAvQkZy/HRTgd+1LKApRcdACc+vU1UXfuXKgnpxx+tOLhXUkFnzt2gcZ9aALsDo2Aw2j2FXrZbFwPNidcDJ2tkVjBgWXPVhyc4Bx6CpY5maIgA4ByD3xTuI2ha2jRbVdlw28k847f4VpabBZswjuLoITwDt6+tctLd7m5LMxO7DDB/w9KlEpbDZJ5+YEcfpTA7PUfDlu8Pm2l5uZeRkZB/GuWmtfLfaQBhe39at2mqSwhQjE5J498fpSXbpcEvGuwkfdDfrmgDNIBI4Cg5GfXnmkfcJfvBcDhl6/rUzH5+UjPqPbH+eapzMqFcEcZOAOtIC4h4VQu45B+akKbizjCjtxmoY5CQMht2AOGORU6SL5RG1dv3lJPIpgRqo2qvQgYHfn61FMyK7Mm4qWAy3GPrU4BDlvuZBJ561HMGZ13BcHjpgD60gJIjiM7cgdeTkimJlHBQn72Ov6UxIzx24ye2KkD4JKkhieSeT/8AXpgWmf5kZgWb2Oa9G8Kulro8jtlTt43H26YrzGFsXKnueAOmT/ntXVpqXl6SkcRDMTlucfhQgO2tboW+hzSLgs2favPr1/OujIy8AdDXRC8zo6orDDANnPFcnMdkh28gnOWpgWvtHlxsVZfTac5NVri/kliX5n2jkYPXFQuAVfLYAPHQ5qs2ViJwCOxx0pAKkrFmIfAI6en41LKz7SCXAXk5zzVES5CrhQPX2rR3fI28NuHJzQBRlkdQoPrx3zUUzuwAB3NnJ5/z2q3PsZgAARnHHT/9dVpl+UsCFI6Y/wA80AUZXyDuVcAdRQdz42qcrgVIyF2Vd/BHXGaVFIRsZ9MA4zSGRpuyMk7iMDPQHrQcu2V+ZQOSveo+rsCUZTjjrxxTm3scEAsuO2P/ANZoAcEEYGAQCcDPHPt+tMUDzAChAHbOcipF3eYQ2ST2PFNUAMyKSQTkE5H+TQArk/NuzjryOT2BxTVVTKG+UZ5UDnt0z/jTdxZmMnJx2XHJp0G4qAhHTPB7/wD6qBE1wZDHhiqZGGXfj9O3XpVcKA2ASozjjtUspKnk5YnG0jrx1qNBuVipO4c8cn8qAJYS4OBxjGRnGf8APpUchzIOnTr6etEYURuXKggZUjnPNKQzEMu0jr0/pQMd97YCMbMYH/6vWpvM2Rli3OcZGT9apy5VCgfgnn/9dNbYYXJ3Y6nAzjP+TQIknkeRWCuSoXsMEjpzQjLhZHBOPXP4CoHbC4QscEkce3FLHueP5lXA43Hp9PrQMtw4RJWkDEDIJJ/kP0pnRCVDL3OTUUAxFlmXIUsM+2eD706PGz52GMZI6UCCUcjLMT9evpg08AIJCNpyccZ3CoVdiQPmBYgjIqe2kaF8AnIyfu5xzQMR3BcgAlWGCG5J9v8A61J8zxjeFXsDnp3xRccyMvGASR2pqZ+8rqrd89CPSgBcmSLOTtGcA84+ntS4dUQSAjjihH3ofMbJLYOBnip8EIu3vz/nik720AyZMmRzjvnGOlWLBY5bhFlLBBjkDJAzyR74qorE/e6k445/OrEMnl3EchjLAEAr0B/xoA9O8QTfDmfw4IdIsryLVYwD5rIVDN7kmvNXkwVEbttQn5Sf5V6T4in8ET+EY5NLtJLfXWAVoyXx/h+NebnchHKqPU9R6HmmwImG6RiQxwuQO5/zmnR7ghwxOSOnJ/z0qdFCMGCrJgc/Nk5qJA21+TnqOcd6QCLjeXyPvccn8Pwp+cBD8xHRhnkn2qEkYcODncByTnpUvzD5SDtGc4HT60wFSVlK7d5PTgVZtpZQ+Nnyjpnt9apSvvCFWBOcLxjge1PjY+ZuOWYDHPf8KBGgz71bBX5e5PWq13uG0HO0glcDNRbSEPJz7jOD6gUpkC7ed64PLDr6D2oAlVj5hDMwLKAQp6ilj6ttAYHt0/SmgoZTlTg849vapP4n3KMtxknJPtQBIJckYVVZaRU3ZKjnOPvZoiiOOMhmzkKucjH6VFjaDlQ2emR09aALa5wV2qxA4JPHH+etRfMTjBAA3cnFIoYRgZGemTSOGA5w+c+oz7UATRooZcA5HocmrgcYDYYD14FVNqGXaAx5+hq3EN6YYA56j/8AXTAuNdn7L5e4ZHRT/P6UxDvb58k46gdf/r1CsJ6Nyy8cnHOetaNlagnPI+nX8KAIPK2xlApOehHBz3qhqEbDcw2g56DjH4V1TWA+zYj+Ujnk5rnr+Jo1KsV+UkDOMcfyoAy1AZvmO3Jxk9zV+I4tyrOQvGR6+9USDvUjOOO/Aq5GW2kjGDyeO/vQBDIBuj2K20Ed+femMqLI+cABicgVYb5gSp5z0Hp/hVd2QKQQ3GBjsKAK6r8xIw2Bjg5AJoYBY+SSxzjtz+FTSAbSAvbccjgmoXUqm0ctk0gI4olEe7KhRjKn5SfpTJiBJ0IHX9eKc4LttZvTJxxUW1TIdy4HJGOQR7UDJM7DxuXjgE59aYS25AxPzc8+9IoyygKc5z3zjvSRtukIUHaTgkg4HtmgBTGpbn5QTyfXmgbVBBwABgnsDSISkhSXIUdgRz6UEqThVG4jAJ5Ge9ADZgSwxyQODnJz605ATlmAXJwM9fcY9KbMzMM7VwcEk9T7UseCHGCOcbTz/OgAEZckAqpxkdgeaSJfmyCARyD0I7dPWhv4TjGVJGMD6UbeSpbquRnvzQAxlLKOuDn73GfpSO/DbtwyO3Bz71Iyq0WSwc4J9AD6jNNmYKhBRio/u8Z/+tQIjjBZMDBfOAfX0qVQUbLAghRwD97/APVUYOwYAxnuOCKljYYR16n7270+tAxSjowLIWB6HPXilCljkqA+3coAH14p8ygLtIzn06D2HvTIUDFVVmyxxgnhfcmgBVDsDkEg92PP50AbTnDHdwKsZjP7zeAivtXPPFdzofibwzpnhx7W88PC51PZxcsAQOODz0oQHn7wjO45ZdhJbn5enaoxGCG/1h7HafQelTuwkllZQAMZ7YFNUYVTt69l7exoAdGhUYGCvXOO1PBJQbskkk4BOBTEJX7nKEcADGRU7yOI41hChVGOBUydkCM545FfC7/xGP8APNLHGpOZVbGcnAJOc9qKKYEzNJkZJUNz9PrUTqQThcsOvHXNFFAEsKAJkkgnJJ9eMdqZGAkZwpOT3HNFFADNvAB6k4IPTGfX1pWjLNhUOc4wOcn6UUUwFkQ7QGUBunHGMUIpD4yAB3HFFFACjJ/vAnnpwT70roSMsASQST6UUUCAjDqRuAA9KsW8jAnPTO4cdqKKBluBlJJYMGC9QfX3pu1cAY5PQk4/H3oooEWZFifTWP7sTLKoy7HzGBBzx02jHX1xVQK8hAC5Gc59RRRTAlSNxIN4I/pWjBEzKq45JBPaiigC6lsQAXjPUYz3+ta1mCGwqbeOh5/KiimBenJW3IXAOAQO1ctq8TksWBJYZ5PWiihiMd45VYHPfscVZSNgTvLnPY9qKKQxvz8uGIPQ1DIDgkYG717f4UUUDItxbgrknrmnlccYJI4yP5e9FFAFeSOVZUYjnG7njj1qORCuQgGCedvGaKKAE2hirK+HJzycACo8MzswChiwJxxmiikIeRhgVKk/oCKiMbMCWViGPDCiigAeMYBLEEjGR1FOiiZVOSQTwBk5oooGM25Uk5Jxg8cfSlliPlxZB2DIX2oooAc0TCN8qTxgt/dPHamujYIIHYZHf60UUAM8pmQsq45Pt/KpI4wAgHXcDtbtRRQBIo2MSrLsHAbJ+Y9j/wDXpqwkbsttJ7DJ/HNFFACxowjyEByQQR296mYEli6/Jgr3zx0oooARI3KlAMdB9PemvG3IYYP3eD06fhRRQIVYQyor7U44bHFSshCLzkZIHFFFDKP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This panoramic radiograph shows regional odontodysplasia that resulted in failure of normal tooth development and eruption in the posterior maxillary arch (see arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wright JT. Normal formation and development defects of the human dentition. Pediatr Clin North Am 2000; 47:975. Copyright &copy; 2000 WB Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35280=[""].join("\n");
var outline_f34_29_35280=null;
var title_f34_29_35281="Rebamipide: International drug information";
var content_f34_29_35281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rebamipide: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4302641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mucosta (JP, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F3902773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Cytoprotective Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F3466673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of peptic ulcer disease and gastritis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F3466675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 100 mg 3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3466676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 100 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10502 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-2345798AF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35281=[""].join("\n");
var outline_f34_29_35281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4302641\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3902773\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466673\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466675\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821193\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3466676\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10502\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10502|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_29_35282="Aortic valve homograft transesophageal echocardiogram";
var content_f34_29_35282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/68507/teeavhom_conv.mp4?title=Aortic+valve+homograft+transesophageal+echocardiogram\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic valve homograft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 233px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a normally functioning aortic valve homograft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35282=[""].join("\n");
var outline_f34_29_35282=null;
var title_f34_29_35283="Congenital leukemia";
var content_f34_29_35283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5mubBkBPOfpVWOEsffNd3qGnBlyozx0rnpLERS5A5rsdPW5ywr30JdMg8srg8muogOAM8+9YNp8pT3rbtfmwG6V1RehhUd3clUZGOlOCHjBwB6U9UUjqc07GCMY96GZqSGRjbMP51sWcnIB6VkP1/GtCybd16UyTobdg6EetNkHGKZagFVIPOKkuRhOtWBmXGD15qjt3H3q1O4Byc+1MgjEjDYQfXmoTQD7OAswyOM+la0MLJGxAy3JFLaQhR0JrQjj4Awc1UY2C6RDZ72TMgwatdEG3jP60/yNw2kEgjqOMUkijIC9utUiG0UpxnOeay7mJpJVA7/wA61p++cDipvD1rHe325iPIQ/M3anogvodx8NPDpCpLIvX1717DaWSxhCewxXn9t4s0Tw/YRRB8yEZ3OwRRj1NZ+q/HLw5pkPDS3kncWoyoPpuPFcNduTOqikl5nrsgATAqi7QxEtNKij3OK+b9f+PmoX7+Xpdj9ijbhWkfc/44rjdc+IN4CZr6/WWQ/wABl3EH/dFc6skbtvQ+wP7b0yIAG7hz6Bsms/UPHXhzT1Y3mq20YXk5ccV8Nan8QdUmkPly7iOjEnH4CsPdrfia7C5nupD0AGFH9KhuJquY+s/Fv7RXh3TXMekg3pH8S9/pXCXfxm8d+LC0XhjTo7G2b/lvKMnHrXMeDPhXBBsu9dYTSLz5X8IP9a9WtIIIrdIIVRIY/wCBVxkVKmkbRw05u5wekeCtR1TUxqvirU59QvD8wVjhF+gr0vTxNZWwt7aQxIvGE4qeOHzE+TCgjgDrVqOzVVbdkAjv1pOrK1kdMcJCOr3KCpLKS7l3y3BJ604xlQxGNzdutaBiOxY+FTpgVILVRgjAH9altvc3jBLoZKxuseX5LDIA6002+Pmb7zL989h9K2fsu8BmG3JO0VG9nvIYgAEgY9fapZolFGRDCQ5Y5IPAzVgqTIFALMT+VX5bbDj5W3bc59vagxhUIQYJHWpKsig0PlscsPfb71C8K7mbseg71oqqrIM5OerMOBTWhBAKAYb9armFyow7iIZ2gZzzULQ4LBIsNgcmtxoCAAAnJ6YpskCsQSAMDr6VSZokkc0uns85LbQT33VWurCOOTMOAF+9jvXWfZgw6AR9M45NNktCUxjAIwMihrmR00px6nN/ZSSvlE7zz171MsTRyEqmJG4I962odOWLaB1HGM5qG9t+V2AknoBUOOh0xlFszrWOUThww2kEbe1SuwVwvy7eu0dzVmC3eNtz7guNrAipJ7dflXjK9Wx0qbWNXa5Arq83lgANjAGai+zq00km1fvcAHqe9TCAxsHAOACS2e1IZzMFzgJ1GOaTQct3ZGXqtsoWKRVIODuFYd22+IkHrjIrpJjJNJKpTehclCew9KxNTtfK3Mo4IwdvrRewnTWzNrwb4mm0jVFWOQeVjG0nivbfDviaz1iLAYRXC/ejY4z7ivmBRtJIJV0OB712eiXweJSkhU4xkHBrohLmVmeDjcGoS5oH0FLe20Y+eeMfVhTBqFo3S4jOP9qvB7uSWNwZJZWjPIJY1XMsxQyLJIq9TljV2RwRoze59DJPC4BSRCPrUn0r54ttVvkwI7mYYPrxW/b+LdYtkwJQ+O7VOncv6vNnzXLdleCAfwrPleNyCGXd/KsxdVDqM9e/NVHvNzMy49sV6DaPLjTaZuR48xcHNbNt0U+1c3YXAcAHFdDaOBj0rRbXM5qxeQcYpx4YUoHynFOChlzmqZzpEEverlh0GemKquMnGfap7Qn7oFMo3rZ+eD2p1zIcCqsTYHpxTpGLfQU2BUuoROhQnGe9O0LS5LVzly4Jz16VcghLMOPzrYtYDgdc0oxAkhiwRV5E6CiKPaanZQFLscKo5PpWjVjNu+xBcny4sKfmJwBVK5uIrSHdM2OCT7/4U+5uookN3cSBFIyucfIvrXkHjrxodTlNpphK2itl5D1lP/xPtWNWuqa0NqVGUmdFrPiATN5l3cLBZ5+VFOWfHvXNan45mAkh0tBGgOFY88euPWuOnuJblwZnZyOBnt9K0bbThDaC8vJliVuFjxlz/hXnyrTlqd8aEVuJfLqt5IH1B5pM85kfIUHvjtV+C/tbIxl4/tLqCFBfEecdT61nT3wkgaIbo4weBnO761Fa2bXTMN4EUZI3dgM1k292aqN9BbjU5pbtpdqEE8IAdv5VDHBPfXPyoS7nsMCulsvDMkrR5XYsmdu8YOB1Y+1d14P8Mf2heNHBEqQQKFd2XG4g9fX8Kz5+hSjrZHJ+GfA0l7PHJdK/kA5AA5k+nt7mvYfDXh+HTkSG2gVN3bjI+tdPoukx+XstWLIpxvK/eNW54fOkktLKTESH/SboD7p/ur7+poudVKmlrIzYrJ72UqH2W6fex3NdDY6cpUMyElQKktLWGNESDIU4Ee8c/U1pRxjEaLnJGCR1xRY6nV0siBIkjl+T5j6DtTvKdnTeuBjj61oR26IzGPuO9BHBBBJA4JoM3O+hUS2YMDu+7x61MkQYnbyo4zSNIytjgg8UsbYwScEdAOec0XRokxRCTkqQGAxz6UzaFXJO5eg/+tTmkLI23GcZGe9LFlyFJBcsalu5VitKWDovvnNM3JDvGCzNnrV+SJQmQcN2PWs6WFpJnKjodoOfpSLWpBNwmDgnqfpVOafYw5y3er5hdhsTHuaoSWhcsrHhjzjrQdFOnF7ircI+FU89fpUoI8oFnHOc56/hVRLdVHyBtyccHmpoFV0x8wYdzUpinRjvEdHmUhEQnHc8/jUhB2sH3FsYApIkxlASQD0zinkNuBDDnpjtWl7GVnFjrazV3CMwjRxgsxzUIt2ZsqqEr0D+1TxMOykDGDnqTUxZc59emD3q9DSM2nqZwjeJQsn3h1K9zVgQrIqAIRxkqe/0q4FRVBGM5Gcj8etSKYmYbeWbk5HSiyNHWutClJbRrBh8hv7uOCfSseeyKl02MrqeY1HSuouizW2whNwYYK8kD2qncWo3CY5dgclmyc5HHFJxuVSqu+pyMtrMLnIB8pR1zjj2qK5CyfNGqrsGMDnNdHNbsUBQ9+vas+6tdm8jAPXIqHGx1Otfc4W/ibzXViA57irPhmVFv/IcA4BP41Y1ZNxJAUAe3OO9YeiTMNch5AVmwaUZWZy4hKULnd6lGXgJA+7hh6CobaA3IQg7h1wOlaF2CtoO4Yd/So9BSaaBVj2on8Tdz9K1d72OBxVuZEctrtYhcFx1FSKnyjON3tWqbdEiKgEDr9aoyRgHacj6VKNIRTR8Y0Akd6SitLs8Q0NOuDG4BJxXaaXIjqAeRXA2/wDrV+tdto2Nq57V6FFuUTkxCR0EY/dc5oPJ4zjtiiPOMVIq9j3rc4uo2NPm5FSxgK+0d6ThcEZ+lOX7+TxihDLatjA74q1ChbPNUgGLDHTFathEW6j6UwuW7O2BcZHbitmGFVwTVS1ceYqR4ZulXrm6jsSqKn2m4P3UXkL9fSrTUCeXneha8tYYDNdYRe27jNc/Lqg1O4uoLeRIrC0UyXMzcADr1rmvE3iG9u9RisLSUXN5K3zrDyIU7kn6Vi+OtcSx8Ow+H9MVUEreZdAHLSt2B9hXFVxFzppYd7M5vxj4tn1ieWC03x2ROAD95wOmfb2rloEUyrvBZOpA6kelX5NOmgtfMmyHcdOpx7020/dyBlO0tntyF9fauCVTmZ6KhGK0NvR7KytNKk1i8nQSFikNsq5/HNYt9PLcu1zcLtUnCL/dHtXQSQ3WtlJp4o7ezs4xHHAq4UDHp39SazY4Bcu8/wDy724OwDnew/pS5gjuUtMtJJblGZTj0xnrXSeF7SO51ScXZVIoZSzZ6BQecjvW94W8Nzt4fn1K42i5lPG4cBc9eP0rmvDcYuGuZZTlWcuozjgck+/UcVLk2ivQ7y2UXeoPIqOkr4SNW5WFOu73bv8AlXqVjBaaTYxW6SLGpTNxLnkZ6D6muE8DNc3UT4y+qTvh2MfEfrj6DGfwrubLSB9oNqu4/Nvnmc5dif5E+npWZtTjoalhevqqGC2V7LTI8CSfG1m46KOwx1NWrZlLrDbIkNnHxHF1B5++349PWss5vrp7O2xHYQMBKyHAcj+Efj1rodL04hpGZww3fKcdcdPwFO7OiMUt2Xba23nzZ/lAztUnP4/jVxdscZwMc4yexPtUYYEttGUHp3xUM06+aUUq4Xk46U+Zhy3LZdVQK33sc1GZgo5HAHX1qDeXVTnacd+9QXMg2jYAQxwaN1dmkKdyUS7k3MhIJyue9IX2429M84quQSquGwp6KOadCDIpIBwD0PrU2NuVLqWI1DTkjIVRtxVuNVzzlSDj8KrNkOyqpAJzUzMyYL4OATx1pkMcDvwy8g8AdveliiRlIYEknnn1p0YUxgpkLnnJ6VOqgL8oAAoI5il5Ay2ABnkfSo47UBWMgGewzWhKyBgDkcdR9aYymR8YA9j2oNFJmasA5LKCCuMjue9QrajcCp/EVptDg7cE4HPbP41X25ZQcAAdO2KaRSqMz5YmRht4GeRjPNDrt+YghvQnoauuoZSQFz6Z71WYiM4Od2PXvRYcdSAEBsevp3oJx/tN79hTzt2+55Oe9RYYMcjj2FBadnqKZSE++MA8k1Zivo1Uqgy5HJPeqpQGMjGHPTNReTgDLde1Jt9DS0Wi/FdoYmDMVAIIAHGanlu4pHMgQBQRlR0rHKA4Jbj2obLKFViw9KanLsKUFuTSSRqXAwD1U56fSqU7IFds8YyfrQ0LNIfnzUclq7BgSdp9Knnb6Du0zmNdjywAbA/nXJmAxTLIh+YPnivSjo8cx+d2wR3qI+FrMgswkYe3FOOruzOpKUlYlimWXSA/Usv9KveFUWW3SNMKAM47mqyaZFDD5cTyKnTBOcVZ02H7Ep+ztz7jmtW03e5ztSUeXqaWo7Ikx3rCUtLLwhY56ir82+eTE25h1wOKsJEUG2JNoHHFK66MpOUVY+HnRlPIINMrqbzSjtOAWx7VlTacQ+B0963cF0PDjNSKEBxIv1rttFYeWM9a5KK2Ikw2ODiur0aMhRXVRVo2Ma70OniHtUwHTjkVFEpK5B/SpmY8Bu1dJ56EWkYHNKGwQal8oldxBCZ6noatDuOt85yOg61ftmlnmW1tOXbqetVNJtzqeo/ZLabyo0BM039wfX1q3r/iTSfDGktBYpI02dok/ikb2PYVz1KtjSnS5mbOtyW/hbSGur2dRPjJUHmvMn8Wa5rznTvDlq0RuTtZ1GZH5657AVZ07w/e67pdx4p8WPJFpaMEtrdmIa6kP3VX8e9dt8PfCuoSATac0dtAzCKS4xjr/DGfQVx+9N6vQ7LRgtrmLpUFn4N024gtV+2+IZM+dcDmOP2z3rCXw1cwJJe3m57udtxY9UB/qc9K98i8J6Xa6jb2GmQx3EkOZGDDO6Tu7n0B/XivOviXdxafdPYpdDzolaW5mHPlZ54x/GfTtUTilqVFtnmGqqPM+yxkbcFpGJztA9apaRpvmIbgxko8m2PfyW9B/Wrto8ssNyfJESXLAEhcnYvIUH9Se9dZp1pHZ2P2q/cpHEhcIBy30+v8/pWFrvQ2voYN3tRVs4yS0vDEdQO+B6n/AAq+dGd0itkCwwo4TZHwdx659eK0/DtozXh1i8twgYfuFI+UDsq+uP510On2Yzdy3AXyrMHdIR1lblv5gVF7FwhqY3i+6i0TwNahXbzbqVlhRTjEScE/ixFec6csfl28EQDKmZXx98/7H6VtfEq8+2an5AysVoqwwxnqOMkN6Ek5P0rU8C+HTGbe7nZds5ZEB4DHHb8zSk7KxcafMz1v4e2KaSTcTojS3UIcDtu9PpjB/Ct0LNb6ZGUA/tLUpGZWx0Gcbj9B0rmbO8dpdGtYyQs9sXJI/hOAxH4g13mkxG7lOoSpt8vAiXP3UHC/nikmtjpgtBujaTFaPb2cQPlwqskmTkknOCfcnn862pyhlMEI2qnLMO3oKht5Fhjur0ktJMwCL644VR+JNSxxG2sT5rb5mbLt6t3P07Va7ItldY3KuS+0nkADj6VQO+N2VQCB0rVnlKqVXAA6nPJrIkklkLElRH2PekdFFNiPLLhd3J7qpqOBpHJ3D5hyoH9aC5QoR9w8Zq1Gg+VyC249RSOp2jEktkkTyt+0gZzU8YOwrnbnOcdhUkkarjGRxkVMkW0gKcn73Pc1VmckpN6leMsN2CxI4yTzU+T5i4xheT60sKDkDGGP1zVleWbKj0/Cmk0Q3qV3cQsiNuDOeT7Vd3qduRwe9MMau3mFQeRz6U87SowPbpVEMG2nlumMUIqfMykZYdT6VIIwu3p1HbpSvGN46cZ/EVmK5X3liyn5Vz1NUZid/DZ7n3/+tWjPjywqkjIxVCSEEjcOcc89KaNoEEjlwWPXPHvTAoZfnXDdOOancKdq7eR0I71DMXjcE9CeRQapFZrcrNucAc4APeklbIYBMH2q2zFn3E5IHJIqvcKwXHOWHY9qOYqLu9SsrHOO9SpGp9z61BGrlfnH0OOasQB9hzyKZpJajDGemDgDjimtCFHPQ+lWySdq5OTTGiLE9Qp4xQKL11IIEBf94PlqcxozEID04FOjgHXIXPapoojjjgdaAlJSZVMDfxD3GKsraAnjkkZAq5FGTHg5GT1qfyw42gcD36c0jCU9TG+y4GABjvTorQqp44rUOFfphs4HvTvL3ABuvWkS5szo7Idc8YyOanjs9qp8vOa0hFtXvx0AqZIhjPU0EqTZ8fGON/unHtVK5s1LAbQM96hNyYxkkAA9akW68wFs9BnivQlGx8zGTTuYzWojn7deMVq2IKHd2o1JF8xJUGEZA1SW0plcFxjaOB61rT2HUbaN/SB57Iu0gE9qt3NsxkZhgAHGDVvQLdbe2e62ZdU+U+hNVJb1bQl3PmTMcAdq6E0kcttSSC3SH95cEcfwAdap3lxJdusVvwTwEXov+NOKmT99cvmWQ/InqKseGdJkuNSLgyhZmH7wc7V/2fQe9c9Ss2+VM3hTsrsh1HURpGnmzsIjG+MO+cnPfJrP0XQFltp/EfimTytLtyCrSDLMc/dRe7H1rqPFdxoihYkt0jsoTmeYnHmEcCNe5Hqe9cYov/HOor9ueS20CwO4qBtVQegx/eP8q5am92dVNadjuvDUTeOLqHXta/0Lw5pwMenabn/Wert7+p/Ktu9+IWzUoYNGtQ4UGGyto1+8x4L4/Qfia858V+KI008Wdky29oP3SLGMbYx1x9cYro/h3pgt0m8Q6pKLe4jh3o79LSI9P+Bnt9anmbdh8p2WsavcaBpjaFo7eb4n1Eqbq6Bz5JP/ACzU9yB+Ved6nosesaovh/S2WdYP32ramxypcHlVbuBk/VvpVyCW/wBZ1KQaMDDd3MZEcjtn7Jb5+aQt/fb1rRt7aOxtBoehBEsLciS+uyP9bKei59ByfwpN332NIq+xJpPhG2k1GwghUC3U5leQfKqr/CD3bpn61X1DTP8AhJ/ENybRALOOXyosdW/2seg5rqbeZ5dOQwOLPS0jMQmIyQo+8y/7THvVzwcsCTyX0cCwWkCbIhn16596iVktC4QvIoa1arpFvbkwqfLjWK2hxgA+v1J5P1rlvHGo3Gi6NHpdlJGL1F8+8kcAkOxyF9z3+grt9fvXR11G5UNcP8ljbnkk/wB8j0HWvEPHuos8kluhaUqS087H78pHJLVny9TST003Meyt5df12GCNZJtz73kb7xH8TH1YnNeweI7CLSU8N2eQJIllutgOAAF4yPfgVifBfQooN15dr5arH5jMf4f8OMmtTxLfxy+IdR1C8DCO0tVDoT93PKr7E8cVm2nqbwXJC3cnsrj7VqkaxOCbWwSNgMjyiTwn15r12NQulDZkSOmFzwc4AFeR/D2xm+xQrcApd30zXFx6hV+YD6DKivVb6VkhtraFj9pMWR38vPf8KSelzdaIfpBM6QyL80NqNkef437t/StW4ZhEqsmM9vWn2FmttZRRIMbBtb8PWqzvIwJkJ2g8Y71olZBdNmXqtwVcgKMGsjz8ZUt16L3H1rduLPLb2YZPJB7e1V4dM+0Tgw7Qc/M+OgqbanfSqU4RsyskZm8v5jhTzgVt20OMDkAjAFRi22gqvB7EdTUsSTKztn93gcHuapabmFSpzbFiTABDZLDoaaD8w29+Pxp4QjaHYHORgUgidpQxIwOMHrWlzLm0FVf3ygD5ACRg01g4mzn5Dxk9zUDLL9oLq4Mf90Vc8ssic5wQf1pDdo7D3bAKhTjt7VNt3RqFHIOTSbNy7eM57U4ELtVlyWxxnpQZIZ5jCASdSegFOkHysM455JqOZiqqE6AkY9aqx3G5lDLjnHPtU2Gi0wJZAeNnamvAHDsM8dWFOQ7toXB5zT1ZlCqpPHXNIrbYyJoZFugQxGB1B4p8YJ+8hOeoHf2q4wJYg7cAY5pudgxgAAbeOmaDVSbRT2eXJ82NxGQO1KYem7AYDAJ/lU7qMjLEsV/DOe1NlwqMwbf0JXHehK4+YrvbsAS+AMZ45Jpnl7GwOw6CrBYkZ5xjIHeoGjaJ8DLk8kpTasap33FBQEYBDZ9KJAGDZyqj881AzNE+U5GMZ70kbEtwc8/xHpSL5OpPDOPNZHYbRx7E1aimRgFyAD6c5rO8n5yUGE64qXftkjYEBh2qbshwTNGOYBRHuGM5PtjtUyuNwKEDJ4z6VkJIBPvPUjAqeG5ZJVZjkqQSfQU7mMqdtjTlQF43Kjk5BHpTd25iRyASPwoMm9uSpw2fl9KIucEkkZ49cZqlqR0LtuCRxyTwMd6uLbBA/wA+XHX2qpZAs6jkEj5iOxHetifyljZl2h3wu7HP407WOeU2mfnjFqQkDLjLYzjFX4QywPM/yx8E4NZGg6bPeXSeWMAHk+g9a0vFNwbQNZRdM5b29q9KUk1qeQ17ygiW6vmn0q3kjA2q+w+uKu6LItxcxohzuYc+lcjHen7HLC2fvBxg9+ldF4CJn1eKPPA5Y/ypU5IVSnZOx6TrF0NP0hYmIVpWBwPQDiuX+3LbtJPcEbgMordCa0tdlWeeeadwtpZjYpz174ry3XNTfUbx3CmOLoq57e9FapZaGVGlzas6STWbjULmKG3AdwcO4b73+ynt612ttrttpvheee5lkkhx5chBw0z9o0PZR615z4Xs5ZyYrYbbib5XnYHbax92PuRW/ouh3fjzxRZ6NpkTrpNkMFhx+7B+Z/qa5lds6nBGpY6Ne+INC/4SnXG2QNL5Gm2aDahI6tj+6PX61kax4kEelR6dpwKWygs7gffz95z7nGB7V23xFnbWtbs/CPhmCWK3tFFssUQ3AKB8zEjge9cbruiW2nQLZy3SBC/712cb5yOmFHIQevc0pXYotXRm+ErD+2NXhLsPJjP7uJifmYc7if7vfPtXrs1rfeJYrfT7Mr9hswZmBxh2/wCeshHb0B6Vy/gZMNDZeHbYNczMA95cqCIwOoC+n1rpvF3imOx086Foc3mq7H7Vdqv7y7k/ix7A8ACojZLU0d3sR208Om7otIYPDJGVe43YMkn8Rz2UH+VaGmwRyaU8kji30iAl5pGGHuHPQKPX61zelIbGKFtUR/tDkBLZTwi9Tn+o74pdd1mTV7lYbeBobOEfuoE4Az/EfVqjn01KUdbI6Ca/m1iYxQJ5cEJwkajgnjAx7V1OntHpGibZSsmW5j6h29/Yd65/w4pV7PToVzcEF5pcY2nuSfpXdR6Nb/YYzM+61X5gc8yHvj296UIOWrNnPkVonmuv3U8KXGoXJklvLlCkAAwsEfds9hXlOn2r6prUFuebWFi8gB4K54/M8V3vjzV5tbuJ7axQw2NqQHY8eaAeAB2+ntUPw+00wsZygJmk34K7iwBwoqZy6RIpLmldo9D0+3/sTQfMkVNoXzpg3QcZAb+ePoK8/mQ6jqNpZyyPJ5k32+/kPHJ5VfwHau18aLMLK10+4JVZWE90pGP3Snv9SAMVi6PprFJ7wxn9+3mn/ZQf0xWU1ZWOpXk9Tofh82X1jWbrcsW/yYl7ADnAHvwD713ug2MrSC4nQC4mcMw7Ko6L9B/OuW8G2wltoLYK3l27GR8dGkY559gMV6Xaqrzlo1KokeDk9z6VpTi7amk5WVh0u4QyMDhuef51i+b58ipGrHaQXAPftWzMVitn83JOQAPUnoKrabGsNsAqqXLF2x/npWj1MUynd2jyWUisWQ55x1qPT7B4FJLHBGACa2FQZw2SCM80oTABPajls7mkar5eUzCsqEpGpIB4JHapnVpJlyuEBy1TzFUY9c9M1CsiIcqS275TS33Kcm1cmaLM6SYxs6UsjY4xyfSnmQAEZA4/WmRQB495LE4+UkUxEMa7UCIMjBJJ5pUDmRlDcHng8Djv6VbW1OEVDyAC3vVgwJErscdMED6Umxc6RWgUkDPbv15pMBk4PK5qwhZYVHy/L6GqrIwDrgKCfmpxBO7H43IMj8emDVVUUjawOQc5FPf5ht5Un3/OlCBUxlScDBznH1qW2aIbGFViVDcHjmohxNI+5iSRx2qcYMiLwF6n3pjYVWODnJOR0pFDnwcn+LqR61FEv7oZHfPI/p60BhJJuyffHU1OCFZl9BQGxUKhJcEYA5UGnKv+yoP94npUzKC4PYnk4/SoJsI3y87ux6irSQ07lcgo/O7BHI/rUrfMA28E4xgdKrXErNJtjZiSc8/rVeOYhzvUk4wTihux0KD3LEq5DblIGP4RkA1WdAPuDKn14xUjMcrzkdNo7/Wk2FwSmVz2xUN3NFsSISR8uNoHBqvMjMCWyFJ5HcVIishORlfQcYqvcTOp5Xg9fpQJb6ESSBWPOSOiihJ+it1NU2l8xMhdpbuO4qqs/l3HPT26AdqzZfJfc6eCfdbxYJLYw3FTNcleI2ycjj0rMsH3QyMxyAeme1P+5Mzg/NgcGtIvQ5WtTbhuX82JiWCr1KnH51pm9dhH0Uk5XJPNclBOMM2cKGIOen0Fblv5RUHdhtgKh/8AGhtsiVM+QNASKyMWTs3jDZ71x+tSG61G4mOAu7iu9m06OSW3zIF8uMkn8OtcNrEYWNpoyPLkevSlqfO0pa36mfZQ+Ylxxnamc+legfDTT4zaSTSA+bIGIJOAAK5TS7BpbJI0Bae7dY41HXnqa9hvtBk0XRbXRrFQs8sWblxztHoT2rOKsrourK65Ty/xrqLTullayKbSMkjaPvc8sfx4xVGy0uGxiF1qe1picRWo5OfVh/IVs6zd2GnuY7CJJrgjmRuhx/ED6Z6Eda586hNHIb1CPMGSrOoJLH+LHYDoBWb31NIK0bLY6bVL5ksIPDekpt1G+dReSg43An5YRjt3P+Fey+FdLTwV4ZbS9GRZtauI2aScLy3HJ/A/KMetcJ8GPBaTXbeINacARjevmZGGOcn3OP510Hinxe6T3Umn/udQuj5IcfdsrcDjj++Rk/U+1VF8quyHr7q2MfxDeL4d0i80fQ7szavPj+2L8HiNj0toj1/3iPeuStdL06LyrvW7lbliqiG3hODIvfA9sck8Y5qy1xa6Ta212Y2lSCXCqOh7tk93Pc+9YF/q97rmtXGo3RjEkm1ERFwI1H3VX2A7etYyqXNYwuju4tUkliaysjFZs4DTzp/q7WL+4PU46n1qvoVxDHq8upWiLFZ20fl2obmWQDq59Mk59qwIozPDBaQSBDISzMRzgdS3c56AVu6npiaKkFuJTLqTjfNFn5YQRwjEdWPp2qOcaj0Ksmp3N3qFzcb22FdgOOmTwB/U1r6FAQzOzhI+pkcfLn1/CsebybSK3gmkjR5DtVd2Dx1J9AOea6n4deGpfFsjXmpmWPwxZNgLH8jXjD09EHP1rKKc5XaNpWhGy3O+8G6ZFNp/2y7Dx6SuWLNw94Rz35C9/eqfjnxss1pJZ2CjfINkOwYAXHLE+g7Duam8V6tJfItlassMUMW9kQcRxL29l/nXCRQCWV7y6LTSTfJCndyemB2Ud62lK2xnFXeoy3t2/sRLdLcIJSI1LZ3uWA3MT64rtNJEGkyIWVDNGVJjHbH3V+ueaq6iINPvNOtMbntIftEzZ48xugrS0mxD2Es8rZu7k7Yo2PKgnlj7k1mldm8dI3RX123kvYba6vpi1xfynei/wRrwoA+pNXL1ljs7txGyjYIYFA79Bn3zV02kBv49haT7OojBXjJHp9Tmo0jM+smELmO1XcR2Lmp3ZtFWR0vg6zXTdLgQnfKy8MRyzH/69dXBGTGq5C8kkDuTWFNIfKhZU27EBHoDjj+RrUubh47JjEfnaPP+7mtU0tETKNyld3BkvodgLRx7iP8AbI4z+tXY5Ajxx5+6mOlZluJE1OOLORHDwAOhyP8A69XbWNZLuSTbwAF69+tNA1pYvo+EJK4LDOO9KW3ruUHHXk00/cyRjB4z3zQx3LIqfKQaGSlYrTJuU5z/ALWfT2qlMDDzBH19K19pYbmA5+XFN8jLEbc4GPpSNoyS3K9rG3WQ5yOgq4isEBAIQjBPahIQMxjcDjHB6VYmUxweWSSuOT1NMmUrvQiUssjnjdnHXikvAdhDAMD0x3qZVD4bLY7dqUIzPjac54zSIIoF2qVYcdcsOlQupZV4bIbqRx9atvHlm3Anj1pXVQAWbIxkjNBUXYy5sq+A5Py8jj9KR0ypO1trDnPHNWZIoY5XdwSD6elRSlZoSYmK8Y56j3qGupspLYr7iXyqkjGD7fSnMrb8Hgdck06xTarAkFmPJByBTmh3BSxPPBzQURRr15xk8YHWnAgAoMDnkVNGpV8DA4IGegpCm2ZgdvbmgBr+pHHQA96rSEKoG3ANWXRizFuoOAO1NjjDSMWAz09cUJXCBmPAQxwjZ6gdKHiJ++ACeBnj8a1QAT1+XJOfSqssKFtyxnJHXdzRaxqpldIAxIZg7A84HT3prW7K5OSFx0PercSIzFVLk4wcHrVkQ7hn7ufzNNIbq2MhwWyoxx14qvNAHUEcDng1pTxmPlEyAecdzVCRslS3vkE9KFoy077GVcRvGmfvE8Csi4Gwbz94/nj+tblw4+ba2cdD2x7Vm3cYlGdp+tZzN4+Y7SZhufeThl4APetCWYEY/hAA5OTWJZ5hl2kYxzgVfVwehGM9c0QMpr3rliI8/fbjnn8uldBoxC4NxDKVUZIGcH3qho9rCz7rpTKiLuEYB+Zvr6VuaVavLF9teVIoC5XazH15H07Vsooyq1FazPlGRVvNOubhV4CeXvBwFHf61xuvWirHDEnAA313KxL9iNvGQxZtwjJ4CjoSP1rnvEVqLy3uiuHeMIicYCDvgetdT23PmYpKR0nwg8J3F/rqatqMR+xQITCMjkjjNd38TNVsLK5e0dzGggE19NG3OO0Q9zwKo/DGJNP0P7SZvJjgtyzNJyBgZJPsK4vx/rUOo+EYr27RZLq/uvLWSH5S8ajJP6rTjK0CuXmnc8wu7t7y9mu3VVJbKxgcL6AD0Ar0PwV4POq69ZWE8TOkGJr5h/z0YfKn4D9TXHxWqWt8kjYltbMbiV6u+eAffJH4CvVrfUH8IeF0tpH2arqRV5v7y7huK5/3SOe2azjbc1m+WyRoeNfE9rpemy2mkxrFbQyG2ttnO9wBvb6DgZ9TXlsM0hvktZnZri6bfKynLEsckZ7Y9ag8Zay0t8sMKqscCeUhH1yT9cnr3wKf4csxb6Df69eH5QDFFuPLueMD+f4VLd9WOKstR/i7U4tQubeys1EWm2i7FCdOPU9yTyaradBJcOgVNsYHDY/M1UsYZXXzXDOxO2MEfeJrqIdPew0k3bqQgJjMhPEsvov+yvr61iza3LGxNZ6pDpGo/bIolk8tcReYOh9T+tRwXV5qV1/oJh+0yZkJY48uMctIx9z0HXnNY+nxLc3AnvCJY4/mWI5Pmc8Aj610+kWVzq18bGxaONuftV03SNf7g9cd6UdWEtjQ8J+ELfxFqc9xdzCPRLch7y5Xhrhh0iXPRfX1716Zd6/bwWUcUcBttNjG23tFTaZsDqfReMe9cqs9vFHb2EL40aw4WNOGuG69fcjqasaE15c3d3rerRiTyP3hyPlQ4/dxKPbrVSdtBKGt2MuY57cSTXUhNzqLB5o1G0E54QegHSltk+yt9s3ma4VxEmfu7zyQPoOaY0k17dNcyjddXH7mBj/CM/M47AdhWvpVtHHFcSxAm1tVaG2DHJMjfec1POaxhcybK2ae6uLieYsZG3ux5yR2H8q6wTMk0EEYVZY13SEc4Zug/AVVtNO+zW0bupYA72z2XsKvWNk0dkbo/M7sRk9WY/4VnsdCjfUuWMY8iQ7h58sm1QB1x1q1o1kqadf3SknkhSe/OM1ato4I9hRMrApwSOMkdambNp4a8vgFlywA59BVJdQLzDdpAkbduYgDpwOAKfuYRIX5DMAfpSSqYNPgRuVhUFie5qWRVit4QW5+UA/jzV7u4gupVgu0mc5cqxVcdc8Cr1vEyIikjzHJaTHTmsywiF1rtxJJykKqo9C3WtxFw8mSC4IHXtVImTSB1IVQW+bBz71HExWMoyk5Oc5p+1mbI5Pf6VLCgcb32qd3cdqAuMkj85UU8KvfPWraLj5VAPGetVVJLM648peM9B+FWIZQqHYuN3AzQQ2LGRuDYJ/AVJuJzgDp3pqnDl8HBoBVSA2Tg849f89qBDyqodq8nPJJ4qWIKXALblPTFQS5aEgH5z3xU0Ubqi7iv0PrQCFlySfmCjHBHeqMrIJSyqdqgj1rQjXMwXGQvJHQHimlQ2zICu2TkcgUhrQz2VXDMqE/LtO8Y79BSR2+3ehO0YGTj+tXJ0aIl1O4qecdfWo/9ecIjKo6knOaGXcoPti2+Vh9vPA5zTGLtOFOeQCT9atv/wAtHAwuD8gHH1pqxFhuI3NIuFC9PWlymsZpIR85ZUAHY+1SInmMWA+ReMnvikRFZGYj5h82elP2mVNqlvKA7DGTRYTkREb33D5R0H+NMdRI2DwQMHAxzUm9YlOFDeuOdtJG6tIQ5ILHP+FCVhrQyV+0Rzh1IMe4A/hVqR43IKJnJ3c8bW706VvLVipG4HcA3Q4qrK0ayhtw+YglQM/rRI2XvFyPaP3gcr65HWpmVyN0RXHTAPJ96oXEgjT72I8Y461PZz7nBCHkA7m5BGKcdSZRe5FI5IKfMezHpWbfQxSAYBUjnp1rak8wIwmQtuPB28CnWkAdBDMygknBx2680uUcajjscdNblhhPlDEcd6ryx5BIJxkn6V0Oo6cbe5ZQ4y3KYPDDviseaMQjbnO49DSasdcavMrmTcpkqRyT3piylGDbRgdBWm0WeigDt9KrLAuACMjqOO9SojcluaenaiYUR13hd35Guih1Byot7dMAZeRWTkH09uK5uCKOezhgNwkLRFiwfIDZ75HftWibg2bQEyrLCYtrSgcl+f0waqMTnqWlsj4+TVGghW5jcttyZAOpYng/TtXa2fhS7uPDjXBDLe3mGAAOUHH9DXn3gmyl1bxNp9uI8xrKvmDtz6/lX1frGkm0ctbMI0jgxkHhcgAH+ddcdUz5yatsebaxZyWfgHV7KzlUhoY0mI6hZGCr+eGryXWJPNOg6dDuMdok0i+5MjEn/wAdFehz3T3N341itp1kiBsooxnoASMfr1965zV7OGxtbC8aILM+mqxIBwv7x/XqTUta2Kg7GT4MjtINTimvh9ojsA13Oh6O4Pyr75461J401ifUdYE07bpFO6UkdHPzMPbqB+FZ2lq7vbWYODdOLiU9PlX5sfpWLPcSXVxPJuYiQliCeuTxUc1lY1UbyHWNnda3qUNvCrSXt5IEjAHUk4A/+vXQeNxAmpxaJYtmy0oCA4P+ul/5aP8Ai3H4Ve+HsZ0qHVPEYXc9pF5FmO5uZBtBHrtXJ/GsaFRKgWU7phwkjH73Pf3JqHLSxtZfcXNCgvLrUIILJWNxKwggI/h7E/XHf610njmRInttEhuEaz00eUzD7rS45IPoCcfmaveBbd9PDXy4TUG/c24PSPP3m/AZrn9dtWE6+chDFi7LnoueM+55NS/dVzNSvIzbAyyKixNsbdwcfcX29+tdnh7Cwj0q22wy3Kh52xzHGeQD7nvVTwxp6ieS6u0Bs7GMO645kbqq/Uk1sWMMmoajeXcxPnzPkgLwGPGB7D+lZuVtTWEOdkmkWj3dzEI4nIH7qJWPTPXJ/DJrsp7M301noNjIVtLcs88h/wCWj9Xc/wAhVXTI/scwgs8GUKEVgernqfwHNbc/k2No62vysD5Rc8l/Uj/PU0J2RtbocrdxO94NmVgQbVx/yzTtx6nmuks7MxQpAAE3EBB/dGOp/Mn8aj0m1RUaeZeSdx/z9K0IF3Eu7fvXHzgdkqe5tGJdmtd8Khy2JHB54+Uen1p9xKqW7SsCY4FBVR6ngD39alT9/wDO5KLGoyP1qvfo7OkS/cx5sg9v4RVFxSsMtJz9mO4kHq3rzW3qDR+TbxnccsDsHfoeT+H61mwxxRaaODlmGfUntV3TUaSczTctENq46A96pENKxozhhDCkhAaRvMbvgDoP5flUtwuLdIn5kORux17k0tqDLMJZEwvOAO57f1p9zKzTBMjKrgmqRDJvD1p9msfNfJaYlzWhJtXawUEtyc01JAlugYABV+Vf8arm7EbEykRr6nkk+mKpGfLdlvDbc5CgZ47HHpUe8SKTjavsay77UI2Ur5khlA4VOcfU06wnZiPMjkcEd0wBSu7j5bK7NQMzFMKQg6L06d6mjO+PdxgHgmqE03K+WH3E5JAORV6CRpIvmUjPAoJZZVRsOOcdKckeTu5Hrj1qJJNx2g8LxxU4f5NuemfrTJFijDS7m4IPIHU1NIoyoAAO7GeuM1BE48xI8/eGWxztqzEY1+Ylhzk8dfegBTCsZyDg+nqO9RzYVSUycYGc0yS6MjmNcqeh/wDrUisEBBG7I2jPrQNXB1Jk2kHafve5odGiG2EFgV5JHapV+bY8gG9l5x2qMS7UII2r0bvxRYZFPEEwxQsq/Njt9KiClEV2XletWI5FLjflQAACTncfbFLtBBZx9R7UFXKoZHiyAVQDgevrThjYxBCkHg+vHApzLE48ttxQ+nGKQRxK21BxtBBPNILormI7i64AcfMM96psBuIBLsG25AxV29IVGcYK5Xn3qtukALEDcDk5oNYvQqTRElt3Ucgk022gKrlQpLA5GMgHHapA4Vds3ygnJI9KY0wUcAhlPBBxmplubR2IBaeZuNu7F1PzKyk5rQRWijI+7CeCo/lVVJSJTLDH8pB3Nk8/WkSUzTBckwMcfTnFCuU9TZaNljIjmVu211PSsy4ae2lYxleD1B6VdW6/d5kaPzNvCg5P/wCuqV6HfZMsuHxhtwyzD6VZlBa6jtbkWSxiYFDPnKkdfeuacySRPv2ghuQF6VvPA1zHEsCjCBjtIwTWXIqrlST5h4AYEfLUyNqdkrGepOAGyDUcBXcyMc7R09KfcAxnbkHJHzD0qOMAOHAB2kNtPQ0jo0sblvHMthCbN4kJLF9xUE+nXtVPUTOx2XTBmxn5SCP0qdL2PYC1nbnj0P8AjVS6nWWRisKRDA4ToferOaLtLVHzh8J47b+1JNTiDSRrIqkuQjCTPXj1GT9a+gPFN+T4eYROqNclUWRu2RwPpXzrDp03hUnTZdrSSEyCVejxn7rD8M/SvcXggu7bTPPcv9njjmyf7ojJzj6kVvFtM+fbuePeFLe7Z/EkgtXYzXaAOyHBCOCcflW78RbcyabpBeJDHtlhYRnDJ8xIz7fd61y+lX1xBdahPbXEpiuLmeERtJgK2Dgr6EnHtV24uLjU/D7zO0ivAvmyxFcmVgMkk/h0+tT1K3dzz7Q5XGulnyTHHKME9AEaorBMWqkrnzOT+Gf8KuaVEDrsZcFRcqeRzt3cfzNaVrp5/tZLXbuEb+WQOfu8f0rKbWxvHc6a7T+y/D+k6bEuyYoZ5GA5Ekg4z7hf51zmnWW+7iTAZM7j7gHp+ddP4pX7X4jt5duI3AfYD9wYIGfwAqKMLb2V3Eik3TgKoxwqD5mP4kgfhU9Rp2Rq2tyXvIpJMLDEnAYbQ+Tz+o/IVh36CbWYHcByyBz1wCST+gArZ1JWisbW3iyXRRgjB4AAz+eadaWhmuPtcsRXzwqKDzjnB/lSm+bYKcG2i5FG9rppgQY810kkz1yRwPyOa3NNhSwhSPdmd8kE+o/w6/jUXlebcq8iBonfzOvp0P5YpVjMweQZIDBQDycdz+NYvuenTw9ki9pRFq0l0oCuWaOMkfxdz+Fasf8ApNxbwscqi7n/AB/+tWXdgx/Z7ZABtG/npk8nNXLNRDBPOQ5ZyAMf5+lS5N6M6I4dKNzVIR4WCHZHI+Acdu+PTgVYASafamA8oBf/AGV7CsxZd8aQHIVcs/HI/wA9K2tNi/eM5Ukkcj19B+FVuZOm4mjHH5uY48bSQXbGB/nAphhRpHIXAc4Axk7RVtVVVKt0Ubmx/ePam7fJjJ3nzWG1f9kZ6VZmV3hVSpwfKU4X64qe3SRFjHOSpJ+ppzwk3cMLkbUXcxzxmtiGBY0SR0ABO854/D2prUmyQ7TwFQfLghcLmo/Jw7MzDEjAfUDtUD3imR5EzIc4CoMAfU1m3s9w0gXoUzlVPK+nNXzJE8t9jVn1SGFSZvnlVuEU8fnWZ511qM6GPMUXOMDB5qvaw24Ul2M1wDwqcgH+VamnQTocvtjjVsg9T+dTzaj5VFX6jreD7MSjsUjwMYPJ9qtMyzKREHwxwD0zSiCOSQyYyzdGznA+tXFgYMI0AIUdR2HrVmUmRRqVQr0AOCe9WoRjlumeP6U7Cwq3BwRxnvS2zqUGOATjntTIuWbZAS2eMDJA71JIAyNuB45yPTpUcTkkkZ5P4EVM6kHaDhX+8Pb0oJIYHDMzj5VHGOlW1XMbjI5wv1HtVRCFZQ4JJz1HSrmdsKKcMPTuBQBGUwNwID5IBp8afuySW25J59ajY/dyMrnnJpk7OuUUjYRkZP8AKi4WHrPiV0Rh0zj+dSpGJIztYYzn8azYY5Vn4bkg/N161dDSpGM4Zcg56Uajsik+BGANm4E8HqTV5Edtgyo+QA8dDVW9gVniYgZ6gg96uDLIjDqAQccc/WgbZHGBlQNuCME+pqFnWFUaQhVLFetQ3srRwxkqclzkf1oWBRGAy8k8jqTQMhlMcrsi4Cg9QO+aYzA2427j8xOevNTzbFlYjqpBxj1qsY3BIDqFXkgdOaDWGxDMgaRBuLDdnOevFR3KBWPJKkD6g0992Vkb5cDPy9xUE65G9HJ3MQVpGsdySArteORQrOflP8P41WvM+cFj/wBUD0XgHB5qwcOMBhGTxn0/+vVR7cxFVlMhywIcnAoNEknctwxrGsog3LkjPtVg27szK++PaOJAc8f1qW1hGWRZHyygMAMhjTLeN7l0W1Lo0LEMjcKAf/rUzFy1Fjtja2RMsxkWPnKrg81hT+a4+0O7MjMdrA8gen61rR6isNxcw3B42/wtkE9KyhHdxwzb4mCKfMUjG36UWLpeZnTKWtN/GwcgjqcVWjTdtdsKSO1Wrz5IUj2AM/7wHPA+lMFrvIYFux6daR1NWVx0KSZwqlh0HHU1auo0UIhjeOXo249fwrQtnSO1Rxv8yFXO0LwSf4s9sVm38yP5SxszeUgQuwwW5J/rTOZtt6Hi9jNb+JpdEN9bxqqKvkXCD5TyVaNv94g4PY12erTpbeFjPk/uA1rKSQG+UlR+mK8V8EeKPOsnsL6QRxlz5mxccOQd4HY7gD9TkV6rNcmbwzfJcEPdApMdy/JIwGM59+DXQmeDZxPHPE8kVi6wwqs8eVuJVHG7Dcg/57VoQ6jJpt3CBI1zZXWQm7o0bDK8+o3YrI14rbeMY7VpNySwxxyZOQpZf6ZqO+aWy06C0nUlIUBde5Un5ZEPfGP8azT3uXayVi/ZaO1jrEUhORCxxk/w43p/L9K2yIjqsupwDCXCrIAegc/fH5/zqDS7jdcW7Sv5sZURmTAGTn/J/OtG2hKM1oMbPtO9R6ZGPyzzWLtfQ2XmVULyXJmZt7bM47dMY/DFWHeCXU5HUjy1RIi3ZixyxPpxVm1sHGls0jFdvmRsQO/+TWQPksZA5PzSqWx7HGPpSem40rm3Z2z3NzcS5UeXH0PY+3511enWkPkacm3lsKM+xJrntOV20+UKPndoxJ67Bzn+ldVpygzJuIZISdoHrj/69Q5HfQpaXYt3EkE4EallClQB2xxSLEq2qFCVUtjGOT3q4kQmlnUMQYiEx9eTTp1EdtEjgKQfx5qXqelTi0rC2tv53nSSIclQBluc1bmjULbQ7gB/Fx3q5bRxNFGoA+diCSfapY7UELhVZz8oPpT5bKw720KEMaG6JZcqWC8e3Na8AaOIOpxLn5R9aprGIUZW6gkipopPMnXc4UHqp7UkhS97Y27LZ5e5yTkbue/p+tRxsLibefuI4Rff1NVDOZfkVztA29OgHcVetEBlcKB5QXA9quxxTVtS3b2zSP8AaADlzu2g9s8Z9qkvJUBEZAbDfdPc9vwqxdyLa2yojLudeecH8v6VnzBRal32pn5mP8RXtmra0MlqVdQvnhlACBtv3VBwFP4d6pxxSTuMuxLHDBPlA79ahhR55vPlyII85z1JPAArct4BEsch/dq2NvYn6elRa5UnyjkSGG32W6mRh1CfKo/HvViHfcSq5iPI+gH496lt41YnCqu4kFu31zRNI7SgCdXIGMr0+gNUomLdxbiV1Voo2RCTwS2cCrCXBNq+WUBgOR3rGkglZy8a5VDn5hyTWhaRyOm+aQ4bgfJ0H0q2S7F1ZWllAOSoHAzmrKIG2NggMMkCqsfylT5pyAAAAOlPjvGD+WPTYc/40EtFkymEKvUehPSh7ti6kDAbuOnFVldpZWXAWPHU85xU0SDyd3DFRxmlYViyshZGaTt0zT0mRwoOBjtiqCtI8jKWbdjPIyKtIxYKEC4HOAO9MBFYlmUqRz37052baAcY9x0FJGVDkyMASf1pNw3NwCMdRQNEiAZfaTv4xinT7UwGP8RHJzUHnhXRs4B9qjumZYGYEEEE880ATRSv5oT5dobireMgRqduVJCjnmsmJWdQWc/MML7GraO6DacfIcZHGaBuIt1GJsbvlUAcD270sjFRu4KsMfNz35qGWVmiYLhWJI9iP8aiR5FZFbnjhccrmgaQTASSFhwM5J+naq4bcSvHGOPWpLhxtYsCBvJA9abK+9RIoX0OKRrEjkYAFsDA4AHY1VkPlqjKQA/Uf7XrVh2wmAvzE4OOcfhQS0kudo2hecjqPSgtECFVXYDwwz8wq3E0ssflswZsENnsMcVCIjkgr93G0emaGE5EuE27h0IyW/KnYbd9SnayzreQtG37uNsH5uuePxqfW7h7S+jjtj5bSxlpAOhPbNR+SI42VztwySZPb2HtU19GbtTcMyswbO7pgfSmLTmuPtoliAVYI5NwDFmxkZ64rL1dbu21CSOcA2cyqGJkAGM8ECtvTJ7cyIygoGGDkdBnkVo+JNNt9SsV8wlBCQyOvJHt9KDOdRxdjnbuxiS0UGKRpFAKMPuEVVZDFGF+/vBZcfyrVimeSOSxmyGHKMeMVn6hbqbhZYlMcUa5O08ZPHFJ6G1Gbasya1kL2ixpIkZ2uHRmxliOKytSbaYk3iR0jCyOvQnn+XStHLi0tzBaRSuGYOSm49eKbqCpJbzeZBFHsiDkqMFXz0/EdqBrRnw5ostuspa4ZxKCMAHG8eh9ea9h8Na7Na6csF8jNbTKYpEJyrDqAp9uwrx3xJaC31V3iB+z3IE8J/2W5x+ByPwrW0XXptMie2Rt6FA0qNyCQRwD24rRtniyi2jQ8XaS9xq893aqXnQeY8Q6uijAdR6YxkCqelXovrG306/kG+I4gl3ZK552Mf7p7eldE+qWN7ALrDLhAUljfEkJJ547g81Ul0e0eFprG4t5InJaQqB8uO+OoPTjGKmT0HFvawuiWwt7t4riPbASFYY+7/tD3rrJVWOSMhmLIwDg/wAPPUexBrL02BriGNLohZkJVJVwQ3cZzWmd0bRRugOe7HO7iskjZbl+82tpcixk/vLkFh6HH+ArlFDFb23Xcdsu4MRz1zW9q1ybfeIP9UzqwHUjj/DioYLaSe8lmWFh5qBgAOM9CfyxUyvI1or3jY01/wDSbdHf5dgVj6oe34ZrqJoPIvblR8iluQB0/wA4rlLC2WJhvPzRkEg9xmujuJXupWJc4ck1LPWowsl5mnp0kTZfOTISGJ6k9vwqrM7Xtw2BtCc4PLZFP09zbvE6IrCPBw4yD7VPCV+2SyIuC3b3J/8Ar1mr7HfycupsQwq8SblKjk5IwelW7aMpDCEIGRwSMmoLEF49rMeOvGTSwXAgsj5hZlBwmOp9vatYnLO45YcymMKXIz+P+RVyKygZVDEpMfbqKraY8xn82UgEHnPIxWiEH2mWSTOUQfKOCeecCtErmM5OLsV/sRDPJuxG3yJk8kA9a19JiEb7pUOwtliehAqO6gQW8O2Tq/lsM8gDk1fWMfZordWChCWO7sOo6e9OxyzncZeooXzfmLnLHd2A9a5y9vEu59pBMWcKB0LVoalNLJH5OWwT87E8+mKpRQrbOshG5yMKo7fh/jUsIqyuy9ptibgMGIUqdwB4AxVy8EKFAHJaP7rHJ/KqsTzs7rIqggcMSdo9gO/1onG7IcncB8rHj8hTTsjOXvMhN3GZh5sr7QcBV4BFTjUlDHy4yiYBXapOfwqCGJtpeDys5OWK8mmme5gYeddBV9FTmlzD5Uacd8JRtUTOSefl24q9bSDaFUKqsehO4j3rnRcM7KIZpOnzZ4/QUrThQsWx2bPG5if/AB0f1p8xk46nRSmFA2+RVkA4weppiXdujeWCJGI6AZ/Wsi3sZnR3KqQSBjuaurarDtCndkcn05pp3C1kX1nUjaAM+v8ASpTMkibGOw46+9V1jIOFA69TzUkY5O5VIA/KmTYmTEUo2qSMckHOeKc7Z4UZHBH0qKB0QuyNtJPQ+lNfLgfMVU8hl4oBIe82V+ZDnqT1oSRiUARlOSG9KrZVghLMVB+6f50/zWijIQkgjoe1IpImkjYopL9OopViQttJYqBnb29etV1ukRWDN0P6ULP5ikxqwQrx6UDsWWmIjX92Oc9ulSkl1id+wJUdc4rPFzt4yVIHO7+lJ55ZgY5CVGMEjlaB8pYZ5GjIYAsSW2+mar3Uu2ZSzbGOFLE96mkIlkV1PT071BPHFMhkk5IcEt6GgaQCTB5YGXpg9qhDujow2iIHP157U5cCcnnPqasod4VgAGBwM9qEWhiDzHZ422+o71LB8xV0yMdWJ4NQtu8vzOAwydwHaljLPCxiwR6dOKYyV3maUsq/yxmo1bdJulcFogckdz6Zqa3mjLMp6A8N6VNGyGOTz4fLR2zjGSfSgV7GdczGayJRF8yNgx9CPSm6mY2tWaElJNqjaP1zWk+yKZ441WKMpgnGcn1rmNXM9peDYNoxv4z6UF09XY2bKVZlgkjXYVATYRncem6uikZ47GIW4SR1wGVumfeuEtbwrJbFGG5PnBfoK3vtE03mTSPtRHDbI2xn3oRFWk7ly8t1jREaTPmNucehz19qybqES21wFLBCiuNx6npT7q/SaN5HUiJQFZt/LH0FV52kmECHI3qF2t0wO9FgpxsMt/s6/ZmVJJJJlYlg5UAqOnFUdVVNsTQoY45E34JJOc45q1GsEVqjPJcZ80lBGQApH171U1ORZpAweRhjBL4z+lBtF+8fEX2h7iNUkkyltkx7ueCelQQM376YgNhSGJ9TxUKNtRgD1qUMfsbIOjOM/hWtzyr3NbTFe20ya8jdCm5VGeRnk4IrUhaCdra8hCKr/fDAg57jI6mqmifZl8L3zXUx2faow8SjO5drfkc960LO1sreGFobi6kglkwo8oYB9OvBrOXcE9TpNFuoFmCbW+zMQSe4Ix+VdTq0SlYm5JJBDE/dBODj+eK5exjgskgvIplkt3Yo6PGQUPoa6m23LNHby7Wjnx5TbshjjkexqEUjD1tJI4xkbWRgvXnjoas+H2EUsIuH5YYQk/dPv/nvUetrvDKOfKyCSeKXR4CZEkZS78Ej19KxbdzpoRNeSQBgD8/DKSOO+RWzaxkwZBwzLnPWsid9kJZlVWVsEenP861NKcskeMFQCME449qlPU9yMVZWNuBI5EBjYnHByMVftYo1lJwd2ARVA+UpDbm2n7w96a19/pUSITtc8E1WxdnNWRuOWj+ZQckZPPIqnpwfzoopVO133MQegzVq2RXdWdyWYfMM0tpaqZZEYHcGBU56VSjchtRLqn7MkewjBY5ye2asPehZ2aLBiCgow6/jUEsYlh8s9AcksP8APFMkVP7NnEbKrod2M/eFaPQ5XaW5bS58/dPkqM4TcOG55/OtSO/ia3O4ZIGduOXPYfh6Vy9peySGYRLujABIfoD6itSNljIjdyU2jO0Y5pxlc56lOw1riZ8/IW3HJK9vbNOBIRyxWNMAnux9MVeeSLIJJREGF9Oe9RF4RENilN38bcs2KlKzIew2Hc7lmjyFBHmyH734dqb5VtGSzkySNjn0o+0Io33Cu+OAdufwIqIzRtHvWOWQ5ztC7VFU9SF5irNGjOIrhw393qMVH5seQGlWUnnaYwMU8RtLgx26hs8736flTxZt5mZ2DIOCI14qbCvEjGWuGUyRrGDtO0Y/lWpYCOFtpQSZ5yOv51VhWOBwBgZ6gqDSvIq42xMB0yU60WtqS1c0UmmmbhEjAOCM8kU5I2SUhBk5yVY1RXUIkK5XZIOvH9KmXUZGx5ETNxnMgxVXuZ8rWxbXzRsyFHbdzwaWO5UEbsrJk8hs1DHK7/NJIdx/gApQu4lXYLnJApg0WpmLBcsSD6CmoXbG3JA4we9RTFoEVhIo2joDmoWllK7kywHOenWkUloW/MccBBtznHWp45GK8BSG/hNZ0dxKdo28g9akZyytvUjHcHrQNofMQm3zVKljzjFWYsKg25JOeDVJGjGQ5bPVd3erKZXbuUYPb3oB7DLyJLiMqzjbjOB2NNto1W3OOWz19qXzgZCD8jKdwAFSNJwOMEnk+tG4XYsuBGegXoD6/hUZO0EKDg4PP+FEgzkuoKY4qKSR/wCFiBjp1/CgqKuJICJGwwbufoaXdhVLsFXJOfUVHMTKu5VCkEZ560oRThmK/L0I9fSncvlaFimdi6r0AwvPBqa3eNJXVz8xPG0cfWq80iqPmHXv70kM0SsysACPvbTnFLmTHZl+FpIzIxYHHXaO1I900rCNRwVxuU9PT6UhlLxOwYOF4Bxg1A8nlxfMT5fXGKehNtSwcMoSTDFAMq3U+9YOowK06mOWRuOr+npV1nEmxn80K+ec8nFZt5JtiKqVbg/hSZrCNpFe0kADiRBKxGF54FXbdYdrhmbcBn5jwKyLMCKMrnJBzmleZfMy3IBxiknY6JRujQUvJslZYxbrJn6kD0q1PO940twzOpUBY1I7VnZaRRFEch+SP7tXoCViRZVymdxyfvf/AFqpMwasaUZYQxpBLFF8xLhsZY+tZWpPLuXzpY5GA4KY6Z9q0JryBlBS2i3E4y2elY+oSxyyLsiWIDsmefeqZMI6nw3jgVIhQxSBhhsDb9e9Mzk89KlVXIKouVPHSn6HmJE9jLJCXERyr4DowyrD3Fdb4dIlDxJGRG/VOsYYdOexrE0/SVUx3F9JHGG5jhaTBl/+tW7p04luBG0iKDwsaLgI46cdKio7aFK0tEdXplvJaxXDyRrLE0f7xGYDI/vj3FWbWQw6d5UoMsUfKSA5KnsSaj0yTbBb3cSJIo4ZG7jOCDU1wo0+WWME/Ybgb4267FzyMe3pUKStcOViXoL2yS8SPjG4HOee4q5p52QfuRsCEDJ71i3RwkckTo+D8si+ma1LGWQphvlPfPQiolqdeHdmmy2VN2GLN91geO9X7f8AchAFyDzj0+tU7aEDeIyQM55q9GjeWVDNuzxk9fTFZPc9ylJSSRqQ3Ie0YMcMrHn1qxarGGDsFKk5Ttg+lZForESDJKHIx6n1rSig/wBDQKCGHJHemndluyWhtaaxLsWY7zwAf4fpWhuPk4BAfJBbua56CTdIQhYMy8EnvVw30rW5WYYkQY+XjcK0UtDGUL7mzBIzxMyH5o/vbjyR7VQvJhEAI2BlI+Vj603zgYopg5RtuCGHUVniZDdzBInRx8wbqG/Gm33M1T1ua+l2zuspMgBwGZTzmtSwuBFO5kQlmOWY9PcVz2m3zW82cKBL8pyf1rcEitAJfNRiTkg04vsY1lZ6l24eEnK7izHKqFxms6eS4JzIfKQcg9KkjNw22beu1gcluePQCi4hAB3SKxJ71bVzmSsUPtFxGN0aKiE53ljk+9WhqMzQFftDMDyTtwPTiojZx5DuxlkHQdhTfs5lBxtAHTbk1Cug90nS5VuZi52Y5HH9ahW+lR3NurbHxnAzViKwf7zQguDnLH734VMbZgCxfaDkbUWj3iHyoS2WecMdzY69QKnihDqFkZ3A7M2c/lVRMR7ciZtp7Y4q3FOY22nzxk8ZXNNJWE3cuwWqKfmGc8jjk1pYBBUJsA6YHasxJ1LjcxyGxkcZ/CrL3EasRI3AHXdkGqVjGV7kqDytu0YHcj/GiR1IyzAqexH86jZg0W5C230DVEWLABFAPTLN1qhkG5/LAU98DC81a89jGRGvIGPm70wlm27gRt44PenDZvPp/s1DdikPjZgAWbkjO3FPZtzxnbx1I9RTYgAoyNwHTjmnO0ZQBDg4O7n1pp3ApzlmfauRx69Oe1WLeYxqFLluO9OkKMUZRyOTTlQMm4EYPAGPzoL30EZTIwJyDkcj0oEzEMo+bDdT2Apsp2goMj15puU2AbsDqCDTDlRPKFMe9SWbHbp71AknmJlsqcYBx2pwYRICCAT1+lMeYsCoPQ/lQCTT0HQj5mV8DIyGBpXfAcY+UmoxLt+V8An7p9Kr3FwFJDEAms+Y09SUzK2WIBI4IqN2IGQMHGST6VBhnRWhYYB6DqaRps7UZQrgYxjrQaaaEn2iSNQW4RsZ96cbo/MrhPU59Paqh4IDkjk8VBIzRyMVIIHA3elMfKixc3TeUNmT2Knr+FVrx98CDBDDtUVvOpfdtPy9m7052+XO0EA8etNtMvlsQorlAWXG49aZcJhtvJyO3rU8YLSL1496r3WfN+Q8lsH2qSk76EsMj/Jncnl9Ae9XoWAZRMC4yMrniqbMGQ4yW6bqfAxQklueCK0SIe2p0Ucf2lP3WnEx5xuM2On1rN1lEt7hU8tYS3O3fuzU0d2qwW7yLIQhaNiBkEMP51T1lwssUS78xJtJdcE/hRsYJNSPhxevHWr0RJVBOS8Aw5UHGRnoP5VSQZbFaQhJtRs6htpPoM1d7HmxWhYuZJL2/jlbCbR8kYGBGn8IHsK6yysfOPmBCrgDlRwD1wa5yygVb+0E+Qu4rI3qp716P4bi2xxrIowR5RJ7kHg/jisnZsvZaFnTIGhlMToBbTgOH/unvn9Ks3trMLT7PKymTfmFzjCn/CtiOxWW1nQZUx/vE4556rVDxJItrBaoP4wVXfwTx1o5Bepx95HLAWMcbdcuT1I9R7VpaUweLcHBDHlQO3tVXVUIMbKMkdWJ/wA/lVfTXkgilVieTz6is5bm9N2R09vJLjDAEZyDnmtFHcQRgqC7/dx2FY9o0zRozqzbemflrRs3Msh8zlx/dPT6VB6VGptY27WPYi8Kdmcc849KuKA6k+aBkYA/wrPtHDowLur9QCOamjm2iNS3zg42nnFVodPPct25DH512YHHrRebRs2HGBuyDk5NRh8I8nVx+tUbbfJK3mHaWx1PHFLbQaely9JcOQytExQjqpA5qdLr93kj58cds1RucrjCjYGyxU81Ue4k8wLjdtH3gelPQJarQ2xG0koYsefl28f1rcs3VkVpAcLx061haWyToFlyrBu+R+Nb0MQSQrltrd/SrgcdSfMybDOcKCAf7vWpIyFUFFLAdQ44NQNvjQsj7segp3m3CombdSnXJPWnc57lrcdo3RBOvQ9akScp0ZNoGO2az2vWXgxL1wFJOR70CRAoJCjnJLj/AAp81gdjWM9vLhWeQ7R26U6EwSsdjmUf3WJH4VRS6V2VYZYhntuIxVpZpkwN8RP86LmTQ9oVWRyqtkeg4pzjzFXevlsOPrVeV5v4UIDdQpzmkjvzGuCCDnGPSndCtIkdFl+RscnqD2qeG2GAUydoIOapySrI5ZcFup9qsQXTcqoyo64PNLQcr9CQ/ICF9eo9PpUlvKhOBk8d6YxiuGJV1z04ODmqvlPBI2MyLjscU0RYu7iGbDDI7EUjhlILbcjsDVOfzcll3qeo5pS082P3rBgM59abKUbFkzNzsVs9Qc1mXM95HcAptkUjBGP5VeiRwrfOWccAn1o8uWTAZV3D1FRKN7WNYySH2t8rgK6+U3T5ulWRNu2q/BHIK1UEcZBDDB6Y96cke3hGyp9e1Jbgy1IGk+dhwBkgGo9ygDCgU47hGOflz19aqTkhsBxjOfpVNDi0yTzRkkjI9PemmUiRipYgj1xUAc/M3TBxSFs53ZPuKRRPISVyxGTzio2xKfnALbe3NV3cgOCrEjoaie4ZAcoST0bpU81yrDRI8c20D930xmmzXO4kOx45BPaqchaSXlSG7c5p3mZXOM8496GXE0Wu2lUF2BIHH/66rzyqsTAbueue1QLLwdoUDuMUxmJZWH3Afmp30KJU+SNDGBgnJwaV16bWwxz8p71RN0wlIUEDPQVZaYtj5QrAZBFC1RbehMpAdTjBHWq8rguAo4PP40+Q8LhsPimIuCMnLCq0JTLEDMoyo6etEkhdh8wLeoFQs5VDyM96jSVoWV0Yh1OQ3pTEblvLFd2EULT/AGd4mY4dSVbPfjvVHWbgO8QRjIsSeXvYY3HOc49KmspZLaySWfUbmLzWYiNIwe/J6+tLqlv58RcXsly6xCYeYmMpnHB9j2obuYLR6nxPZqHuFVuh4/OtiG3cW8hHG1+Qe45/wrJtMGRM9mBP0rqH3biqAAM20nqcY61U3pY8+GxPaxRnBKF5MZJPIx6V6R4RjWWAWeMuq+ZG3dh/9auH0qPyJQz8qjL1HZuCK9D8MwCRI5U3K8Z4P6j/AArNLULM7KxszIVYKBKnJIHX/wDXXAfFm6VbazKJhYZcsMZAJwM16ObtbeJpNxXaMntt9q8h+IOrJdTzCJRHbzqYyH657Ejtn+lbPRBJXdhJQtzGSOFzyo4Cjt+OaoyW6rICG2lTtPvWJpN/cwLPbXn3opFWQZ5Cjv8AQ54rqhGs0CTBV+cmQsRgY61hJXHF20HW86EMWJ3gfdY5ArQsb2KeQERsHIwDnGcVjTQeXiaMs+/qSODzVyXNpdSJEFZVHzHPc4NZ7HbSklob0F0VZ9hBbaTyadaXchdjKBzyW7isy3KS4XBVTycjJNWHl+URbSWVQOP4hmhnfGV9TYiuQQkQOXPPQ9PrT7d9k4EmSAWIz0PHSs5XmtoF2KCCQzZ/z0qXO+TdHxtweTx/9aiw27IuxN5kBfr5gOFzyKYiMgO1S6ng8dKv6fZh7VJkCsS2eOxqZk4kjTZu6HacH680+TqYuuiTTwY4g25GUHO0nk57e1bSt+7OUZouow3IrnILpYpAlwFUL1LZBYfyrYgncNI8Z3qMY2nORVRZzTdzRDDbsjJIPPzD+dNhjmZyvlgLzkE4phkjdfMGV54Kt1qUTsAzTOMdm29aq1yVoibhU2NbhCfXnNRyMq87Bg+gAqykjSpkLuJGagaBXZ9xcYI+70o5bDuupHGjMRuZUX2qTa6LmPBbrkU9rT+LeG65U8GmM3lEFSQp7lgRRyi0LaThUJZOev1p6m3mQbXZJcfxLwaqLJFI2BtGOu1iamkhicbop5FbOCDxTsZydxs6TQFiiDzCMhx3oFw80YDxJFKO+OtIHljwqSbmUfdPOaZJcO4KPHtyMgpwSaaEhJ/3pVtpVz/EvtTob25ReGEmOPm4NJHHgIS2fXjBH4VNDGQ+Yih+tNIeg4XE8hJjiJb3Oackl25yQisBg5p375XLIpJxyM0kZlDfOAfU9DTAlVZeBPOxxyMDGKfgqSVLcnPJo8wlQcfU4pr4OCpyPTGKQ7CfMHJAyCe5ofIwQAM8mmeYyH5VHB6E0y4lAXjA5yAe4qbFp9Cf7Rvi2cgrxz3qGSRA454IxVVpCVJJ+Xtnn9ailL9GUEjpzihspRJ5Cpbng565pGm2xkhhVFrhlb7hAI5Of0pEmJHBAz1GKgp7lr7bjqOvvUM1zEEHmN8p5qFmIyA+OM81DPyg+ZSexxRYfMWI50lI2DaQeMc1I6hgGX7y9cVj3TMIw0SopBySOtRJc3DD5Bk+ooem41d6o2ijAZRlz7HFQAv5mD+PvUVlc+aMSLhu/sasgLI/XB/Si1yrocFDZzjHbFJnAZSc8cUpVRjsDTCQPlIy3XFUh3uPaIhSoPJ4z3pkCtyrcEcZNSJJltr8e9OzntkYoSJvYjYZbpk9zVKeTbNg5x14qxE2Q245INQFdzBsBiaopO5rabODpwOoNa/ZizeUJlLNnvjb2pb64miMi/uWSaJQjxDA8sdl9BmqEU9q1ultfwSSCIkxtG+0gHsexq5cAssDbBHB5WIlDbiFyep9c5pWM2tT4208n7QoAByR1rrkhAOSOTKuCfQrXI2B3XEYDbG6Bu3rzXaQLutolcnGB055HvVTPLT00NqOwVbiItuCyLyOxPevRfCtq0Fuoz8wwmBzznA/PisW3s1n0+KQIGMYyM9eeK17W4a1EZhKrNIwjBfoTjBfHsKk0UktzU1w26ZWe42GHDMi8l374ryrxVq0FwZUZ5J90gAZU3hdpJ6jv2r0bUNNSQMWlfyI32Nk/vJCRkknt+Fcbq1naJqUFrb2yIEhZ842cnoxNaT2JWp5xdXEkbjUFkE8ZXyZATy47AjsRXZaTdpcW9nCrARzWysq46MCQawvEelWwE1wt/E91wGKuM/l3/nVLQJ2ezeKSXD20hkURnGEY8keoB7Uo+8Zy0PRZ226WAoYlfkKjnHvVRA63irKuIZBvGO/HIz71Qtdejup1mQbLmIhLmJOVlj6b1/nXRXMMEwVLJtzBRiMHnr1FQ46lRmS28TxxhWcRx8kDuM01BukDHeR0LL0z7mljlgLCKTYkipyshOf1qW32206BZXEMnXPKn61Ljc6Y130NGEjc0UrZzwVPBH1q1ZqbdnSRVAKnBbkHFUrqOJkDuWUvysqZZP8RVm0vyYWhuVSeIfKZEPIFHKX7TzL4aK2ujIqqsMx6gkAE1PMkTkgyvE55xI2QfoazLCa3kt3gS5AVRhhgEr6cGpkj82PY86nJyCqjDY9uxpt3EmuhXvYwpPnKoUHrHJn8xTVlsUjjZLmSIkbf3b56d8CiayEUoYKsi4yV37h+RpkU9rNJt2C3kHCnGP5UJdUVe+5NBqF3FJttZpZVx1eEkGtSLU7hyFNpOoP8Ua5H5daz4gygut/EYRwCecUst0sVwJnmDhjgiMnA96XM0Fo33N2z1VN/lSRSiQn5SUKVeF/ADi4U+X67TxXMPqFoq7STJ3GXzmootVnVCLVDGR2DdfzHNHNfcTVtmdd9ttp9oiO7jAx3pnnmMk+Wgx0yc8fSuWGoajcHcbNUbPys5Cj8qvwS3cx/exWx2j5drkmmmHK+xsu7v8ANCGB9Qu0YpVeY7SJmDdeBmqSTzRcq4IPZR0/Crizu6jluPbFOIi5AmV/eqCScgj5SDUhk8tyrIzg88YJFVUZmChmJ5yWPenmbHBjLgcA96b0F1HSSLMQBIS4Gc9DToroKoEgII4yBVCWfcchHGPQcj8amtrmGcfvGVgByQOc+4pJsdjXWdmwUZWPXPrUrygkM6lWHtwayo5fLPyKPKPcf4VO11sCohLK3UHg1VwsS/aTu2owKnqPSlMx28/hiqbG3k3FXKP0NQrcCFwrkOByDjNJspLQstctG4YjkcnimXF0GjAjwB6AVVnu1mJO3ay+h/zmoDLKil1RZR7nBpD8x5ugkmzO0k5CseCPQH1p/neZkMcnt83I9qyZbhXVllTdG/VTwV/xqqt39mwhfzLfdgP3X6ilYOc3ZNsaLuJ+bvVcyqFyjnI/SqguJVRfMffC2CG68+9SnaiuYznd0zzn8arlBSuyvdTbh99mOeQR96pLd/MZBnKnBJ/u/wD6qrzs2dsg2svQZ6ioIJjBIUZgwJypqRqzZrSgY7FjwrHpQiRAEnGW+8B2+lRecm0MMbTzlee/SoUdlZ2XkHqB3x7UWK1RYjASYOepHIFWYDsBJOVzjntVRSk0ZVmXcVJAzg/SmpKYo2jlBHHGOc0FGosgcDbjIPNK5GVJwc5PHrVK0nxErso2nJBNWlYGNGG3BaiK0GFwQVBBG7rTGleOAKW+Uj8qZc8YHf0odWeHCcsTxVbCuMUZjyDwR3pkZKzqkzNsJyQPvbfap1+YN2yKjit2lu1CAPISFHPc1VjWMi6E0lmVg+oc+ydqtXEkMptxbeb5USBMyYyeSe31pFsbNWZHvsSLwdkRZQfr3pktubQrHuWWJxvVwPvDpSZnofGluQIzxg7h83t3FdtogYLAFG5T1GK4uy2tHMh+8R8tdv4VUvHbnO4kFQP9rH/1qUzzY6o9M0p3htYzGGbYPnUjjnv9Kfpkhu533H5YpBEi45AHzMPxwBTtE+VCSN0bLuJ6ZGP8aq6qk9lNbQafKq3fSeYniMdQx9z0qldIXqbPi7VrXTdLEkjZkY7kjA+Zj7CvM72e/vJGnkt447l/3jPIxbav93b06V1F0La5ure0UMxifzrmV+Wd8fKuf1qHxDGvkG0hcCRiGZwMFVGSCPqeKmV7lX7HHNarJ5InuYLdXJJUwoMDpz71WtfDrRTG+tZkuooyWXyzscj2HTFaFpaW1rJI15Gr+co3SONxz+PSlFvbiQfYUaGTqSj4AHb6VKlZkyV1qYdzYuVae3WSNuWjkVSNh7g+1dJpupXH9lpcRRjz4sMzBuMHgj/PrVFvt8cmYx9rZydxU9cep6Vf0vUI8SZTybhifMhkwCrdAR25FbRtIwldWZOfENvdkG5MomTHylPnX6H0q/Ff20zRqYleF/8AVyFtnPQ8evtXP31hMzyT2eWjj/1tuBueMn26kVVTU4Ld447oLNCzBtqrwD6gDv2pSjYtSvsdtJbX8SeXZvIzIuArSZVh9MVni/v9NuUkk0qSKRW+9C2UYf7Sn8ayGZzayNpl7K0SsZLcjJ69Yz6VDb+L7iNRHqqSxheA8XY+4NZvzNISudtDLpt7bT3kDGOCRcTIy4aB898c7feljjiaNWgnG9B/DIR/TNcq2vQRfvrS+IWUFWZ7fCY7gleuafFNb6nuMMMW+IZU27YwPz/SjpZC5uXdHRSRaklwohY5Iz8rK2fzpIxqcZUypBNzkIy7D+dYUV9cQTMFDMqjnMY/DketX11wyBSwiychlckc1DjIr2kXudLbwoz+e1o8EjLlghGD6gYzUtpDAg2rGsp7CY5PNYdtqQkKh2kiVeB5WTWta38VyAhvsSY+Vmi6+xNXuaqXLtqbP2aVhxDGhP8Ad5qeKwdNquyYJ4xwaxIVuI3ASTZg5z8zKx/Gt2wv5WLLcQJux8skYzk+9PluUqtugiaYcbxIGXPQYNWo7Jem9wfQCpISxywHlnGXUg4P0qaOXaoyAyjncKfKP2rluQLCg484BsYAYCljmngY4JZeppXdCd0luj5PXGad5Slf+PMgEfwnrQlZg2SJfuhBC9e/FTJqMUoAcBHwc/LWfNH5aDFq5z2Jqj+8SRigKHrgmm2xG5Iwba8ahz0OOCarFlEvzL5R7EjBzWfBfXMYOZlweoHWpZrxZQC28kDqajzGrmkrvt4kV1PcdanVi5K/KT2OORWAp8py4UqSOzH/ACauGfft2MC2P72CPxp7ju0XJ3zuVdxXvgDNRuY0QHncOp6Z+oqr50iDe0nzjgh+341WurpHYMQ5OegGR/8AWqkiec0EmhuF2qo3jgg9aqTy+S4WTJhz0POfpWTcahbyOo3lHHODwy89j3qVrgvbqJzu3D5ZUHyn6jsaA5h8rrLERkMM4APb/Csa7llt5A7IwQcCUckfUdxU1zC4SR1beCv3QcfiazIdTktwYZwzAnHqfzqHoHMX7bU2tIsbhLbk87TkL7j29q0FuCYd9ud8PUAHsa5+e1SdjPbSLBKerL91vqOlVLWa4s5W2JtHUoGyrDPVT2PtSUh3sdn9tjnYAr+8Bwyt1xVG/hWVN0RZMdGU8g+9RWs0V7B5kbASD+Icn6MOxqWa6ijGyXETHgbh8p/Gra0CM2SWs7xsUlKlWwTt7e9acQSVd8RJ/i4/UVhT/voZGtmUzwchSeoPb6Vo6ZMHginhYMjDDKP4D3FQjSMiObctx0DgZBxT8+Y6IrfMDkZOM0t04EzMSfLQ5baOmfWhceXG42sUcDI7ik0acxftXLwlMBlBIweop6uBAAWJCkAD8aq72V98eRyQwAz+NKzfu2OSRuDAgfnTCxemI2EqW+Xr60QMFjkGSSACpzUUZ7Z++OPegtjIPBArVbCJEl27eMB+ntUtmXSUNGcOpyMDPNU0YtEVbgr3qa1mbG4MfNQ5G31oHdm0bmOSQyTaVmQn5ipdQT64qK5uZJpF82IRALtRACAoHpmr8k2s3aRzCO7U7AG2sRu98VmTzTyTYvWkMy8YfOQPTFIIM+N7CTyrlW/Cu48IqPN8pQRtYSLz2rgUBz8vUc/lXoHhGMTSW8oP3MNgenpSlG55kXoerTzpaaccgc8x4HOfSsxG8i2udTvog/mgsHDjOegXBrQkt4pLaN5JMDO2PJxwa5xsXt0ttbziS0tPndQwIaY9AfoMn61V7IIu+5HawokCmO7MV9IxknQsN4PUEeoAxUeo3s8MckepeQxlUJHdRH5DyCM9wa2prMNGssy2U6KM7N20uv8AEDngke9Zms2OmoA2ngwwzDcsB4LHpjb0P4cU18Nwk7PQpNoJeyVnm89XBDbjwpz1rBvxJpcu2dRcWy8r6/Q1tLNPpqlLaGSeJjkwKcFOOSDnA/3TXO6slxqK+cAohPzGKNfnX03jqKlwvqCld2K8msosgZJxaqOduOPwFQX+uW93t+03dxOq5/hGG/SqcemROGkjk3BeoIz371ajiWNiVggVgMbk/wDriklbU1cblrTNaS2kWX+0d0kYyshxvA9Dnhh7V00SafqyKiG2+0O2XKODE4+nVTXDPeJE3l3gQxHnau05+oHSj7VpX2gTKxt5V5DW4K4I9K1jJnPOkt0d9NoUemW8z2v2qO1k4ljB8wKezc9PqKwtVv8A7NDGLiONkIKm4jUOsg7H1zW94U+I9laOseqFXLZTzQv3l/2xjGfpWjrfhyy1a1l1bwjdRzwkkzWeQCnqyiiVPmV4mcZ8krSOHsri2tcmCdcOASjqSpq1BfxNuE8dtKM53j5CPf1rJNtJHfuhDxEruK4xj3IoRnWbbc2yKynBLZx+YrFRadjdtSOw026soZWuo4ptoAEgSTeGGOuev5itVit3DmxuYpYpTlfPQfKe/wBK4xJvswS4QSpgkHY2c+wq5p2saTeArdvkngMp2sp/vCr5uhk49jWWxu7Ry8liVAzny2yD9DU1tJZnJlE0A9WBYH2NaVja30kH/Es1CzuTjCxyyGJj7Z6Z96y7yW6t3kXVbCWJz3B3Bf8AgQ6im4roEZSR0Wn3cCKI1uwUH3VzyPpmt+2ubfIk89wf9qMsPzFedW11OVX7HPG+OqyR5yf510Wk3t1MhD2sJCnlomCtu+h5pJF+0aOll1KBnEcmzJO0EEgGrcFxc28RkWNpEHHA3/yrnpReuwDiQnOFwmGP+NOnuYLV9siOsw4ClCGz7ds1XKP2hqX2qFSPMR4HH8QBx+INNXVr5AohaOU/wqQeRWVcXF/Ku+KIOh6tOxUn9aje91AowXyAAMFY+v5ioejK5mzpYtQv5Dm705hj+OFwf0NP+325G6SOZD23KT/KuUi1m5idRIjKnRhjOa0YtWmkUeUyBD0GeSPpTTQ1KUdjoIZbRydjpvPRe9OMG45UOrZ6HoRWILmWQ4LpGX4UlQcmnR3k6t5MhdCGwHUna3t7UXiUpyRsiQj5Jos8HBqtcxJkMsRAZcgodw+tQPfzLGXtZjMMgFfQ1FPfGFGFxA0ROSH29PbNO0SvaNbIsSRx4ykmHA6SDr9Ko3EX7rGZI5QeuPlIqn/aAZT55JycD0xSy3EU+xY5GjZQQwzuU0csXsTzyKWtRkbfMTzgQCGAAZfpVGK9aznzHLvt2PzI3UNjoRU2p/aEjdUXzYccFDjbXPmQtKzQ4WUDLwzfxfTtUN8rFzOx1onWRcPxC2CN39D/AEqtcQKzGKTLA8qxHasLTtUjEhjcskR5aOTkoew+nvXQ+VLLGrxeXMv90klT7+op6SQKb2ZVjt5Le3ENttkQZJjZuv0PUfjUsYj2Kzvsz/BIfm/A9CKRLfYwYLIhJ+44yv59RUcv2Z2kjEohZuMMfkJ9eaVgTtoDwvDMLuxuQsg6gjIP1FWnv1MZ+3WygY57ofcHsfasuQTWhZ1MS7R1SQBT+HNPtr5mVy0LZI+ZQ4IP4VLZXMh4lMcyXWmyKVwVMfUH2PpVvS9VVZHCoYwzfOq849QR7evvWbJe2S5c20ccjjBIbGCPftVKW5SKdZLcNu6gM2VI+vUUaIpTfY7m7cGUsjK26PgjofrUVijxAA8RNwvPAPpXM6Vr8F6GEq+TPEmQA3UZxkDvXX2zlbdlkRm2jKlQOnr1p2vqjSNVFqIlZXDfdYknmmP8jyJn5T8yHP5ionvd0WXhbJ43H6U+WaOYDbkMoyPlqmjW5Oj4WDcQOwIqw+HOR1x0NY8dyWPlshDL8wz396vRzb0Dq3IPp0ov0EOjk2zBjgdj9anglSC+SfAfa4Zk/vYOaoyANkkkBufTmrdj5QuoBct+6DgyAdxmmM1plgubl5l1YDzCWxIr7x7f/qpuoXKS3EHlNJJ5UYjMrrgycnn9cVYubxxfS2mp+VJbOcxyRAfugfulSO2OopNZQRiwjWWNytuBvQ5B+Y80DjLofFyHDrnp3rsPB1yYFZGzlckE9sdq448YrY0GcrekkgJtBYn0yM09zzY2s0en6xEjaQZbku0sgCQxqfmaR+FUn61z0OkahoPlRSSp9lU/vd0eRk98jBA7ZottY/tTV2vHz/Z+nE+UgP8ArH6bvriuosNft76NSoUsx2q0jjB+oNKYJWVxdP13F7DBqFu8RYDyLhHVkYf3Q3f8a2JNJs57qSKQ7YXwUlRfLMR+n179K51EubWaRba1iltmOWt2BZD6lfT8KjnvPs8T+RI8tkh/48nYi4h9SufvL7U432JmaM2qw2TyJqUsPnfdE8RDCVfRh2OO/Sua1zWdHumBtFLPxl4s5zjnDAdfateG1sIrJdSkYXyF8b2zhFPVce3pWXrA06Nt+nXNvbF1yxUjYR0yw/vH2pma0dzi9S1V/O2gB1x8rSx7WUdunX61my3MkwAmmZwf4QcD8a2dQu4XjaBIvtAX5vMQHB9PotZVx9lVAPJm80jLE4UD6D/Gho6FJtDLfJlzFbhkzyG5GPqav20kMMrPFa245584s4A/CshJHQ/ITj0PIqUXcgAACAjuF5qQuupt2xgu85toVbPHkRllPtgj+tWxLd6a8bRSXME3ARl27FHp9PauY86UvzN1568VYa5kIVCYG5znb/WrUmQ4XVjt7DxNpNwTb6taTSSAnE6EDB9cHj8KvvYaXPYi5sbqe5252NCnCn+6V7fWvOLidmQ71gbjqpOfqBU2matLaTJiaVFBHzIcYH0707rqZunbY6aw1O1SV1cyBBwy4+6e+fSugtPDel63EHEDRsw4khYZx9K5ybxLp92xa9sleZcYntlCOxHcqeKWx1vShKqSq1uoY4lT5WGfUDII/KhJN6ClzWudFceDNSs4gbbUBIFH7tJuDx2qhDF4mtmZSjoi9FkbcJPZT/jW9pd9ZXKora350B52o3zD8DW8lqiZEOqwzNjcm8Y/MEfTpVKmm7oy9q4rU4tblhdn7Yp0+c/xMOCffFb1hrOpQFfMkttSiPOBjJ9Md6kvri5vD5eo22mXCJxwTu/A9a5q6FhZT7o7GQQnqyOSBUum1sXzqR28HiS/mSXOnSRpGB91/mUeozVqx16S5KBbhInI6zIVP65BrgFuoZZFS0uZYFJGXMhJAx6GtGHTNRhg8y11dZR99YyOceuelSnLpqEl2Ol1GWVmbzLUXjt911kADfSuaivL+O+ZP7NeJc4y0oIP5VUeXV4Yw9xD50AOQy9uPUVSl1CVDua3Uqx4JY4/nVNpsaTR3em62NojcQySHgKUGSfxq9Lc3EJLrGqBugEQGK8unfUrrL2+myyrGMnYC2BTbW51rBaKG+TC9GDKFHvnip0RWp6Zc3+7abmLcMcgDg+5xUc8rRqrWjukZ+bg5AP07V59b67q1oGZdWgDEZMBcTFvbHakfXdWmbzBbgyBckoCnPrgcGs+paeh6LbzTTENbSRmUc8cMPw71auNVnKeXdb2D/fKjgYrzRPF+oQCP7TYiQk5jlQ7XX2yOv41bi8bQNOr3KTQSBTkGPIJ9wKFK2gXudDc3iJKx2+Yi9ZI1wxHbI70aZfWuoI0cbZnByoU4Zh9Kx013Tr2NyJokkTlTnbt/A/WqptYL2dZLCdRJjcMHDcehHShDuzqJTOB5tmN2Qcx+vsRWYvk38EgHzlD8yMDn/EVn2+oXNlIjXHmywk/MwGGHv6Vu3C299Gl7p0xSYjG5OQ2OxX/ACaGuZC5zn7/AE+e2YyhH8s9Q3I/A9qtaXrEtnH5bmV4h91iOR+PcVoW92Cwhvj5EpPXlkbtg+lVryyKkrG7JKvAPXI/qKmzRV0zWttainUByG90649xVqW5imiOxUfJxvK8CuagubeXbb6lGltOT8syHaGP+92PtW3ZtLChhjcSKfn2TLnP0I5NUnfcomje1kxHcQxF+gJUDI+tRX+jWc6EopGMchuc+lWWitjGA6tahm3KQQ6E+x7Uz7Gd6tFMjgtySMg+2afKx8xhX2irDwl4UUjGWAYVgXEV3ZTAxvBcKnOzlcj0rthLHva2vIRby7iMuPl/A96WfRVeASKpLDnB4HvisnBtmsWjz6W4ikGZkeKRWJCOcbcj+FhxXbeFPEbPDHBefPhNpLH7w7H61OnhyC5QorRGORcAE9+pFc/qXg66t5t+mu8ZUg4PzKP/AK1JRnEd77HosV0BC8S5JA4B5JBplvPIrAMARjbnviuc0fVWxFDq0X2e/T7kmcxy/Q9vpXQJLtwzKGfacritVqi1NFuSMOiSICduAM062fy5GZRkMeRjoajiKvEdhznoDSAvH95SQDzxg0FRkaDhM7lK9QOajMhDKCPmB9KqSSnaGHbpU+n3SQ39rLPgxrIrMfQZqlsK7Nc2aRfu5ruGKbHMe1jtPuQMA1A6PbOY3TJXkkcjHYj1Bq48bRXlm8lzKjQAbRHEz+ZySWUgYbdnvVDWZESaGNDskjQhgDkLliwX8AQKVwUj5HPQfSlV2TO1iMjacelFFUcB3nhQBNBQqq7sM5OOpyRz+VdNpmnWl5pb3EkCLNjlkyM8UUVEd2av4TDgVrSW5kt5JEZU3/eyCR6g8Vs6NOmvaXbNqVtbyvIdpYKQRz2OePwooq0RLc4/xBfXXh3Xbu2024lW3kPzRudyngfr71Y0vSLKfT7e6li3TGRskkkHHtRRVogXR4Yb5gjwpGhLEiPjuRWRqttDaGZrdNjJ0IJ5570UUpblU92Ys1zI5BYg/hUBYscHH4CiikxybBOTg0Pwx5NFFLoLoNLEjkk0lFFIkcKdjHTIooplLYa3ykYJrT03V722LCKduRjJJOPpRRTW4jpX1++s/KkDRTBgPlmiVh/Kmarq/wDaCRbtPsIGcfM0EZQn9aKKraOhlZXK9paxPNIhUgFQMhiD/OpbiJrO3cQTzqEGR85NFFZwHIoprOpQsmy9m2NIAUJ+Wuy029lKoGCsGIyGyaKK2RM0rm8l3JexiKXaqbgn7tdpwcdxWVqMMYu5FlUzsVOXmdnJx0zk4/Siir3Rgm+Yn0ixtruydmhSIquf3Shc/Wsq/iSGZAq5BboxJoopo0Rp+H4Ir7f58a4R8AKMDpUmvW9tBZyFLWEnHVgT/WiilIaOL1KRP7PMqwQK47iMc1FpMKXpuHcGJ1jDgxHbzRRXLPc6I/EWYNYv9LGIrhpo3B3JOA4PJrT1C4kt/LubZjC8i+YyoTtJwO1FFAPc2tNum1GKL7UkbMygFgOaW/mfTo7eWI+ZuJQpL8y4zj60UUCLcm2VGilRJI242suf161leI2fw7c2A06RwkjfckO4L/u9xRRUT2LOh027kNzbq4V0nX51YZAPqPSpJQLZJJYPkLSeWyj7rD6etFFU9iluS2Lfag0E6q8TA/Ke3NR+H7qWLW7nTd2+1VNyh+SD9aKKUdyjYuECz5X5QcnA6A1ZsX+1QB5lUsG25Hpiiit0LoU72ygukaOaMMjZyPT6Vz2k3EqzyW28mOMAqTyw9s0UVzS+I0R0aMVZWHByD+dXRIxYZxhuvFFFXEfUZMio3yjqKYyAgdQAOgooqixbe7uYdsMVzMkTA5VZCAaCOo/u4IP40UUgP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Red-brown nodules are present on the skin of this neonate with congenital leukemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35283=[""].join("\n");
var outline_f34_29_35283=null;
var title_f34_29_35284="Fenoldopam: Drug information";
var content_f34_29_35284=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenoldopam: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"    see \"Fenoldopam: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Corlopam&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Dopamine Agonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension, severe: I.V.: Initial: 0.03-0.1 mcg/kg/minute (associated with less reflex tachycardia); may be increased in increments of 0.05-0.1 mcg/kg/minute every 15 minutes until target blood pressure is reached; the maximal infusion rate reported in clinical studies was 1.6 mcg/kg/minute",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=see_link\">",
"      see \"Fenoldopam: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertension, severe: I.V.: Initial: 0.2 mcg/kg/minute; may be increased to dosages of 0.3-0.5 mcg/kg/minute every 20-30 minutes (maximum dose: 0.8 mcg/kg/minute); limited to short-term (4 hours) use",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170203\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F170204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required; the effects of hemodialysis on fenoldopam have not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13135801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment required.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170180\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (1 mL, 2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Corlopam&reg;: 10 mg/mL (1 mL, 2 mL) [contains propylene glycol, sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For continuous I.V. infusion only.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10 mg in 250 mL (concentration: 40",
"     <b>",
"      mcg",
"     </b>",
"     /mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     60",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F3068095\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable with NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alfentanil, amikacin, aminocaproic acid, amiodarone, ampicillin/sulbactam, argatroban, atracurium, atropine, azithromycin, aztreonam, butorphanol, calcium gluconate, cefazolin, cefepime, cefotaxime, cefotetan, ceftazidime, cefuroxime, chlorpromazine, cimetidine, ciprofloxacin, cisatracurium, clindamycin, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, dolasetron, dopamine, doxycycline, droperidol, enalaprilat, ephedrine, epinephrine, erythromycin lactobionate, esmolol, famotidine, fentanyl, fluconazole, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;),  hydrocortisone sodium succinate, hydromorphone, hydroxyzine, inamrinone, iodixanol, iohexol, iopamidol, ioxaglate meglumine and ioxaglate sodium, isoproterenol, labetalol, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, mannitol, meperidine, metoclopramide, metronidazole, micafungin, midazolam, milrinone, morphine, nalbuphine, naloxone, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, pancuronium, phenylephrine, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, promethazine, propofol, propranolol, quinupristin/dalfopristin, ranitidine, remifentanil, rocuronium, sufentanil, sulfamethoxazole/trimethoprim, theophylline, ticarcillin/clavulanate, tobramycin, vancomycin, vecuronium, verapamil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Aminophylline, amphotericin B, ampicillin, bumetanide, cefoxitin, dexamethasone sodium phosphate, diazepam, fosphenytoin, furosemide, ketorolac, methohexital, methylprednisolone sodium succinate, pentobarbital, phenytoin, prochloperazine edisylate, sodium bicarbonate, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of severe hypertension (up to 48 hours in adults), including in patients with renal compromise; short-term (up to 4 hours) blood pressure reduction in pediatric patients",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cutaneous flushing, hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;5%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Angina, bradycardia, chest pain, extrasystoles, heart failure, MI, orthostatic hypotension, palpitation, ST-T abnormalities, T-wave inversion, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Anxiety, dizziness, fever, insomnia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperglycemia, hypokalemia, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/fullness, constipation, diarrhea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding, leukocytosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Transaminases increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, limb cramps",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Intraocular pressure increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: BUN increased, creatinine increased, oliguria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed within the manufacturer&rsquo;s approved labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Serum potassium concentrations &lt;3 mEq/L were observed within 6 hours of fenoldopam initiation; monitor potassium concentrations appropriately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tachycardia: Dose-related tachycardia can occur, especially at infusion rates &gt;0.1 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Angina: Use with extreme caution in patients with obstructive coronary disease or ongoing angina pectoris; can increase myocardial oxygen demand due to tachycardia leading to angina pectoris.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Use with caution in patients with open-angle glaucoma or intraocular hypertension; fenoldopam causes a dose-dependent increase in intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intracranial pressure: Use with caution in patients with increased intracranial pressure; use has not been studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Contains sulfites; may cause allergic reaction in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration:  For continuous infusion only (no bolus doses).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F170177\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F170189\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies; however, safety and efficacy have not been established for use during pregnancy. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F170206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16354751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fenoldopam is excreted in breast milk. The manufacturer recommends that caution be exercised when administering fenoldopam to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Corlopam Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $92.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $185.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Fenoldopam Mesylate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $213.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/2 mL (2 mL): $411.47",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F170178\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, ECG; serum potassium concentrations (eg, every 6 hours)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Corlopam (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A selective postsynaptic dopamine agonist (D",
"     <sub>",
"      1",
"     </sub>",
"     -receptors) which exerts hypotensive effects by decreasing peripheral vasculature resistance with increased renal blood flow, diuresis, and natriuresis; 6 times as potent as dopamine in producing renal vasodilatation; has minimal adrenergic effects",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: 10 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.6 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: I.V.: Children: 3-5 minutes; Adults: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via methylation, glucuronidation, and sulfation; the 8-sulfate metabolite may have some activity; extensive first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%); feces (10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allaqaband S, Tumuluri R, Malik AM, et al, &ldquo;Prospective Randomized Study of N-acetylcysteine, Fenoldopam, and Saline for Prevention of Radiocontrast-Induced Nephropathy,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2002, 57(3):279-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35284/abstract-text/12410497/pubmed\" id=\"12410497\" target=\"_blank\">",
"        12410497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Erstad BL and Barletta JF, &ldquo;Treatment of Hypertension in the Perioperative Patient,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(1):66-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35284/abstract-text/10669188/pubmed\" id=\"10669188\" target=\"_blank\">",
"        10669188",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &ldquo;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35284/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stone GW, McCullough PA, Tumlin JA, et al, &ldquo;Fenoldopam Mesylate for the Prevention of Contrast-Induced Nephropathy: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 290(17):2284-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35284/abstract-text/14600187/pubmed\" id=\"14600187\" target=\"_blank\">",
"        14600187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8629 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35284=[""].join("\n");
var outline_f34_29_35284=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170199\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170214\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170202\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170211\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170203\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170204\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13135801\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170180\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170167\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170183\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472625\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472626\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3068095\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170182\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170212\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170186\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170171\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299316\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170175\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170177\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170189\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170206\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16354751\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323147\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170178\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170190\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170170\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170185\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8629\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8629|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/35/5684?source=related_link\">",
"      Fenoldopam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_29_35285="Bismuth: Drug information";
var content_f34_29_35285=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bismuth: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/44/29380?source=see_link\">",
"    see \"Bismuth: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/14/30948?source=see_link\">",
"    see \"Bismuth: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F141521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bismatrol Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Bismatrol [OTC];",
"     </li>",
"     <li>",
"      Diotame [OTC];",
"     </li>",
"     <li>",
"      Kao-Tin [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; Extra Strength [OTC];",
"     </li>",
"     <li>",
"      Kaopectate&reg; [OTC];",
"     </li>",
"     <li>",
"      Peptic Relief [OTC];",
"     </li>",
"     <li>",
"      Pepto Relief [OTC];",
"     </li>",
"     <li>",
"      Pepto-Bismol&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Pepto-Bismol&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F141539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiarrheal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F141524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of nonspecific diarrhea, control/relieve traveler's diarrhea:",
"     </b>",
"     Subsalicylate: Oral: 524 mg every 30 minutes to 1 hour as needed up to 8 doses/24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      eradication:",
"     </b>",
"     Oral: Subsalicylate: 524 mg 4 times/day with meals and at bedtime; requires combination therapy",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F141534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/14/30948?source=see_link\">",
"      see \"Bismuth: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonspecific diarrhea, control/relieve traveler's diarrhea:",
"     </b>",
"     Subsalicylate: Oral: Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F141525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F141526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bismuth has been associated with nephrotoxicity in overdose (Leussnik, 2002); although there are no specific recommendations by the manufacturer, consider using with caution in patients with renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F141504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as subsalicylate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg [sugar free; contains sodium 2 mg/caplet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as subsalicylate: 262 mg/15 mL (120 mL, 240 mL, 360 mL, 480 mL); 525 mg/15 mL (240 mL, 360 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismatrol: 262 mg/15 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismatrol Maximum Strength: 525 mg/15 mL (240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diotame: 262 mg/15 mL (30 mL) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kao-Tin: 262 mg/15 mL (240 mL, 473 mL) [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 262 mg/15 mL (236 mL) [contains potassium 5 mg/15 mL, sodium 5 mg/15 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 262 mg/15 mL (177 mL) [contains sodium 4 mg/15 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg;: 262 mg/15 mL (236 mL, 354 mL) [contains sodium 4 mg/15 mL; vanilla flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaopectate&reg; Extra Strength: 525 mg/15 mL (236 mL) [contains potassium 5 mg/15 mL, sodium 5 mg/15 mL; peppermint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peptic Relief: 262 mg/15 mL (237 mL) [sugar free; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg/15 mL (240 mL, 360 mL, 480 mL) [sugar free; contains benzoic acid, sodium 6 mg/15 mL; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg/15 mL (120 mL, 240 mL, 360 mL, 480 mL) [sugar free; contains benzoic acid, sodium 6 mg/15 mL; wintergreen flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg; Maximum Strength: 525 mg/15 mL (120 mL, 240 mL, 360 mL) [sugar free; contains benzoic acid, sodium 6 mg/15 mL; wintergreen flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as subsalicylate: 262 mg/15 mL (30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as subsalicylate: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bismatrol: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diotame: 262 mg [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peptic Relief: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto Relief: 262 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg [sugar free; contains sodium &lt;1 mg/tablet; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pepto-Bismol&reg;: 262 mg [sugar free; contains sodium &lt;1 mg/tablet; wintergreen flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F141491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F141507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liquids must be shaken prior to use. Chewable tablets should be chewed thoroughly. Nonchewable caplets should be swallowed whole with a full glass of water.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F141505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Subsalicylate formulation: Symptomatic treatment of mild, nonspecific diarrhea; control of traveler's diarrhea (enterotoxigenic",
"     <i>",
"      Escherichia coli",
"     </i>",
"     ); as part of a multidrug regimen for",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication to reduce the risk of duodenal ulcer recurrence",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F141546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Kaopectate&reg; may be confused with Kayexalate&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Maalox&reg; Total  Relief&reg; is a different formulation than other Maalox&reg; liquid antacid products which contain aluminum hydroxide, magnesium hydroxide, and simethicone.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Canadian formulation of Kaopectate&reg; does not contain bismuth; the active ingredient in the Canadian formulation is attapulgite.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F141537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined; subsalicylate formulation:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, confusion, headache, mental depression, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Discoloration of the tongue (darkening), grayish black stools, impaction may occur in infants and debilitated patients",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle spasms, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss, tinnitus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F141510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to bismuth or any component of the formulation",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Subsalicylate formulation: Do not use subsalicylate in patients with influenza or chickenpox because of risk of Reye's syndrome; hypersensitivity to salicylates or any component of the formulation; history of severe GI bleeding; history of coagulopathy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F141495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurotoxicity: Bismuth products may be neurotoxic with very large doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aspirin: Bismuth subsalicylate should be used with caution if patient is taking aspirin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use subsalicylate. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye's syndrome; patients should be instructed to contact their healthcare provider if these occur. Patients should be instructed to contact healthcare provider for diarrhea lasting &gt;2 days, hearing loss, or ringing in the ears. Not labeled for OTC use in children &lt;12 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F141499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Bismuth may decrease the serum concentration of Tetracycline Derivatives.  Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13755164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following oral administration, bismuth and salicylates cross the placenta. The use of salicylates in pregnancy may adversely affect the newborn (Lione, 1988). Use during pregnancy is not recommended (Mahadevan, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13755169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Low amounts of salicylates enter breast milk; refer to the aspirin monograph for additional information (Bar-Oz, 2004). A case report describes bowel obstruction in a breast-fed infant whose mother applied a bismuth-containing ointment to her nipples prior to breast-feeding (Anonymous, 1974).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F141512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Drink plenty of fluids to help prevent dehydration caused by diarrhea. Some products may contain potassium and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Bismuth Subsalicylate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg (30): $6.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pepto-Bismol InstaCool Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg (30): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pepto-Bismol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg (30): $4.14",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Pepto-Bismol To-Go Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg (12): $3.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Soothe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg (48): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Kaopectate Extra Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     525 mg/15 mL (236 mL): $5.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Kaopectate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg/15 mL (177 mL): $4.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Kola-Pectin DS Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     525 mg/15 mL (118 mL): $7.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pepto-Bismol Max Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     525 mg/15 mL (236 mL): $5.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Pepto-Bismol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg/15 mL (236 mL): $3.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Soothe Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg/15 mL (473 mL): $6.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Pepto-Bismol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     262 mg (24): $4.14",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F141513\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      A-Migdobis (MX);",
"     </li>",
"     <li>",
"      Assure (TW);",
"     </li>",
"     <li>",
"      Bisbacter (CO);",
"     </li>",
"     <li>",
"      Bismucar (PE);",
"     </li>",
"     <li>",
"      Bismuthum subgallicum (PL);",
"     </li>",
"     <li>",
"      Bismutol (EC, PE);",
"     </li>",
"     <li>",
"      Bismutsubsalicylat-Steigerwald (DE);",
"     </li>",
"     <li>",
"      Cytribin (PL);",
"     </li>",
"     <li>",
"      De-nol (PL);",
"     </li>",
"     <li>",
"      Dermatol (DE, PL);",
"     </li>",
"     <li>",
"      Facidmol (MX);",
"     </li>",
"     <li>",
"      Gastro-Bismol (TH);",
"     </li>",
"     <li>",
"      Jatrox (DE);",
"     </li>",
"     <li>",
"      Kalbeten (IL);",
"     </li>",
"     <li>",
"      Pylorid (PL);",
"     </li>",
"     <li>",
"      Stobiol (ID);",
"     </li>",
"     <li>",
"      Subsalicilato de Bismuto (MX);",
"     </li>",
"     <li>",
"      Trigastronol (ES);",
"     </li>",
"     <li>",
"      Ulcolind Wismut (DE);",
"     </li>",
"     <li>",
"      Ventrisol (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F141494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bismuth subsalicylate exhibits both antisecretory and antimicrobial action. This agent may provide some anti-inflammatory action as well. The salicylate moiety provides antisecretory effect and the bismuth exhibits antimicrobial directly against bacterial and viral gastrointestinal pathogens.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F141509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Bismuth: &lt;1%; Subsalicylate: &gt;90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Bismuth subsalicylate is converted to salicylic acid and insoluble bismuth salts in the GI tract.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Terminal: Bismuth: Highly variable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Bismuth: Urine and feces; Salicylate: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bar-Oz B, Bulkowstein M, Benyamini L, et al, \"Use of Antibiotic and Analgesic Drugs During Lactation,\"",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2003, 26(13):925-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/14583068/pubmed\" id=\"14583068\" target=\"_blank\">",
"        14583068",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Health and Human Services, Food and Drug Administration, &ldquo;Antidiarrheal Drug Products for Over-the-Counter Human Use; Final Monograph, (21 CFR Parts 310, 335, 357, 369),&rdquo;",
"      <i>",
"       Fed Regist",
"      </i>",
"      , April 17, 2003, 18869-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/10177739/pubmed\" id=\"10177739\" target=\"_blank\">",
"        10177739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department of Health and Human Services, Food and Drug Administration, &ldquo;Labeling for Oral and Rectal Over-the-Counter Drug Products Containing Aspirin and Nonaspirin Salicylates; Reye's Syndrome Warning; Final Rule (29 CFR Part 201),&rdquo;",
"      <i>",
"       Fed Regist",
"      </i>",
"      , April 17, 2003, 18861-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/10177739/pubmed\" id=\"10177739\" target=\"_blank\">",
"        10177739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Drumm B, Sherman P, Karmali M, et al, &ldquo;Treatment of",
"      <i>",
"       Campylobacter pylori",
"      </i>",
"      -Associated Antral Gastritis in Children With Bismuth Subsalicylate and Ampicillin,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1988, 113(5):908-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/3183851/pubmed\" id=\"3183851\" target=\"_blank\">",
"        3183851",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, Lew GM, Evans DG, et al, &ldquo;Effect of Triple Therapy (Antibiotics Plus Bismuth) on Duodenal Ulcer Healing,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1991, 115(4):266-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/1854110/pubmed\" id=\"1854110\" target=\"_blank\">",
"        1854110",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Graham DY, Lew GM, Klein PD, et al, &ldquo;Effect of Treatment of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection on the Long-Term Recurrence of Gastric or Duodenal Ulcer,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1992, 116(9):705-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/1558340/pubmed\" id=\"1558340\" target=\"_blank\">",
"        1558340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      \"Ingestion of Bismuth-Containing Ointment by a Breast-Fed Infant,\"",
"      <i>",
"       Mt Sinai J Med",
"      </i>",
"      , 1974, 41(3):498-501.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/4545567/pubmed\" id=\"4545567\" target=\"_blank\">",
"        4545567",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Leussnik BT, Nagelkerke JF, van der Water B, et al, &ldquo;Pathways of Proximal Tubular Cell Death in Bismuth Nephrotoxicity,&rdquo;",
"      <i>",
"       Toxicol Appl Pharmacol",
"      </i>",
"      , 2002, 180(2):100-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/11969377/pubmed\" id=\"11969377\" target=\"_blank\">",
"        11969377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lione A, \"Nonprescription Drugs as a Source of Aluminum, Bismuth, and Iodine During Pregnancy,\"",
"      <i>",
"       Reprod Toxicol",
"      </i>",
"      , 1987-8, 1(4):243-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/2980389/pubmed\" id=\"2980389\" target=\"_blank\">",
"        2980389",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mahadevan U, \"Gastrointestinal Medications in Pregnancy,\"",
"      <i>",
"       Best Pract Res Clin Gastroenterol",
"      </i>",
"      , 2007, 21(5):849-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/17889812/pubmed\" id=\"17889812\" target=\"_blank\">",
"        17889812",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ormand JE and Talley NJ, &ldquo;",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      : Controversies and an Approach to Management,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 1990, 65(3):414-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/2179647/pubmed\" id=\"2179647\" target=\"_blank\">",
"        2179647",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Soriano-Brucher HE, Avendano P, O'Ryan M, et al, &ldquo;Use of Bismuth Subsalicylate in Acute Diarrhea in Children,&rdquo;",
"      <i>",
"       Rev Infect Dis",
"      </i>",
"      , 1990, 12(Suppl 1):51-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/29/35285/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9156 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-0970125B04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35285=[""].join("\n");
var outline_f34_29_35285=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141521\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141539\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141524\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141534\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141525\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141526\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141504\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141491\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141507\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141505\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141546\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141537\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141510\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141495\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298868\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141499\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755164\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13755169\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141512\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323019\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141513\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141494\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F141509\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9156\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9156|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/44/29380?source=related_link\">",
"      Bismuth: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/14/30948?source=related_link\">",
"      Bismuth: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_29_35286="Grades pan duct adenoCA";
var content_f34_29_35286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56909&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 541px\">",
"   <div class=\"ttl\">",
"    Histology of pancreatic ductal adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 521px; height: 198px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Well differentiated (grade 1) carcinoma invading fat. B) Poorly differentiated (grade 3) carcinoma is desmoplastic and has prominent fibrous stroma. Hematoxylin and Eosin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel S Longnecker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35286=[""].join("\n");
var outline_f34_29_35286=null;
var title_f34_29_35287="Antiphospholipid syndrome and the kidney";
var content_f34_29_35287=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiphospholipid syndrome and the kidney",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35287/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/29/35287/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antiphospholipid syndrome (APS) is characterized by antibodies directed against either phospholipids or plasma proteins bound to anionic phospholipids. Patients with the APS may display a constellation of clinical features including venous and arterial thrombosis, recurrent fetal losses, and thrombocytopenia. This disorder is referred to as the primary APS when it occurs alone; however, it can also be found in association with systemic lupus erythematosus (SLE), other rheumatic diseases, and with certain infections and drugs.",
"   </p>",
"   <p>",
"    Four types of antiphospholipid antibodies have been characterized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Antibodies causing a false positive VDRL",
"     </li>",
"     <li>",
"      Lupus anticoagulants",
"     </li>",
"     <li>",
"      Anticardiolipin antibodies",
"     </li>",
"     <li>",
"      Antibodies to beta2-glycoprotein I",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There appears to be a relationship between the isotype and titer of antiphospholipid antibody, and the risk of thrombotic events. Higher titers of IgG antiphospholipid antibody, for example, have been reported to be associated with a greater incidence of thrombotic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The kidney is one of the organs that can be compromised in patients with antiphospholipid antibodies (aPL). Renal complications directly resulting from thrombotic events associated with these antibodies include glomerular disease, large vessel renal involvement, and coagulation problems relating to dialysis and renal transplants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathology, manifestations, and treatment of renal involvement in patients with APS are presented here. General discussions of the clinical manifestations, diagnosis, and treatment of this disorder are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=see_link\">",
"     \"Clinical manifestations of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=see_link\">",
"     \"Diagnosis of the antiphospholipid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"     \"Treatment of the antiphospholipid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL MANIFESTATIONS OF APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement occurs in as many as 25 percent of patients with the primary APS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/3-5,8,9\">",
"     3-5,8,9",
"    </a>",
"    ]. APL also frequently occurs in patients with lupus in whom renal disease is more frequently caused by immune deposits. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal disease in primary APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement in primary APS is primarily characterized pathologically by noninflammatory occlusion of a broad spectrum of renal blood vessels, ranging from glomerular capillaries to the main renal artery and vein (",
"    <a class=\"graphic graphic_picture graphicRef63511 graphicRef54840 graphicRef69687 \" href=\"mobipreview.htm?41/13/42202\">",
"     picture 1A-C",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef75317 \" href=\"mobipreview.htm?8/3/8255\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/4,8,10-13\">",
"     4,8,10-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involved arteries and arterioles often have a thrombotic lesion, resulting in reactive intimal mucoid thickening, subendothelial fibrosis, and medial hyperplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Affected glomerular capillaries reveal thrombi with associated mesangiolysis, mesangial interposition along the glomerular capillary wall, and electron lucent areas in the subendothelial space.",
"     </li>",
"     <li>",
"      Focal atrophy of the cortex in association with interstitial fibrosis may be observed, presumably resulting from tissue ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings resemble those found in other diseases associated with a thrombotic microangiopathy, including the hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and scleroderma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=see_link\">",
"     \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, if kidney biopsy is delayed, focal segmental glomerulosclerosis may be a prominent finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/14\">",
"     14",
"    </a>",
"    ]. This is a described sequela of thrombotic microangiopathy.",
"   </p>",
"   <p>",
"    The clinical signs of thrombi in the glomeruli and small arteries are variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/15\">",
"     15",
"    </a>",
"    ]. Some patients have only asymptomatic mild proteinuria (less than 2",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    with normal renal function, while others develop acute or subacute renal failure with proteinuria (which can reach the nephrotic range), an active urine sediment (that can include red cell casts), and often marked hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/4,10,16\">",
"     4,10,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Large renal arterial thrombosis with renal infarction can present with unilateral or bilateral flank pain, hematuria, and decreased renal function. Renal vein thrombosis may be silent or, if acute and complete, may present with sudden flank pain and a decrease in renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19782557\">",
"    <span class=\"h2\">",
"     Other glomerular lesions associated with primary APS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other glomerular lesions are described in patients with primary APS including membranous nephropathy, minimal change disease, and pauci-immune glomerulonephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In a retrospective study of 160 patients who were diagnosed with primary APS, renal involvement (defined as serum creatinine &gt;1.4",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/l)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proteinuria &gt;0.3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with or without hematuria) was identified in 14 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/18\">",
"     18",
"    </a>",
"    ]. Of these, ten patients had a renal biopsy that showed membranous nephropathy (n = 4), diffuse proliferative glomerulonephritis (n = 2), thrombotic microangiopathy (n = 2) and vascular lesions consistent with chronic antiphospholipid nephropathy (n = 2). Both patients who had diffuse proliferative glomerulonephritis developed full-blown lupus 13 and 18 years after the diagnosis of primary APS. At a mean followup of 8.5 years (range 6.9 to 14 years) none of the patients with membranous nephropathy had developed clinical evidence of lupus although it is possible that lupus-related signs or symptoms were suppressed by immunosuppressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal disease in APS associated with SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lupus and aPL commonly have a history of systemic thromboses, fetal loss, neurologic disorders, and thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/1,19,20\">",
"     1,19,20",
"    </a>",
"    ]. In patients with lupus, the principal clinical features that positively correlate with the presence of high titers of IgG aPL are thrombocytopenia, the presence of a false positive VDRL for syphilis (FTA negative), and a prolonged activated PTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/1,8,21\">",
"     1,8,21",
"    </a>",
"    ]. Renal disease in this setting may result from microthrombi",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deposits of immune complexes.",
"   </p>",
"   <p>",
"    Isolated microangiopathic thrombosis is a relatively unusual finding in patients with APS and lupus. Only about 10 percent of such patients in whom renal biopsies are performed show glomerular microthromboses as the major histopathologic finding. Nevertheless, aPL can cause significant renal damage in patients with lupus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These histologic and clinical features are similar to those with the APS alone or those with lupus-like features in whom the ARA criteria for a diagnosis of SLE are not fulfilled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To better address the relationships among thrombi, aPL, renal dysfunction, and traditional lupus nephritis, a retrospective study evaluated the findings on renal biopsy in 114 patients with SLE and kidney dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/24\">",
"     24",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasoocclusive lesions were found in approximately one-third of biopsies and were independent of traditional lupus nephritis.",
"     </li>",
"     <li>",
"      Thrombi independently contributed to elevations in the serum creatinine concentration and the development of hypertension.",
"     </li>",
"     <li>",
"      The presence of renal thrombi correlated with the presence of a lupus anticoagulant but not with anticardiolipin antibodies (aCL).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    APS in patients with SLE can occur in addition to and independent of lupus nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. In a review of 111 patients with lupus nephritis who were followed for a mean of almost 15 years and were tested regularly for anticardiolipin antibodies and lupus anticoagulant, the overall prevalence of aPL was 26 percent. aPL occurred more frequently in patients with membranous lupus (50 versus 22 percent with other lesions).",
"   </p>",
"   <p>",
"    It is important to document the presence of glomerular microthromboses in patients with the APS and SLE, since the therapy for microthrombi differs from the immunosuppression required for immune complex-mediated lupus nephritis. Such thrombi often recanalize in the absence of an inflammatory infiltrate and in the absence of immune deposits on immunofluorescence or electron microscopy.",
"   </p>",
"   <p>",
"    Little is known concerning the relationship between aPL and the overall risk of progressive chronic kidney disease. A prospective long-term study (median follow-up of 167 months) evaluated 111 patients with lupus nephritis, of whom 29 had aPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/25\">",
"     25",
"    </a>",
"    ]. There was a significant correlation between antibody presence and the eventual development of chronic renal failure (RR of 2.2).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     APS IN END-STAGE RENAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;APL can occur in patients with end-stage renal disease treated with maintenance hemodialysis or renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16727?source=see_link\">",
"     \"Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have found that patients on maintenance hemodialysis have a high prevalence of aPL, a finding associated with an increased incidence of thrombotic events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. In one study, for example, aPL were present in 31 percent of 97 hemodialysis patients (the lupus anticoagulant and aCL in 17 and 16 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/26\">",
"     26",
"    </a>",
"    ]. The frequency of vascular access thrombosis was much higher in the patients with aPL as measured by the lupus anticoagulant (62 versus 26 percent in those without these antibodies). Similar findings were noted in another report in which a significant increase in the odds of having two or more episodes of AV graft thrombosis was found among the patients with raised aPL titers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of aPL may vary with the type of hemodialysis access used. This was suggested in a cross-sectional study that evaluated hemodialysis patients at a single dialysis facility: 22 percent of 74 patients with arteriovenous (AV) grafts had a raised titer of IgG aPL, versus only one of 17 patients (6 percent) with arteriovenous fistulas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/27\">",
"     27",
"    </a>",
"    ]. Whether AV grafts induce aPL or patients with aPL require AV grafts could not be determined.",
"   </p>",
"   <p>",
"    The experience at our medical center lends further support to these findings. In a review of 230 patients undergoing chronic hemodialysis, the following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Titers of IgG aPL were elevated in 26 percent",
"     </li>",
"     <li>",
"      Titers of IgM aPL were elevated in 4 percent",
"     </li>",
"     <li>",
"      Titers of both antibodies were elevated in 3 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mean time to AV graft failure was significantly decreased in the group with elevated IgG antibodies even though there was no difference in AV fistula clotting between those with and without high IgG antibody titers.",
"   </p>",
"   <p>",
"    There does not appear to be an association between the development of aPL and age, gender, or dialysis duration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/26\">",
"     26",
"    </a>",
"    ]. However, the incidence of such antibodies appears to correlate positively with the type of dialysis modality as well as the use of dialysis, since a much lower incidence of aPL has been found both in patients with renal insufficiency in whom dialytic support is not yet required and in those treated with peritoneal dialysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/28,30,31\">",
"     28,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A substantial number of renal transplant recipients have circulating aPL, which can damage the allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective study of 178 transplant recipients, 28 percent had aPL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/33\">",
"       33",
"      </a>",
"      ]. Compared to patients without such antibodies, these individuals had a significantly higher incidence of arterial (18 versus 6 percent, p&lt;0.001) and venous (8 versus 2 percent, p&lt;0.001) thrombosis; testing of pretransplant sera revealed that the aPL were present prior to the operation in 85 percent of patients.",
"     </li>",
"     <li>",
"      A second retrospective series, which evaluated transplant recipients with SLE, also found a high incidence of significant thrombotic events among those with aPL (60 versus 8 percent in patients without these antibodies) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although suggestive, these retrospective observations cannot prove causality. Another retrospective study, for example, reported no increased incidence in allograft loss or reduction in glomerular filtration among the 61 of 337 patients with positive aCL, despite increased use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in those with positive antibodies (20 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/36\">",
"     36",
"    </a>",
"    ]. However, early allograft loss was observed in two of five patients with very high titers who were not being anticoagulated.",
"   </p>",
"   <p>",
"    In addition to systemic thrombotic events, a renal thrombotic microangiopathy (TMA) may be observed in HCV-infected renal transplant recipients with aCL. This association was suggested in a report of 18 anti-HCV positive patients, five of whom developed renal TMA between 5 and 120 days after transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/37\">",
"     37",
"    </a>",
"    ]. APL were found in all five patients of these patients, but in only one of the thirteen without a microangiopathy. The hypothesis that anticardiolipin antibodies, HCV infection, and renal thrombosis were correlated was supported by the observation that normal aCL titers were found in the seven HCV-negative transplant recipients who presented with renal",
"    <span class=\"nowrap\">",
"     TMA/hemolytic",
"    </span>",
"    uremic syndrome during the same time period and served as a control group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of the patient with APS is generally the same whether or not renal disease is present. Many patients with aPL do not experience thrombotic events or have evidence of renal thrombosis. Indiscriminate anticoagulation of such patients would therefore place a large population at risk for bleeding to achieve a dubious benefit. In contrast, patients with evidence of venous or arterial thromboembolic disease, thrombotic microangiopathy in the glomeruli and small arteries, or thrombi in the larger vessels",
"    <strong>",
"     must",
"    </strong>",
"    be treated to avoid life threatening vascular damage.",
"   </p>",
"   <p>",
"    Issues related to the general therapy of thromboembolic events in patients with the APS are discussed in detail elsewhere. Summarized briefly, moderate intensity",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (target INR of 2 to 3) appears to be as effective as more intensive anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/38,39\">",
"     38,39",
"    </a>",
"    ], while immunosuppressive therapy generally has little effect on aPL. Patients with catastrophic APS are often treated with plasma exchange. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link&amp;anchor=H27#H27\">",
"     \"Treatment of the antiphospholipid syndrome\", section on 'Catastrophic APS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hemodialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with APS treated with hemodialysis have an increased incidence of recurrent thrombosis in AV grafts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. In such patients, treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may increase AV graft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with SLE, a positive APL, a history of thromboembolic events and lupus nephritis, as well as those with the APS, may benefit from continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy after renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. If untreated, these patients appear to be at risk for both intrarenal and systemic clotting events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/32,36,40\">",
"     32,36,40",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study reported the outcomes of 11 renal transplant recipients with the APS, of whom four were treated with anticoagulant therapy after transplantation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/40\">",
"       40",
"      </a>",
"      ]. All seven patients not administered anticoagulants lost their allograft to renal thrombosis within one week of surgery; by comparison, three of four treated patients had functioning allografts for over two years, but the remaining patient also thrombosed his graft within one week of the procedure. No allografts were lost to renal thrombosis among 37 other patients with high titers of aCL, but no previous history of thrombosis.",
"     </li>",
"     <li>",
"      A protective effective of anticoagulation was also suggested in another report in which five patients at high risk for thrombosis were treated preemptively with postoperative",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and subsequently with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/43\">",
"       43",
"      </a>",
"      ]. Allograft thrombosis occurred in one patient who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      rather than warfarin. The target INR for warfarin therapy was 2.0 to 2.5.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acute renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selected patients with acute renal failure may respond either to plasmapheresis, which presumably acts by removing the pathogenic antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/4,5,44\">",
"     4,5,44",
"    </a>",
"    ], or to corticosteroids and chronic anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/45\">",
"     45",
"    </a>",
"    ]. In an uncontrolled report of 12 patients, for example, complete renal recovery occurred only in the two patients treated with plasma exchange [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35287/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal apheresis regimen for acute renal failure is uncertain. However, a prescription of three to five one-plasma volume exchanges over a seven day period should produce substantial lowering of antiphospholipid antibody levels. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16642?source=see_link\">",
"       \"Patient information: The antiphospholipid syndrome (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=see_link\">",
"       \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=see_link\">",
"       \"Patient information: Hemodialysis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=see_link\">",
"       \"Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antiphospholipid syndrome (APS) is characterized by antibodies directed against phospholipids or plasma proteins bound to phospholipids. APS may occur alone (primary APS) or in association with systemic lupus erythematosus (SLE), other rheumatic diseases, and certain infections and drugs. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary APS causes noninflammatory occlusion of renal blood vessels that, depending on the type of the involved blood vessels, results in renal infarction, ischemic changes, or in thrombotic microangiopathy involving the glomeruli. Patients who have large vessel involvement present with unilateral or bilateral flank pain, hematuria, and decreased renal function. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Renal disease in primary APS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with glomerular involvement, histology often resembles the hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura, and scleroderma. Other glomerular lesions that may be observed include membranous nephropathy, minimal change disease, and pauci-immune glomerulonephritis. (See",
"      <a class=\"local\" href=\"#H19782557\">",
"       'Other glomerular lesions associated with primary APS'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with APS associated with systemic lupus erythematosus (SLE) present with systemic thromboses, fetal loss, neurologic disorders, thrombocytopenia, a false positive VDRL for syphilis, and a prolonged activated PTT. Among such patients, renal disease may result from microthrombi",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deposits of immune complexes. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Renal disease in APS associated with SLE'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients on maintenance hemodialysis have a high prevalence of antiphospholipid antibodies that are associated with an increased incidence of thrombotic events often involving the vascular access. The incidence of such antibodies appears to correlate with the use of dialysis and with the type of dialysis, but not with age, gender, or dialysis duration. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A substantial number of renal transplant recipients have circulating antiphospholipid antibodies, which can damage the allograft. A renal thrombotic microangiopathy has also been observed in HCV-infected renal transplant recipients with antiphospholipid antibodies. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of the patient with APS is the same whether or not renal disease is present. Patients with thrombotic microangiopathy in the glomeruli and small arteries, or thrombi in the larger vessels",
"      <strong>",
"       must",
"      </strong>",
"      be treated to avoid life threatening vascular damage. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=see_link\">",
"       \"Treatment of the antiphospholipid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Plasmapheresis and corticosteroids are of unproven value in the treatment of acute kidney injury related to antiphospholipid syndrome. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Acute renal failure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"       \"Prescription and technique of therapeutic plasma exchange\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/1\">",
"      Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med 1995; 98:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/2\">",
"      Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antibody syndrome and renal disease. Curr Opin Nephrol Hypertens 2001; 10:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/3\">",
"      Amigo MC, Garcia-Torres R, Robles M, et al. Renal involvement in primary antiphospholipid syndrome. J Rheumatol 1992; 19:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/4\">",
"      Kincaid-Smith P, Fairley KF, Kloss M. Lupus anticoagulant associated with renal thrombotic microangiopathy and pregnancy-related renal failure. Q J Med 1988; 68:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/5\">",
"      Farrugia E, Torres VE, Gastineau D, et al. Lupus anticoagulant in systemic lupus erythematosus: a clinical and renal pathological study. Am J Kidney Dis 1992; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/6\">",
"      Sonpal GM, Sharma A, Miller A. Primary antiphospholipid antibody syndrome, renal infarction and hypertension. J Rheumatol 1993; 20:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/7\">",
"      Asherson RA, Lanham JG, Hull RG, et al. Renal vein thrombosis in systemic lupus erythematosus: association with the \"lupus anticoagulant\". Clin Exp Rheumatol 1984; 2:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/8\">",
"      Nicholls, K, Kincaid-Smith, P. Antiphospholipid syndrome and renal thrombotic microangiopathy. J Nephrol 1995; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/9\">",
"      Asherson RA, Harris EN. Anticardiolipin antibodies--clinical associations. Postgrad Med J 1986; 62:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/10\">",
"      D'Agati V, Kunis C, Williams G, Appel GB. Anti-cardiolipin antibody and renal disease: a report three cases. J Am Soc Nephrol 1990; 1:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/11\">",
"      Nochy D, Daugas E, Droz D, et al. The intrarenal vascular lesions associated with primary antiphospholipid syndrome. J Am Soc Nephrol 1999; 10:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/12\">",
"      Griffiths MH, Papadaki L, Neild GH. The renal pathology of primary antiphospholipid syndrome: a distinctive form of endothelial injury. QJM 2000; 93:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/13\">",
"      Aydin Z, Bruijn JA, Vleming LJ. ARF and cerebral infarcts in a young woman. Am J Kidney Dis 2004; 44:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/14\">",
"      Saracino A, Ramunni A, Pannarale G, Coratelli P. Kidney disease associated with primary antiphospholipid syndrome: clinical signs and histopathological features in an case experience of five cases. Clin Nephrol 2005; 63:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/15\">",
"      Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. \"Black swan in the kidney\": renal involvement in the antiphospholipid antibody syndrome. Kidney Int 2002; 62:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/16\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 18-1999. A 54-year-old woman with acute renal failure and thrombocytopenia. N Engl J Med 1999; 340:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/17\">",
"      Fakhouri F, No&euml;l LH, Zuber J, et al. The expanding spectrum of renal diseases associated with antiphospholipid syndrome. Am J Kidney Dis 2003; 41:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/18\">",
"      Sinico RA, Cavazzana I, Nuzzo M, et al. Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients. Clin J Am Soc Nephrol 2010; 5:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/19\">",
"      Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/20\">",
"      Nast C, Appel G. A case of lupus nephritis. Clin J Am Soc Nephrol 2008; 3:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/21\">",
"      Hughes GR. The antiphospholipid syndrome: ten years on. Lancet 1993; 342:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/22\">",
"      Appel GB, Pirani CL, D'Agati V. Renal vascular complications of systemic lupus erythematosus. J Am Soc Nephrol 1994; 4:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/23\">",
"      Tektonidou MG, Sotsiou F, Nakopoulou L, et al. Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome. Arthritis Rheum 2004; 50:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/24\">",
"      Daugas E, Nochy D, Huong DL, et al. Antiphospholipid syndrome nephropathy in systemic lupus erythematosus. J Am Soc Nephrol 2002; 13:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/25\">",
"      Moroni G, Ventura D, Riva P, et al. Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/26\">",
"      Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/27\">",
"      Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/28\">",
"      Garc&iacute;a-Mart&iacute;n F, De Arriba G, Carrascosa T, et al. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. Nephrol Dial Transplant 1991; 6:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/29\">",
"      Prieto LN, Suki WN. Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies. Am J Kidney Dis 1994; 23:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/30\">",
"      Radhakrishnan J, Williams GS, Appel GB, Cohen DJ. Renal transplantation in anticardiolipin antibody-positive lupus erythematosus patients. Am J Kidney Dis 1994; 23:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/31\">",
"      Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/32\">",
"      Asherson RA, Khamashta MA, Ordi-Ros J, et al. The \"primary\" antiphospholipid syndrome: major clinical and serological features. Medicine (Baltimore) 1989; 68:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/33\">",
"      Ducloux D, Pellet E, Fournier V, et al. Prevalence and clinical significance of antiphospholipid antibodies in renal transplant recipients. Transplantation 1999; 67:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/34\">",
"      Kazory A, Ducloux D. Acquired hypercoagulable state in renal transplant recipients. Thromb Haemost 2004; 91:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/35\">",
"      Stone JH, Amend WJ, Criswell LA. Antiphospholipid antibody syndrome in renal transplantation: occurrence of clinical events in 96 consecutive patients with systemic lupus erythematosus. Am J Kidney Dis 1999; 34:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/36\">",
"      Forman JP, Lin J, Pascual M, et al. Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation. Am J Transplant 2004; 4:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/37\">",
"      Baid S, Pascual M, Williams WW Jr, et al. Renal thrombotic microangiopathy associated with anticardiolipin antibodies in hepatitis C-positive renal allograft recipients. J Am Soc Nephrol 1999; 10:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/38\">",
"      Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/39\">",
"      Mackworth-Young CG, Loizou S, Walport MJ. Antiphospholipid antibodies and disease. Q J Med 1989; 72:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/40\">",
"      Vaidya S, Sellers R, Kimball P, et al. Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation 2000; 69:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/41\">",
"      Vaidya S, Gugliuzza K, Daller JA. Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 2004; 77:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/42\">",
"      Vella J. Significance of anticardiolipin antibodies on short- and long-term allograft survival and function following kidney transplantation. Am J Transplant 2004; 4:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/43\">",
"      Friedman GS, Meier-Kriesche HU, Kaplan B, et al. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. Transplantation 2001; 72:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/44\">",
"      Kaplan AA. The use of apheresis in immune renal disorders. Ther Apher Dial 2003; 7:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35287/abstract/45\">",
"      Sokunbi DO, Miller F, Wadhwa NK, Nord EP. Reversible renal failure in the primary antiphospholipid syndrome--a report of two cases. J Am Soc Nephrol 1993; 4:28.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3073 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-41B8DEA544-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35287=[""].join("\n");
var outline_f34_29_35287=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL MANIFESTATIONS OF APS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal disease in primary APS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19782557\">",
"      Other glomerular lesions associated with primary APS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal disease in APS associated with SLE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      APS IN END-STAGE RENAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acute renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3073\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3073|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/51/22329\" title=\"picture 1A\">",
"      HUS Glomerular",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/61/12246\" title=\"picture 1B\">",
"      HUS Vascular I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/49/26389\" title=\"picture 1C\">",
"      HUS Vascular II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/3/8255\" title=\"picture 2\">",
"      HUS IF IV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/29/27096?source=related_link\">",
"      Diagnosis of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/21/16727?source=related_link\">",
"      Overview of the treatment of stenosis and thrombotic complications of hemodialysis arteriovenous grafts and fistulas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/26/9635?source=related_link\">",
"      Patient information: Dialysis or kidney transplantation &mdash; which is right for me? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/57/40852?source=related_link\">",
"      Patient information: Hemodialysis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/35/29238?source=related_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16642?source=related_link\">",
"      Patient information: The antiphospholipid syndrome (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_29_35288="Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea";
var content_f34_29_35288=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Surgical risk and the preoperative evaluation and management of adults with obstructive sleep apnea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     Eric Olson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     Stephanie B Jones, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35288/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/29/35288/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15227495\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. The incidence of perioperative complications (ie, preoperative, intraoperative, and postoperative complications collectively) is increased among patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The Joint Commission has suggested that a National Patient Safety Goal be the reduction of perioperative complications among patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/3\">",
"     3",
"    </a>",
"    ], while the American Society of Anesthesiology (ASA) and American Academy of Sleep Medicine (AASM) have developed clinical practice guidelines for the perioperative management of patients with OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Common among the guidelines is an emphasis on maintaining a high index of suspicion for OSA, careful use of medications, vigilant monitoring for evidence of upper airway obstruction, an integrated team approach to perioperative management, and recognition that many recommendations are based upon clinical rationale and indirect evidence because direct evidence is scarce. Such interest in the perioperative management of patients with OSA probably reflects in part the recognition that the number of patients with OSA encountered in operating rooms is likely to increase as recognition of the disease and the prevalence of obesity increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that contribute to the increased surgical risk of patients with OSA and the preoperative evaluation and management of patients with OSA are reviewed here. The intraoperative and postoperative management of patients with OSA are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link\">",
"     \"Postoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"     \"Intraoperative management of adults with obstructive sleep apnea\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227501\">",
"    <span class=\"h1\">",
"     SURGICAL RISK IN PATIENTS WITH OSA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227509\">",
"    <span class=\"h2\">",
"     Contributing factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA who are undergoing procedures that require sedation, anesthesia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    analgesia are at higher risk for periprocedural complications than patients who do not have OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This may be related to upper airway collapse",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    OSA-related comorbidities.",
"   </p>",
"   <p>",
"    Upper airway collapse contributes to perioperative complications by inducing hypoxemia and other physiological perturbations. The following perioperative factors may increase the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    duration of upper airway collapse in patients with OSA (",
"    <a class=\"graphic graphic_table graphicRef71284 \" href=\"mobipreview.htm?5/53/5979\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Perioperative medications (eg, sedatives, general anesthetic agents, narcotic analgesics) &mdash; Perioperative medications reduce upper airway dilator tone, while inhibiting protective airway reflexes, central ventilatory drive, and arousal mechanisms. These effects mimic sleep and, therefore, may exacerbate repetitive upper airway collapse in patients with OSA. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17127?source=see_link\">",
"       \"The effects of medications on sleep quality and sleep architecture\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Upper airway narrowing &mdash;A smaller amount of upper airway collapse is necessary to cause obstruction if the upper airway is narrowed by surgical factors, such as post-intubation edema, postoperative edema, nasal packing, nasal tubes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematomas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/8-12\">",
"       8-12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Supine positioning &mdash; Patients are often required to lie in the supine position perioperatively. However, this may increase the severity of the OSA, since many patients have OSA that develops or worsens in the supine position. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of obstructive sleep apnea in adults\", section on 'Sleep position'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep deprivation &mdash; Patients often develop sleep deprivation during the perioperative period due to anxiety, the disease requiring the operation, pain, alterations in circadian rhythm,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nursing activity. Sleep deprivation may be associated with worsening OSA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/13-16\">",
"       13-16",
"      </a>",
"      ], although this is controversial.",
"     </li>",
"     <li>",
"      Cessation of continuous positive airway pressure (CPAP) therapy &mdash; Many patients with OSA temporarily discontinue their CPAP therapy perioperatively. This is often due to pain, anxiety, nausea, agitation, the presence of a nasogastric tube, failure to bring equipment to the hospital, or failure of the hospital to resume CPAP postoperatively.",
"     </li>",
"     <li>",
"      Rapid eye movement (REM) rebound &ndash; Potentially a consequence of sleep deprivation, increased REM sleep is important because OSA is typically most severe during REM sleep.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    OSA-related comorbidities include systemic hypertension, pulmonary hypertension, cardiac arrhythmias, coronary artery disease, stroke, and heart failure. These comorbidities probably contribute to the increased risk of perioperative complications among patients with OSA. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"     \"Cardiovascular effects of obstructive sleep apnea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38518?source=see_link\">",
"     \"Sleep related breathing disorders and stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227527\">",
"    <span class=\"h2\">",
"     Types of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous perioperative complications are more common among patients with OSA than among those without OSA. This was illustrated by a study of 471 patients who underwent non-cardiac surgery, which found that OSA was associated with a higher incidence of overall complications (odds ratio 6.9, p = 0.003), particularly postoperative hypoxemia (odds ratio 7.9, p = 0.009) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/17\">",
"     17",
"    </a>",
"    ]. Additional postoperative complications that have been associated with OSA are difficulty intubating patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], complicated post-extubation courses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/20-22\">",
"     20-22",
"    </a>",
"    ], large blood pressure fluctuations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/20\">",
"     20",
"    </a>",
"    ], profound oxyhemoglobin desaturation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/20\">",
"     20",
"    </a>",
"    ], myocardial ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/20\">",
"     20",
"    </a>",
"    ], cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/20\">",
"     20",
"    </a>",
"    ], delirium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/23\">",
"     23",
"    </a>",
"    ], postobstructive pulmonary edema (from breathing against an obstructed upper airway) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/5,8\">",
"     5,8",
"    </a>",
"    ], and respiratory arrest [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/19,21,22\">",
"     19,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While these complications have been associated with OSA, it is unknown whether OSA is causative. Similarly, while it has been observed that most unexpected and unexplained deaths within seven days of surgery occur at night [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/24\">",
"     24",
"    </a>",
"    ], it is unknown whether OSA contributes to this observation. At least one case report has attributed postoperative death to OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227533\">",
"    <span class=\"h2\">",
"     Magnitude of the risk for complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available data suggest that OSA increases the odds of various post-operative complications by a factor of two to three. In a meta-analysis examining the association between OSA and postoperative outcomes in 13 studies published through 2010, a significant association was reported for the following outcomes: postoperative cardiac events (odds ratio [OR] 2.07, 95% CI 1.23&ndash;3.50), acute respiratory failure (OR 2.43, 95% CI 1.34-4.39), postoperative oxygen desaturation (OR 2.27, 95% CI 1.20-4.26), and postoperative ICU transfer (OR 2.81, 95% CI 1.46-5.43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/26\">",
"     26",
"    </a>",
"    ]. Significant heterogeneity was noted across studies in the way OSA and outcomes were defined and in the risk estimates for the latter two outcomes, decreasing confidence in these associations.",
"   </p>",
"   <p>",
"    Several studies have found that the incidence of perioperative complications tends to be greatest among those with severe OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/5,8,24,27\">",
"     5,8,24,27",
"    </a>",
"    ]; however, this finding has not been universal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/17,28\">",
"     17,28",
"    </a>",
"    ]. The invasiveness of the surgical procedure has been shown to contribute to the magnitude of the risk for complications, with more invasive surgery having a higher risk for complications than less invasive surgery. This is probably a consequence of more invasive surgery requiring more anesthetic agents, sedatives,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    opioids, as well as other factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227539\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preoperative evaluation differs depending upon whether or not the patient has been previously diagnosed as having OSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2677200\">",
"    <span class=\"h2\">",
"     Patients without known OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;OSA is a prevalent disorder, and most individuals who have OSA are undiagnosed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Thus, all preoperative medical histories and physical examinations should look for symptoms and signs of OSA, rather than just asking whether the patient has been previously diagnosed with OSA. This is particularly true among patients who are scheduled to undergo bariatric surgery, since this population has a very high prevalence of OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are instruments available to help identify individuals who may have OSA, including one from the AASM and one from the ASA.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The AASM advocates using a questionnaire that asks about snoring, daytime sleepiness, falling asleep while relaxing, waking up at night with a feeling of shortness of breath or choking, waking up in the morning still feeling tired or with a headache, chronic nasal congestion, and others reporting that the patient is sleepy or gasps, chokes, snorts, or stops breathing while asleep (",
"      <a class=\"graphic graphic_table graphicRef81751 \" href=\"mobipreview.htm?31/11/31932\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/5\">",
"       5",
"      </a>",
"      ]. Such questionnaires probably save time and insure consistent and complete medical histories. The AASM also uses certain signs to categorize a patient as being at high or low risk for OSA. Signs associated with a high risk of OSA include being male, having a BMI &gt;25",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      having a neck circumference &gt;17 inches in men or &gt;16 inches in women, habitual snoring or gasping, and systemic hypertension, while signs associated with a low risk include the absence of snoring, being premenopausal, and being thin.",
"     </li>",
"     <li>",
"      The ASA puts the symptoms and signs of OSA into three categories (",
"      <a class=\"graphic graphic_table graphicRef59695 \" href=\"mobipreview.htm?41/20/42316\">",
"       table 3",
"      </a>",
"      ): predisposing physical characteristics (BMI &gt;35",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      neck circumference &gt;17 inches in men or &gt;16 inches in women, craniofacial abnormalities that affect the airway, nasal obstruction, tonsil touching or nearly touching the midline), history of apparent upper airway obstruction during sleep (loud snoring, frequent snoring, observed pauses in breathing during sleep, awakens with a choking sensation, frequent arousals), and somnolence (frequent somnolence or fatigue despite seemingly adequate sleep, falls asleep easily in non-stimulating environments despite seemingly adequate sleep) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/6\">",
"       6",
"      </a>",
"      ]. A patient who has signs or symptoms in &ge;2 of the above categories has a significant probability of having OSA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are many other screening tools for OSA, but few have been examined in preoperative patients. A group of investigators assessed the ASA screening instrument, the Berlin questionnaire, the STOP screening tool, and the STOP-Bang screening tool in a surgical population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The ASA screening instrument identified preoperative patients with OSA (apnea hypopnea index [AHI] &gt;5 events per hour of sleep) with a sensitivity and specificity of 72 and 38 percent, respectively. The Berlin questionnaire consists of questions on snoring, excessive daytime sleepiness, sleepiness while driving, hypertension, and BMI. It then stratifies patients as having a high or low risk for OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/34\">",
"     34",
"    </a>",
"    ]. Its sensitivity and specificity for identifying preoperative patients with OSA were 69 and 56, respectively. The STOP questionnaire is a condensed modification of the Berlin questionnaire that requires yes or no responses to four questions about",
"    <strong>",
"     s",
"    </strong>",
"    noring,",
"    <strong>",
"     t",
"    </strong>",
"    iredness,",
"    <strong>",
"     o",
"    </strong>",
"    bserved apneas, and blood",
"    <strong>",
"     p",
"    </strong>",
"    ressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/33\">",
"     33",
"    </a>",
"    ]. It identified preoperative patients with OSA with a sensitivity and specificity of 66 and 60 percent, respectively. Finally, the STOP-Bang questionnaire also incorporates data on",
"    <strong>",
"     B",
"    </strong>",
"    MI,",
"    <strong>",
"     a",
"    </strong>",
"    ge,",
"    <strong>",
"     n",
"    </strong>",
"    eck circumference, and",
"    <strong>",
"     g",
"    </strong>",
"    ender. For a score of &ge;3, it identified preoperative patients with OSA (defined as an AHI",
"    <span class=\"nowrap\">",
"     &gt;5/hour)",
"    </span>",
"    with a sensitivity and specificity of 84 and 56 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef87572 \" href=\"mobipreview.htm?10/50/11052\">",
"     table 4",
"    </a>",
"    ). All of these tools favor sensitivity at the expense of specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At our institution, the Flemons&rsquo; screening tool is routinely used to screen preoperative patients for OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/36\">",
"     36",
"    </a>",
"    ]. Data on neck circumference, hypertension, and clinical symptoms are incorporated into the model to derive a sleep apnea clinical score (SACS). Values greater than 15 indicate that the patient has a high risk for OSA. An advantage of the Flemons&rsquo; instrument is that it can also be applied postoperatively. A high SACS combined with an increased frequency of respiratory events (ie, apnea, bradypnea, desaturations, and pain-sedation mismatch) in the post-anesthesia recovery unit predicts an increased risk for subsequent post-operative oxygen desaturation events and respiratory complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the factors included in these tools, a history of difficult intubation or upper airway characteristics that predict a difficult intubation should prompt suspicion of OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. The Mallampati score (",
"    <a class=\"graphic graphic_figure graphicRef75229 \" href=\"mobipreview.htm?2/36/2626\">",
"     figure 1",
"    </a>",
"    ) is one approach used to identify patients who are at risk for a difficult intubation that has been shown to predict OSA. A study of 137 adults being evaluated for possible OSA found that every one-point increase in the Mallampati score increased both the risk of having OSA (odds ratio [OR] 2.5, 95% CI 1.2-5.0) and the AHI (coefficient 5.2 events per hour of sleep, 95% CI 0.2-10), even after adjustment for more than 30 potential confounders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It can be difficult to decide whether a patient who has symptoms or signs compatible with OSA warrants a diagnostic evaluation, since the cardinal manifestations of OSA (ie, snoring, daytime sleepiness, obesity, systemic hypertension) are extremely common and nonspecific, and diagnostic testing is expensive and time consuming. Generally speaking, we believe that the decision to perform diagnostic testing for OSA should be guided by the routine implementation of the instruments described above. In the absence of this, we advocate diagnostic testing for all preoperative patients who snore and have either excessive daytime sleepiness or at least two clinical features of OSA (",
"    <a class=\"graphic graphic_table graphicRef55633 \" href=\"mobipreview.htm?12/10/12460\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35095?source=see_link\">",
"     \"Quantifying sleepiness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among preoperative patients in whom it is determined that diagnostic evaluation is warranted, the optimal timing of the evaluation is uncertain. The decision whether to defer surgery until after a formal sleep evaluation or to manage the patient presumptively must be made on a case-by-case basis after carefully weighing the urgency of the condition requiring surgery versus the importance of confirming OSA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients in whom surgery is deferred until after a diagnostic evaluation, a sleep specialist should be consulted to expedite the process. The diagnostic evaluation of suspected OSA is described separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who require presumptive management, a reasonable approach is described below (See",
"      <a class=\"local\" href=\"#H15227571\">",
"       'Preoperative management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227547\">",
"    <span class=\"h2\">",
"     Patients with known OSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA who are planning to undergo surgery should have a preoperative medical history and physical examination performed. The purpose of the evaluation is to estimate the surgical risk and to determine if further assessment is necessary. The medical history and physical examination should review all of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type of surgical procedure",
"     </li>",
"     <li>",
"      Severity of the OSA &mdash; Determining the severity of the OSA requires that prior data be reviewed, particularly the apnea hypopnea index (AHI), but also the nadir of oxyhemoglobin saturation, arrhythmias associated with episodes of upper airway obstruction, the impact of body position, and the presenting symptoms and signs. Clinicians should be aware that different organizations define severity differently. The American Academy of Sleep Medicine (AASM) and the American Society of Anesthesiology (ASA) use the AHI alone to categorize the severity of OSA. In contrast, we define the severity of OSA on the basis of the AHI, symptoms, signs, and physiological variables. Our definitions of mild, moderate, and severe OSA are described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of obstructive sleep apnea in adults\", section on 'Disease spectrum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Consequences of OSA &mdash; Potential consequences of OSA include systemic hypertension, pulmonary hypertension, cardiac arrhythmias, stroke, and coronary artery disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=see_link\">",
"       \"Cardiovascular effects of obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38518?source=see_link\">",
"       \"Sleep related breathing disorders and stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Conditions that predispose to OSA and also independently increase surgical risk &mdash; The major predisposing condition to OSA that may also independently increase surgical risk is obesity. Other conditions that should be considered include craniofacial and upper airway soft tissue abnormalities (eg, abnormal maxillary or short mandibular size, a wide craniofacial base, tonsillar hypertrophy, adenoid hypertrophy), chronic nasal congestion, and smoking. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=see_link&amp;anchor=H9969828#H9969828\">",
"       \"Overview of obstructive sleep apnea in adults\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Current, prior therapies, and residual symptoms &mdash; Therapies that patients with OSA may be using or may have tried include positive airway pressure (eg, continuous positive airway pressure [CPAP]), oral appliances,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      upper airway surgery. Patients who are using therapy should be asked about residual symptoms, as well as problems with adherence and technical difficulties. Patients who were previously treated but are no longer receiving therapy should be asked why therapy was discontinued. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"       \"Management of obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227553\">",
"    <span class=\"h3\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The invasiveness of the surgical procedure and the severity of the OSA are the primary determinants of the risk of perioperative complications (ie, preoperative, intraoperative, and postoperative complications collectively), according to consensus opinion that has not been empirically tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. However, consequences of OSA (eg, hypertension) and conditions that both predispose to OSA and independently increase surgical risk (eg, obesity) may also contribute. These variables should all be considered when estimating the risk of perioperative complications.",
"   </p>",
"   <p>",
"    The ASA has developed a scoring system to help assess the risk of perioperative complications in patients with OSA, although it has not yet been validated (",
"    <a class=\"graphic graphic_table graphicRef70982 \" href=\"mobipreview.htm?21/41/22173\">",
"     table 6",
"    </a>",
"    ). The scoring system has three components: the severity of the OSA (based upon a sleep study or clinical indicators), the invasiveness of the surgery and type of anesthesia planned, and the anticipated need for postoperative opioid analgesia. These components are used to calculate a score between zero and six. Patients with a score of five or six are at significantly increased risk for a perioperative complication from OSA, while patients with a score of four may be at increased risk for a perioperative complication from OSA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227559\">",
"    <span class=\"h3\">",
"     Further evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with OSA who are asymptomatic, adherent with therapy, and have not experienced excessive weight gain or weight loss since their last sleep evaluation can proceed to surgery without further sleep evaluation or modification of their therapy, assuming that the potential benefits of the surgery outweigh its risks. Assessment of a patient&rsquo;s adherence with therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44006?source=see_link\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with OSA who report persistent or recurrent symptoms, have not adhered with therapy, have had technical difficulties with therapy, or have had significant weight gain or weight loss since their prior sleep evaluation should be referred for evaluation by a sleep specialist prior to surgery (",
"    <a class=\"graphic graphic_table graphicRef55204 \" href=\"mobipreview.htm?3/13/3291\">",
"     table 7",
"    </a>",
"    ). Many sleep specialists will perform repeat polysomnography to confirm the diagnosis of OSA, assess its severity, evaluate the adequacy of current therapy, and, if necessary, re-titrate therapy. The preoperative evaluation should be scheduled far enough in advance of surgery to allow time for such additional sleep evaluation if necessary. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=see_link\">",
"     \"Polysomnography in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227571\">",
"    <span class=\"h1\">",
"     PREOPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the preoperative evaluation described above, patients will fall into one of the following categories, which can be used to guide preoperative management:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with confirmed OSA who are being treated with positive airway pressure therapy or an oral appliance and are asymptomatic, adherent with therapy, and have not experienced excessive weight gain or weight loss since their last sleep evaluation &ndash; These patients should be encouraged to continue their current therapy preoperatively.",
"     </li>",
"     <li>",
"      Patients with confirmed OSA who have indications for treatment, but who are either not being treated or are insufficiently treated (ie, they have persistent symptoms) &ndash; These patients should be reevaluated prior to surgery by a sleep specialist. The evaluation may include having the therapy titrated to an effective level and resumed preoperatively. Continuous positive airway pressure (CPAP) is the preferred therapy in this setting because it is immediately effective, accessible, and easily initiated.",
"     </li>",
"     <li>",
"      Patients with suspected OSA who undergo a diagnostic evaluation prior to surgery and are confirmed to have OSA &ndash; These patients should have therapy initiated preoperatively if indicated. The indications for therapy are discussed separately (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of obstructive sleep apnea in adults\", section on 'Indications for treatment'",
"      </a>",
"      ). CPAP is the preferred therapy in this setting for the same reasons as those stated above, but the optimal duration has not been defined. A minimum of one week of pre-operative CPAP should be considered, although this should be modified according to patient-specific circumstances, such as the urgency of surgery, severity of OSA, and extent of challenges to CPAP implementation.",
"     </li>",
"     <li>",
"      Patients with suspected OSA for whom presumptive management has been chosen &ndash; Presumptive therapy may be chosen if it is judged that the harm or burden of delaying surgery exceeds the benefits of making a definitive diagnosis. Patients for whom presumptive therapy is chosen will not have undergone polysomnography with positive airway pressure titration, the level of positive airway pressure must be derived empirically. We suggest initiating either fixed continuous positive airway pressure (CPAP) or autotitrating CPAP and selecting a level of positive airway pressure using an approach similar to that used to titrate positive airway pressure with portable monitoring. This is described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link&amp;anchor=H13#H13\">",
"       \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\", section on 'In-home studies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of preoperative treatment of OSA on patient-important surgical outcomes (eg, postoperative mortality) has been scarcely studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35288/abstract/6\">",
"     6",
"    </a>",
"    ]. However, there is moderate to high quality evidence from non-surgical patients that the treatment of OSA improves physiological outcomes that may be risk factors for perioperative complications (eg, blood pressure, hypoxemia). This provides the rationale for initiating therapy preoperatively.",
"   </p>",
"   <p>",
"    Patients who do not tolerate preoperative therapy should undergo multidisciplinary troubleshooting. This is described separately in the context of the evaluation of patients who are nonadherent to therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44006?source=see_link&amp;anchor=H7#H7\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\", section on 'Interventions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25953414\">",
"    <span class=\"h1\">",
"     INPATIENT OR OUTPATIENT SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision about whether to perform surgery on an inpatient or outpatient basis must be individualized. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link&amp;anchor=H257780#H257780\">",
"     \"Intraoperative management of adults with obstructive sleep apnea\", section on 'Inpatient or outpatient surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15227577\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive sleep apnea (OSA) is a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. (See",
"      <a class=\"local\" href=\"#H15227495\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical risk and preoperative aspects of managing patients with OSA are discussed in this review. Intraoperative and postoperative issues are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=see_link\">",
"       \"Postoperative management of adults with obstructive sleep apnea\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=see_link\">",
"       \"Intraoperative management of adults with obstructive sleep apnea\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The incidence of perioperative complications (ie, preoperative, intraoperative, and postoperative complications collectively) is increased among patients with OSA. This is likely due to increased upper airway collapse and OSA-related comorbidities. (See",
"      <a class=\"local\" href=\"#H15227501\">",
"       'Surgical risk in patients with OSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with known OSA who are planning to undergo surgery should have a preoperative medical history and physical examination performed. The medical history should review the type of surgery planned, the severity of the OSA, consequences of the OSA, the presence of conditions that both predispose to OSA and independently increase surgical risk, and prior or current therapies. (See",
"      <a class=\"local\" href=\"#H15227547\">",
"       'Patients with known OSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with OSA who are asymptomatic, adherent with therapy, and have not experienced excessive weight gain or weight loss since their last sleep evaluation do not require a sleep evaluation or modification of their therapy prior to surgery. (See",
"      <a class=\"local\" href=\"#H15227547\">",
"       'Patients with known OSA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15227571\">",
"       'Preoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with OSA who report persistent or recurrent symptoms, have not adhered with therapy, have had technical difficulties with therapy, or have had significant weight gain or weight loss since their prior sleep evaluation should be reevaluated by a sleep specialist prior to surgery. Those who have indications for treatment, but who either are not being treated or are being ineffectively treated, should have their therapy titrated to an effective level and then continued preoperatively. (See",
"      <a class=\"local\" href=\"#H15227547\">",
"       'Patients with known OSA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15227571\">",
"       'Preoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients without known OSA, the preoperative evaluation should include a medical history and physical examination that looks for symptoms and signs of OSA, rather than just asking whether the patient has been previously diagnosed with OSA. Several OSA screening tools have been assessed in preoperative patients, including one proposed by the American Society of Anesthesiology, the Berlin questionnaire, the STOP questionnaire, the STOP-Bang questionnaire, and the Flemons&rsquo; instrument. Among preoperative patients in whom it is determined that diagnostic evaluation for OSA is warranted, clinicians need to decide whether to defer surgery until after a formal sleep evaluation or to manage the patient presumptively. This decision must be made on a case-by-case basis after carefully weighing the urgency of the condition requiring surgery versus the importance of confirming OSA. (See",
"      <a class=\"local\" href=\"#H2677200\">",
"       'Patients without known OSA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with suspected OSA whose surgery is deferred until after a sleep evaluation, a sleep specialist should be consulted. The sleep specialist can expedite the diagnostic evaluation and guide the initiation of preoperative therapy, if indicated. (See",
"      <a class=\"local\" href=\"#H2677200\">",
"       'Patients without known OSA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15227571\">",
"       'Preoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients in whom presumptive management is chosen, a reasonable approach to initiating empiric therapy is similar to the initiation of positive airway pressure using portable monitoring. This is described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link&amp;anchor=H13#H13\">",
"       \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\", section on 'In-home studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For preoperative patients in whom the initiation of therapy for OSA is indicated, we suggest initiating therapy prior to surgery, rather than waiting until the postoperative period (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For the same patients, we recommend positive airway pressure therapy, rather than an oral appliance (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15227571\">",
"       'Preoperative management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/1\">",
"      Hillman DR, Loadsman JA, Platt PR, Eastwood PR. Obstructive sleep apnoea and anaesthesia. Sleep Med Rev 2004; 8:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/2\">",
"      Boushra NN. Anaesthetic management of patients with sleep apnoea syndrome. Can J Anaesth 1996; 43:599.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.hcpro.com/NRS-66500-975/Sleep-apnea-among-proposed-National-Patient-Safety-Goals.html (Accessed on June 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/4\">",
"      Benumof JL. Obstructive sleep apnea in the adult obese patient: implications for airway management. Anesthesiol Clin North America 2002; 20:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/5\">",
"      Meoli AL, Rosen CL, Kristo D, et al. Upper airway management of the adult patient with obstructive sleep apnea in the perioperative period--avoiding complications. Sleep 2003; 26:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/6\">",
"      Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/7\">",
"      Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/8\">",
"      Esclamado RM, Glenn MG, McCulloch TM, Cummings CW. Perioperative complications and risk factors in the surgical treatment of obstructive sleep apnea syndrome. Laryngoscope 1989; 99:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/9\">",
"      Gabrielczyk MR. Acute airway obstruction after uvulopalatopharyngoplasty for obstructive sleep apnea syndrome. Anesthesiology 1988; 69:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/10\">",
"      Fairbanks DN. Uvulopalatopharyngoplasty complications and avoidance strategies. Otolaryngol Head Neck Surg 1990; 102:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/11\">",
"      Burgess LP, Derderian SS, Morin GV, et al. Postoperative risk following uvulopalatopharyngoplasty for obstructive sleep apnea. Otolaryngol Head Neck Surg 1992; 106:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/12\">",
"      McColley SA, April MM, Carroll JL, et al. Respiratory compromise after adenotonsillectomy in children with obstructive sleep apnea. Arch Otolaryngol Head Neck Surg 1992; 118:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/13\">",
"      Persson HE, Svanborg E. Sleep deprivation worsens obstructive sleep apnea. Comparison between diurnal and nocturnal polysomnography. Chest 1996; 109:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/14\">",
"      Haraldsson PO, Carenfelt C, Knutsson E, et al. Preliminary report: validity of symptom analysis and daytime polysomnography in diagnosis of sleep apnea. Sleep 1992; 15:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/15\">",
"      Stoohs RA, Dement WC. Snoring and sleep-related breathing abnormality during partial sleep deprivation. N Engl J Med 1993; 328:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/16\">",
"      Guilleminault C, Rosekind M. The arousal threshold: sleep deprivation, sleep fragmentation, and obstructive sleep apnea syndrome. Bull Eur Physiopathol Respir 1981; 17:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/17\">",
"      Kaw R, Pasupuleti V, Walker E, et al. Postoperative complications in patients with obstructive sleep apnea. Chest 2012; 141:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/18\">",
"      Hiremath AS, Hillman DR, James AL, et al. Relationship between difficult tracheal intubation and obstructive sleep apnoea. Br J Anaesth 1998; 80:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/19\">",
"      Siyam MA, Benhamou D. Difficult endotracheal intubation in patients with sleep apnea syndrome. Anesth Analg 2002; 95:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/20\">",
"      Reeder MK, Goldman MD, Loh L, et al. Postoperative obstructive sleep apnoea. Haemodynamic effects of treatment with nasal CPAP. Anaesthesia 1991; 46:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/21\">",
"      Rennotte MT, Baele P, Aubert G, Rodenstein DO. Nasal continuous positive airway pressure in the perioperative management of patients with obstructive sleep apnea submitted to surgery. Chest 1995; 107:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/22\">",
"      Ostermeier AM, Roizen MF, Hautkappe M, et al. Three sudden postoperative respiratory arrests associated with epidural opioids in patients with sleep apnea. Anesth Analg 1997; 85:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/23\">",
"      Lee JW. Recurrent delirium associated with obstructive sleep apnea. Gen Hosp Psychiatry 1998; 20:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/24\">",
"      Gupta RM, Parvizi J, Hanssen AD, Gay PC. Postoperative complications in patients with obstructive sleep apnea syndrome undergoing hip or knee replacement: a case-control study. Mayo Clin Proc 2001; 76:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/25\">",
"      Cullen DJ. Obstructive sleep apnea and postoperative analgesia--a potentially dangerous combination. J Clin Anesth 2001; 13:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/26\">",
"      Kaw R, Chung F, Pasupuleti V, et al. Meta-analysis of the association between obstructive sleep apnoea and postoperative outcome. Br J Anaesth 2012; 109:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/27\">",
"      Riley RW, Powell NB, Guilleminault C, et al. Obstructive sleep apnea surgery: risk management and complications. Otolaryngol Head Neck Surg 1997; 117:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/28\">",
"      Weingarten TN, Flores AS, McKenzie JA, et al. Obstructive sleep apnoea and perioperative complications in bariatric patients. Br J Anaesth 2011; 106:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/29\">",
"      Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 1997; 20:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/30\">",
"      Singh M, Liao P, Kobah S, et al. Proportion of surgical patients with undiagnosed obstructive sleep apnoea. Br J Anaesth 2013; 110:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/31\">",
"      Sareli AE, Cantor CR, Williams NN, et al. Obstructive sleep apnea in patients undergoing bariatric surgery--a tertiary center experience. Obes Surg 2011; 21:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/32\">",
"      Chung F, Yegneswaran B, Liao P, et al. Validation of the Berlin questionnaire and American Society of Anesthesiologists checklist as screening tools for obstructive sleep apnea in surgical patients. Anesthesiology 2008; 108:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/33\">",
"      Chung F, Yegneswaran B, Liao P, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology 2008; 108:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/34\">",
"      Netzer NC, Stoohs RA, Netzer CM, et al. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999; 131:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/35\">",
"      Chung F, Elsaid H. Screening for obstructive sleep apnea before surgery: why is it important? Curr Opin Anaesthesiol 2009; 22:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/36\">",
"      Flemons WW, Whitelaw WA, Brant R, Remmers JE. Likelihood ratios for a sleep apnea clinical prediction rule. Am J Respir Crit Care Med 1994; 150:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/37\">",
"      Gali B, Whalen FX, Schroeder DR, et al. Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and postanesthesia care assessment. Anesthesiology 2009; 110:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35288/abstract/38\">",
"      Nuckton TJ, Glidden DV, Browner WS, Claman DM. Physical examination: Mallampati score as an independent predictor of obstructive sleep apnea. Sleep 2006; 29:903.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13516 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35288=[""].join("\n");
var outline_f34_29_35288=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15227577\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15227495\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15227501\">",
"      SURGICAL RISK IN PATIENTS WITH OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15227509\">",
"      Contributing factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15227527\">",
"      Types of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15227533\">",
"      Magnitude of the risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15227539\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2677200\">",
"      Patients without known OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15227547\">",
"      Patients with known OSA",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15227553\">",
"      - Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15227559\">",
"      - Further evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15227571\">",
"      PREOPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25953414\">",
"      INPATIENT OR OUTPATIENT SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15227577\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/13516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/13516|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/36/2626\" title=\"figure 1\">",
"      Modified Mallampati airway classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/13516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/53/5979\" title=\"table 1\">",
"      Periop factors aggravating OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/11/31932\" title=\"table 2\">",
"      OSA symptoms questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/20/42316\" title=\"table 3\">",
"      Identify and assess OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/50/11052\" title=\"table 4\">",
"      STOP-Bang questionnaire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/10/12460\" title=\"table 5\">",
"      Clinical features OSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/41/22173\" title=\"table 6\">",
"      OSA scoring system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/13/3291\" title=\"table 7\">",
"      Indications preop consultation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/62/44006?source=related_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/47/18169?source=related_link\">",
"      Cardiovascular effects of obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37893?source=related_link\">",
"      Intraoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/30/38374?source=related_link\">",
"      Polysomnography in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/9/34965?source=related_link\">",
"      Postoperative management of adults with obstructive sleep apnea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/17/35095?source=related_link\">",
"      Quantifying sleepiness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/39/38518?source=related_link\">",
"      Sleep related breathing disorders and stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17127?source=related_link\">",
"      The effects of medications on sleep quality and sleep architecture",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_29_35289="Multiple atypical nevi";
var content_f34_29_35289=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F78891%7EDERM%2F53622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F78891%7EDERM%2F53622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple atypical nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple atypical nevi on the posterior trunk of an adolescent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean L Bolognia, MD, and Julie V Schaffer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Eclipse nevus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A compound nevus on the scalp of a child showing a light brown center and a more intensely pigmented rim.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35289=[""].join("\n");
var outline_f34_29_35289=null;
var title_f34_29_35290="Anaphylaxis: Rapid recognition and treatment";
var content_f34_29_35290=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anaphylaxis: Rapid recognition and treatment",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     F Estelle R Simons, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     Carlos A Camargo, Jr, MD, DrPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/29/35290/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/29/35290/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is a potentially fatal disorder. The rate of occurrence is increasing in industrialized countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Anaphylaxis is not always recognized as such because it can mimic other conditions and is variable in its presentation.",
"   </p>",
"   <p>",
"    This topic will review the recognition and treatment of anaphylaxis by healthcare professionals working in settings such as an emergency department (ED), surgical unit, hemodialysis facility, hospital ward, clinic, or clinician's office [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Unique features of anaphylaxis in pregnant women and infants are presented separately, as is the pathophysiology of anaphylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=see_link\">",
"     \"Pathophysiology of anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and may cause death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The diagnosis of anaphylaxis is based primarily upon clinical symptoms and signs, as well as a detailed description of the acute episode, including antecedent activities and events occurring within the preceding minutes to hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diagnostic criteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic criteria for anaphylaxis were published by a multidisciplinary group of experts in 2005 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. These criteria were intended to help clinicians recognize the full spectrum of symptoms and signs that comprise anaphylaxis. Anaphylaxis is underrecognized and undertreated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/1-3,5\">",
"     1-3,5",
"    </a>",
"    ]. This may partly be due to failure to appreciate that it can present without obvious skin symptoms and signs or overt shock. Anaphylaxis is a much broader syndrome than \"anaphylactic shock,\" and the goal of therapy should be early recognition and treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    to prevent progression to life-threatening respiratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cardiovascular symptoms and signs, including shock. Recognition of the variable and atypical presentations of anaphylaxis is therefore critical to providing effective therapy in the form of epinephrine, as well as reducing overreliance on less effective medications such as antihistamines and glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are three diagnostic criteria, each reflecting a different clinical presentation of anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12\">",
"     12",
"    </a>",
"    ]. Anaphylaxis is highly likely when any",
"    <strong>",
"     ONE",
"    </strong>",
"    of the following criteria is fulfilled:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Criterion 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute onset of an illness (minutes to several hours) involving the skin, mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-uvula)",
"    <strong>",
"     and at least one of the following",
"    </strong>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia).",
"     </li>",
"     <li>",
"      Reduced blood pressure (BP) or associated symptoms and signs of end-organ dysfunction (eg, hypotonia [collapse] syncope, incontinence). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Criterion 3'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note: Skin symptoms and signs are present in up to 90 percent of anaphylactic episodes. This criterion will therefore frequently be helpful in making the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Criterion 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <strong>",
"     Two or more of the following",
"    </strong>",
"    that occur rapidly after exposure",
"    <strong>",
"     to a likely allergen for that patient",
"    </strong>",
"    (minutes to several hours):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involvement of the skin-mucosal tissue (eg, generalized hives, itch-flush, swollen lips-tongue-uvula).",
"     </li>",
"     <li>",
"      Respiratory compromise (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak expiratory flow, hypoxemia).",
"     </li>",
"     <li>",
"      Reduced BP or associated symptoms and signs (eg, hypotonia [collapse], syncope, incontinence).",
"     </li>",
"     <li>",
"      Persistent gastrointestinal symptoms and signs (eg, crampy abdominal pain, vomiting).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note: Skin symptoms or signs are absent or unrecognized in up to 20 percent of anaphylactic episodes. Criterion 2 incorporates symptoms and signs in other organ systems and is applied to patients with exposure to a substance that is a likely allergen for them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Criterion 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced BP after exposure",
"    <strong>",
"     to a known allergen for that patient",
"    </strong>",
"    (minutes to several hours):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced BP in adults is defined as a systolic BP of less than 90 mmHg or greater than 30 percent decrease from that person's baseline",
"     </li>",
"     <li>",
"      In infants and children, reduced BP is defined as low systolic BP (age specific)* or greater than 30 percent decrease in systolic BP",
"     </li>",
"     <li>",
"      Low systolic BP for children is defined as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Less than 70 mmHg from 1 month up to 1 year",
"     </li>",
"     <li>",
"      Less than (70 mmHg + [2 x age]) from 1 to 10 years",
"     </li>",
"     <li>",
"      Less than 90 mmHg from 11 to 17 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Note: Criterion 3 is intended to detect anaphylactic episodes in which only one organ system is involved and is applied to patients who have been exposed to a substance to which they are known to be allergic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis may present with various combinations of approximately 40 potential symptoms and signs (",
"    <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/7-13,15-22\">",
"     7-13,15-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common symptoms and signs of anaphylaxis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin symptoms and signs, which occur in up to 90 percent of episodes, including generalized hives, itching or flushing, swollen lips-tongue-uvula, periorbital edema, conjunctival swelling.",
"     </li>",
"     <li>",
"      Respiratory symptoms and signs, which occur in up to 70 percent of episodes, including nasal discharge, nasal congestion, change in voice quality, sensation of throat closure or choking, stridor, shortness of breath, wheeze, cough.",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms and signs, which occur in up to 45 percent of episodes, including nausea, vomiting, diarrhea, and crampy abdominal pain.",
"     </li>",
"     <li>",
"      Cardiovascular symptoms and signs, which occur in up to 45 percent of episodes, including hypotonia (collapse), syncope, incontinence, dizziness, tachycardia, and hypotension.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anaphylaxis may be mild and resolve spontaneously due to endogenous production of compensatory mediators (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , angiotensin II, endothelin, and others) or it may be severe and progress within minutes to respiratory or cardiovascular compromise and death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17\">",
"     17",
"    </a>",
"    ]. The factors that determine the course of anaphylaxis in an individual patient are not fully understood. At the onset of an anaphylactic episode, it is not possible to predict how severe it will become, how rapidly it will progress, and whether it will resolve promptly and completely or become biphasic or protracted.",
"   </p>",
"   <p>",
"    Death from anaphylaxis usually results from asphyxiation due to upper airway edema or respiratory failure due to bronchial obstruction, and less commonly, from cardiovascular collapse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14,23-30\">",
"     14,23-30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unique aspects of the clinical manifestations of anaphylaxis in infants, and in women in labor and delivery, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link\">",
"     \"Unique aspects of anaphylaxis in infants\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=see_link\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Time course",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is usually characterized by a defined exposure to a potential trigger, followed by rapid onset, evolution, and resolution of symptoms and signs within minutes to hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Biphasic anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biphasic anaphylaxis is defined as a recurrence of symptoms that develops following the apparent resolution of the initial anaphylactic episode with no additional exposure to the trigger. Biphasic reactions have been reported to develop in up to 23 percent of anaphylactic episodes in adults and up to 11 percent of episodes in children. They typically occur within 8 to 10 hours after resolution of the initial symptoms, although recurrences up to 72 hours later have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19847?source=see_link\">",
"     \"Biphasic and protracted anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Protracted anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protracted anaphylaxis is defined as an anaphylactic reaction that lasts for hours, days, or even weeks in extreme cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Pitfalls in making the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is not always easy to recognize clinically. The patterns of target organ involvement are variable and may differ among individuals, as well as among episodes in the same individual. Anaphylaxis is likely underdiagnosed and underreported for a variety of reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/3,7-10,18-22,33\">",
"     3,7-10,18-22,33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some healthcare professionals remain reluctant to diagnose anaphylaxis in the absence of hypotension or shock, even though changes in blood pressure are not required for the diagnosis according to Criterion 1 or Criterion 2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypotension may go undetected when the initial blood pressure measurement is obtained after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      administration, or in infants and young children in whom normal blood pressure is low compared to adults.",
"     </li>",
"     <li>",
"      Many of the dramatic physical signs associated with hypoxia and hypotension in anaphylaxis are nonspecific, such as dyspnea, stridor, wheeze, confusion, collapse, unconsciousness, and incontinence (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Skin symptoms and signs (such as hives, itching, flushing, and angioedema), which are helpful in making the diagnosis, are absent or unrecognized in up to 20 percent of all episodes. Skin symptoms and signs may be absent if a patient has taken an H1 antihistamine. They may also be missed if an individual cannot describe itching or is not undressed and fully examined during the episode, or in patients who are draped during surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=see_link\">",
"       \"Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anaphylaxis may be difficult to recognize in certain clinical situations; for example, hemodialysis, surgery, or childbirth when, for other reasons, patients may experience dramatic physiologic shifts with consequent changes in vital signs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/7-11,17,33,34\">",
"       7-11,17,33,34",
"      </a>",
"      ]. In addition, inability of the patient to communicate the presence of early symptoms (eg, if dysphonic, dyspneic, in shock, unconscious, or anesthetized) also impedes prompt recognition of anaphylaxis.",
"     </li>",
"     <li>",
"      Anaphylaxis in a known asthmatic may be mistaken for an asthma exacerbation if accompanying skin symptoms and signs such as itching and hives, or dizziness suggestive of impending shock, are overlooked [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients experiencing their first episode may not recognize the symptoms as anaphylaxis. As a result, they may not report symptoms fully, or may focus on one prominent symptom (eg, unless specifically asked, a patient presenting with vomiting may not report that the episode was preceded by diffuse itching).",
"     </li>",
"     <li>",
"      The above factors are further compounded in patients with neurologic, psychiatric, or psychologic problems, or those who take medications or substances such as a sedating H1 antihistamine, ethanol, or recreational drugs that potentially impair cognition and judgment, making anaphylaxis particularly difficult to recognize (",
"      <a class=\"graphic graphic_table graphicRef53777 \" href=\"mobipreview.htm?10/11/10427\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17,21\">",
"       17,21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TRIGGERS AND MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most anaphylaxis episodes are triggered through an immunologic mechanism involving IgE. Foods are the most common trigger in children, while medications and insect stings are more common triggers in adults than in children. The table provides a more comprehensive list of potential anaphylaxis triggers, categorized by causative mechanism (",
"    <a class=\"graphic graphic_table graphicRef70667 \" href=\"mobipreview.htm?29/0/29708\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12,13,15,18-22\">",
"     12,13,15,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this review, the term anaphylaxis applies to all of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute systemic reactions involving IgE-dependent mechanisms.",
"     </li>",
"     <li>",
"      Acute systemic reactions involving other immunologic mechanisms (formerly called anaphylactoid reactions).",
"     </li>",
"     <li>",
"      Acute systemic reactions that occur independently of any immunologic mechanism due to direct release of histamine and other mediators from mast cells and basophils, eg, after exercise or exposure to cold or (ultraviolet), ingestion of opioids, etc.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     The acute management of anaphylaxis is the same, regardless of the trigger or mechanism involved",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12,13,15\">",
"     12,13,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTRIBUTORY FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comorbidities and concurrent medications may impact the severity of symptoms and signs and response to treatment in patients with anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef65161 \" href=\"mobipreview.htm?35/39/36476\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22,35\">",
"     18-22,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Comorbidities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asthma and cardiovascular disease are the most important risk factors for a poor outcome from anaphylaxis. Other disorders may also increase risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent asthma is a risk factor for anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. Asthma is also associated with increased risk of death from anaphylaxis, especially in adolescents and young adults with poorly controlled disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14,23-27\">",
"       14,23-27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cardiovascular disease is an important risk factor for death from anaphylaxis in middle-aged and older individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other respiratory diseases, eg, chronic obstructive pulmonary disease (COPD) or pneumonia are also risk factors for severe or fatal anaphylaxis in older adults [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute infection such as an upper respiratory tract infection, fever, emotional stress, exercise, disruption of routine, and premenstrual status may also increase the risk. With the exception of exercise, these amplifying factors have not been systematically studied in the context of anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Concurrent medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concurrent administration of certain medications, such as beta-adrenergic blockers, angiotensin-converting enzyme inhibitors, and alpha-adrenergic blockers may increase the likelihood of severe or fatal anaphylaxis, and may also interfere with the patient's ability to respond to treatment and with the patient's compensatory physiologic responses (",
"    <a class=\"graphic graphic_table graphicRef65161 \" href=\"mobipreview.htm?35/39/36476\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/38-41\">",
"     38-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta-adrenergic blockers, administered orally, parenterally, or topically (eg, eye drops) may be associated with severe anaphylaxis and may also potentially make anaphylaxis more difficult to treat by causing unopposed alpha-adrenergic effects and hypotension, as well as reduced bronchodilator response to the beta-adrenergic effects of endogenous or exogenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Glucagon for patients taking beta-blockers'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Alpha-adrenergic blockers may decrease the effects of endogenous or exogenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      at alpha-adrenergic receptors, potentially making anaphylaxis less responsive to the alpha-adrenergic effects of epinephrine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      ACE inhibitors are of particular importance in regards to patients who have experienced anaphylaxis to Hymenoptera venom [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/41,42\">",
"       41,42",
"      </a>",
"      ]. They not only block the effect of angiotensin, a compensatory response, but also block the degradation of kinins which are active in the production of symptoms and signs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LABORATORY TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical diagnosis of anaphylaxis can sometimes be supported by documentation of elevated concentrations of serum or plasma total tryptase or plasma histamine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/35,43-45\">",
"     35,43-45",
"    </a>",
"    ]. It is critical to obtain blood samples for measurement of these mast cell and basophil mediators soon after the onset of symptoms, as elevations are transient. Instructions for proper collection of samples are provided in the table (",
"    <a class=\"graphic graphic_table graphicRef72041 \" href=\"mobipreview.htm?21/8/21644\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Serum or plasma total tryptase",
"      </strong>",
"      - The test for measurement of total serum or plasma tryptase is widely available in clinical laboratories (normal range 1 to 11.4",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      Phadia AB, Uppsala, Sweden). Optimally, the blood sample for tryptase measurement needs to be obtained from 15 minutes to 3 hours of symptom onset. Tryptase elevations are more likely to be detected in anaphylaxis from stinging insect venoms or medications, and following reactions that involve hypotension [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A tryptase level that is within normal limits cannot be used to refute the clinical diagnosis of anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/35\">",
"       35",
"      </a>",
"      ]. The history trumps the test results. As an example, in individuals with food-induced anaphylaxis, or in patients who are normotensive, tryptase levels are seldom elevated, even in optimally-timed blood samples obtained within 15 minutes to 3 hours of symptom onset [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/23\">",
"       23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Serial measurements of total tryptase in serum or plasma over several hours may increase the sensitivity and the specificity of the tests. Comparison of a level obtained during the acute episode with a level obtained 24 hours after resolution of clinical symptoms and signs may be useful for confirming the clinical diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/15\">",
"       15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link\">",
"       \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a tryptase level obtained 24 or more hours after resolution of clinical symptoms and signs is still elevated, the patient should be referred to an",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      specialist for evaluation of possible systemic mastocytosis or clonal mast cell disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Plasma histamine",
"      </strong>",
"      - Plasma histamine levels typically peak within 5 to 15 minutes of the onset of anaphylaxis symptoms, and then decline to baseline by 60 minutes due to rapid metabolism by N-methyltransferase and diamine oxidase. Elevated plasma histamine levels correlate with anaphylaxis symptoms and signs, and are more likely to be increased than are total serum tryptase levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/43\">",
"       43",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Measurement of this mediator may be useful in cases of anaphylaxis occurring in a hospital setting, in which blood samples can be collected soon after the onset of symptoms. In many cases of anaphylaxis in the community, however, it is not practical to measure histamine because typically, by the time the patient reaches the emergency department, levels have returned to baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/35,43\">",
"       35,43",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Histamine should be measured in plasma, not serum. Blood samples for histamine require special handling: draw blood through a wide-bore needle, keep it cold at all times, centrifuge it immediately, and freeze the plasma promptly [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Histamine and histamine metabolites can sometimes be detected in the urine following anaphylaxis, and elevations are less fleeting than elevations in plasma histamine. However, a 24 hour urine collection, started as soon as possible after the reaction begins, is required. This is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link&amp;anchor=H19#H19\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\", section on 'Histamine metabolites'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Potential future tests",
"      </strong>",
"      - The development of a rapid, sensitive, specific laboratory test or panel of tests that helps clinicians to confirm the diagnosis of anaphylaxis in real time remains an important goal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/15,35\">",
"       15,35",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A laboratory test for mature beta-tryptase, a better marker of mast cell activation than total tryptase (which measures constitutively secreted alpha-tryptase in addition to beta-tryptase) has been developed, although it is not widely available [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/15,44\">",
"       15,44",
"      </a>",
"      ]. Testing for mature beta-tryptase is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link\">",
"       \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other potential markers of mast cell",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      basophil degranulation, such as mast cell carboxypeptidase A3, chymase, and platelet-activating factor, are under investigation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/35,46,47\">",
"       35,46,47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 other diseases and conditions might need to be considered in the differential diagnosis of anaphylaxis (",
"    <a class=\"graphic graphic_table graphicRef65677 \" href=\"mobipreview.htm?40/61/41948\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/48-55\">",
"     48-55",
"    </a>",
"    ]. The most common disorders in the differential diagnosis include acute generalized urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angioedema, acute asthma exacerbations,",
"    <span class=\"nowrap\">",
"     syncope/faint,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anxiety/panic",
"    </span>",
"    attacks. These are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=see_link\">",
"     \"Differential diagnosis of anaphylaxis in children and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=see_link&amp;anchor=H17#H17\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\", section on 'Differential diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=see_link&amp;anchor=H22500641#H22500641\">",
"     \"Unique aspects of anaphylaxis in infants\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     IMMEDIATE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tables provide rapid overviews of the initial assessment and emergency management of anaphylaxis in adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 8",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Prompt assessment and treatment are critical in anaphylaxis, as respiratory or cardiac arrest and death can occur within minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14,23-30\">",
"     14,23-30",
"    </a>",
"    ]. The cornerstones of initial management are the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/56-61\">",
"     56-61",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of the inciting antigen, if possible (eg, stop infusion of a suspect medication)",
"     </li>",
"     <li>",
"      Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)",
"     </li>",
"     <li>",
"      Intramuscular injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"     </li>",
"     <li>",
"      Placement of the patient in the supine position with the lower extremities elevated, or if dyspneic or vomiting, placement of the patient semi-recumbent with lower extremities elevated",
"     </li>",
"     <li>",
"      Supplemental oxygen",
"     </li>",
"     <li>",
"      Volume resuscitation with intravenous fluids",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a series of 164 fatalities due to anaphylaxis, the median time interval between onset of symptoms and respiratory or cardiac arrest was 5 minutes in iatrogenic anaphylaxis, 15 minutes in stinging insect venom-induced anaphylaxis, and 30 minutes in food-induced anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14\">",
"     14",
"    </a>",
"    ]. A more detailed review of fatal anaphylaxis is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"     \"Fatal anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of critical components in the initial management need to be instituted concomitantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initially, attention should focus on airway, breathing, and circulation, as well as adequacy of mentation. The skin should be examined.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      should be injected intramuscularly into the mid-anterolateral thigh (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 8",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 9",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/57-64\">",
"       57-64",
"      </a>",
"      ]. If symptoms are severe, an intravenous epinephrine infusion should be prepared. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Dosing and administration'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      The patient should be placed in the recumbent position with the lower extremities elevated to maximize perfusion of vital organs. This also helps prevent the \"empty ventricle syndrome,\" in which severe hypotension leads to inadequate cardiac filling and pulseless cardiac activity. In this syndrome, death can occur within seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/61\">",
"       61",
"      </a>",
"      ]. Individuals with respiratory distress or vomiting may not tolerate the recumbent position and should be placed in a position of comfort. Empty ventricle syndrome is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=see_link\">",
"       \"Fatal anaphylaxis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Supplemental oxygen, 6 to 8 liters by facemask, up to 100 percent, should be administered.",
"     </li>",
"     <li>",
"      Two large-bore intravenous catheters (ideally 14 to 16 gauges for most adults) should be inserted in preparation for rapid administration of fluids and medications.",
"     </li>",
"     <li>",
"      In normotensive adults, isotonic (0.9 percent) saline should be infused at a rate of 125 mL per hour to maintain venous access. In normotensive children, isotonic saline should be infused at an appropriate maintenance rate for weight, in order to maintain venous access. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=see_link\">",
"       \"Maintenance fluid therapy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Continuous noninvasive monitoring of cardiopulmonary status, including blood pressure, heart rate, respiratory rate, and oxygen saturation is required for the duration of the episode.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Airway management",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the initial steps in anaphylaxis management involve a rapid assessment of the patient's airway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intubation should be performed immediately if marked stridor or respiratory arrest is present.",
"     </li>",
"     <li>",
"      Preparations for possible intubation should be made if there is any airway involvement or significant edema of the facial or neck tissues.",
"     </li>",
"     <li>",
"      In a minority of cases, an emergency cricothyroidotomy may be required to secure the airway.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Intubation may be difficult in individuals in whom edema distorts the upper airway anatomical landmarks. Failed attempts can lead to complete airway obstruction and fatality. Therefore, upper airway closure in the setting of anaphylaxis should be managed by the most experienced clinician available. This may require immediate collaboration between an emergency medicine specialist and an anesthesiologist, otolaryngologist, or intensivist with training and experience in the management of the difficult airway. Hospitals and other healthcare facilities should have clear, written policies about how such situations will be handled.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Intravenous fluids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous access should be obtained in case fluid resuscitation is required. Massive fluid shifts can occur rapidly in anaphylaxis due to increased vascular permeability, with transfer of up to 35 percent of the intravascular volume into the extravascular space within minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/57\">",
"     57",
"    </a>",
"    ]. Any patient whose hypotension does not respond promptly and completely to injected",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    should be assumed to have intravascular volume depletion causing persistent hypotension despite maximum vasoconstriction. These patients should receive large volume fluid resuscitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22\">",
"     18-22",
"    </a>",
"    ]. The following principles should guide therapy:",
"   </p>",
"   <p>",
"    Fluid resuscitation should be initiated immediately in patients who present with orthostasis, hypotension, or incomplete response to intramuscular",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adults should receive 1 to 2 liters of normal saline at a rate of 5 to 10",
"      <span class=\"nowrap\">",
"       mL/per",
"      </span>",
"      kilogram in the first minutes of treatment. Large volumes of fluid (eg, up to 7 liters) may be required.",
"     </li>",
"     <li>",
"      Children should receive normal saline in boluses of 20 mL per kilogram, each over 5 to 10 minutes, and repeated as needed. Large volumes of fluid (up to 100 mL per kilogram) may be required.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal saline is preferred initially for the first few liters, as Lactated Ringer's solution may potentially contribute to metabolic acidosis, and dextrose is rapidly extravasated from the circulation into the interstitial tissues.",
"   </p>",
"   <p>",
"    Patients with a history of cardiovascular or renal disease must be monitored carefully and continuously for clinical response and for volume overload. In patients requiring larger volumes, colloid (albumin or hydroxyethyl starch [",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/13/9430?source=see_link\">",
"     hetastarch",
"    </a>",
"    ]) and crystalloid (normal saline) appear equally effective. Anaphylaxis to colloid has been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnant women",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional precautions and considerations are important in the management of anaphylaxis in pregnant women; for example during labor and delivery, positioning of the patient on her left side and continuous fetal monitoring are important [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=see_link&amp;anchor=H21#H21\">",
"     \"Anaphylaxis in pregnant and breastfeeding women\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In humans experiencing anaphylaxis, randomized, placebo-controlled trials that meet current standards have not yet been performed for any pharmacologic intervention.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is the best studied medication in anaphylaxis. The evidence for its use comes from observational studies during anaphylaxis, randomized controlled clinical pharmacology studies at baseline, studies of anaphylaxis in animal models, and epidemiologic studies, including fatality studies. The evidence for use of H1-antihistamines in anaphylaxis is extrapolated from their use in urticaria. The evidence for the use of beta-2 adrenergic agonists and glucocorticoids in anaphylaxis is extrapolated from their use in acute asthma.",
"   </p>",
"   <p>",
"    In the future, it is possible that randomized controlled trials will be conducted in anaphylaxis with glucocorticoids, H1 antihistamines, or H2 antihistamines; however, placebo-controlled trials with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    will never be performed, due to ethical considerations: anaphylaxis can kill within minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14,23-28\">",
"     14,23-28",
"    </a>",
"    ] and delayed epinephrine injection is associated with fatalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/64-69\">",
"     64-69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Epinephrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is the drug of choice for anaphylaxis. The pharmacologic actions of this agent address the pathophysiologic changes that occur in anaphylaxis better than any other medication. Moreover, it is the only medication that prevents or reverses obstruction to airflow in the upper and lower respiratory tracts, and prevents or reverses cardiovascular collapse (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 8",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 9",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Therapeutic actions and adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic actions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    include the following (",
"    <a class=\"graphic graphic_table graphicRef65684 \" href=\"mobipreview.htm?32/4/32844\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/58,64,66-70\">",
"     58,64,66-70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alpha-1 adrenergic agonist effects: increased vasoconstriction, increased peripheral vascular resistance, and decreased mucosal edema (eg, in the upper airway).",
"     </li>",
"     <li>",
"      Beta-1 adrenergic agonist effects: increased inotropy and increased chronotropy.",
"     </li>",
"     <li>",
"      Beta-2 adrenergic agonist effects: increased bronchodilation and decreased release of mediators of inflammation from mast cells and basophils.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In patients of all ages,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    administered in therapeutic doses by any route often causes mild transient pharmacologic effects, such as anxiety, restlessness, headache, dizziness, palpitations, pallor, and tremor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/58,68-70\">",
"     58,68-70",
"    </a>",
"    ]. These symptoms and signs are similar to those occurring during the physiologic \"fight or flight\" response and are due to endogenous epinephrine that occurs normally in sudden frightening or life-threatening situations.",
"   </p>",
"   <p>",
"    Rarely, and especially after overdose,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    may lead to ventricular arrhythmias, angina, myocardial infarction, pulmonary edema, sudden sharp increase in blood pressure, and intracranial hemorrhage. Serious adverse effects occur most commonly after an intravenous bolus injection or an overly rapid intravenous infusion in patients without continuous noninvasive monitoring of blood pressure and heart rate and function. They also occur after erroneous intravenous injection of a 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (1:1000) epinephrine solution instead of an appropriately diluted 0.1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    (1:10,000) or 0.01",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    epinephrine solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/64,68,71\">",
"     64,68,71",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Situations requiring caution'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Confusion persists among clinicians regarding the optimal",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    dose and route of administration for the initial treatment of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Intramuscular injection",
"      </strong>",
"      &mdash; Intramuscular injection is recommended over subcutaneous injection because it consistently provides a more rapid increase in the plasma and tissue concentrations of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. Epinephrine is commercially available in several dilutions, and great care must be taken to use the correct dilution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22\">",
"       18-22",
"      </a>",
"      ]. The epinephrine dilution for intramuscular injection contains 1 mg per mL and may also be labeled as 1:1000.",
"      <br/>",
"      <br/>",
"      For adults, the recommended dose of epinephrine (1 mg per mL) is 0.3 to 0.5 mg per single dose, injected intramuscularly into the mid-anterolateral thigh (vastus lateralis muscle). This treatment may be repeated at 5 to 15 minute intervals. This recommendation is based on clinical experience and consensus opinion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/19-21,70\">",
"       19-21,70",
"      </a>",
"      ]. Typically, only one or two additional doses are needed.",
"      <br/>",
"      <br/>",
"      For infants and children, the recommended dose of epinephrine (1 mg per mL) is 0.01 mg per kilogram (up to 0.5 mg per dose), injected intramuscularly into the mid-anterolateral thigh (vastus lateralis muscle). The dose should be drawn up using a 1 mL syringe. This treatment may be repeated at 5 to 15 minute intervals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/58,64,72\">",
"       58,64,72",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Epinephrine can also be administered into the mid-anterolateral thigh using an autoinjector. These are available only in 0.15 mg and 0.3 mg doses. Children weighing less than 25 kilograms should receive the 0.15 mg dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/58\">",
"       58",
"      </a>",
"      ]:",
"      <br/>",
"      <br/>",
"      EpiPen 0.3 mg or Adrenaclick 0.3 mg or Twinject 0.3 mg or Auvi-Q 0.3 mg per dose (adult dose).",
"      <br/>",
"      <br/>",
"      EpiPen Jr 0.15 mg or Adrenaclick 0.15 mg or Twinject 0.15 mg or Auvi-Q 0.15 mg per dose (pediatric dose).",
"      <br/>",
"      <br/>",
"      The needle used in adults and children should be long enough to penetrate the subcutaneous adipose tissue over the vastus lateralis muscle. Realistically, however, intramuscular injection into the thigh may be impossible in some patients, especially those who are overweight or obese [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. Although the best approach in this situation has not been studied, we suggest as deep an injection as possible into the muscle.",
"     </li>",
"     <li>",
"      <strong>",
"       Intravenous infusion and indications",
"      </strong>",
"      &mdash; Patients who do not respond to intramuscular injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      and fluid resuscitation may not be adequately perfusing muscle tissues, as most commonly occurs in individuals presenting with profound hypotension or symptoms and signs suggestive of impending shock (dizziness, incontinence of urine",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      stool).",
"      <br/>",
"      <br/>",
"      Such patients should receive epinephrine by",
"      <strong>",
"       SLOW",
"      </strong>",
"      intravenous infusion, with the rate titrated according to response and the presence of continuous hemodynamic monitoring. Slow continuous infusion is preferred over an intravenous bolus dose as the latter is associated with more dosing errors and more adverse effects [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/20,64,75\">",
"       20,64,75",
"      </a>",
"      ]. An intravenous infusion of epinephrine should preferably be given by clinicians who are trained, skilled, and experienced in its use and can titrate the rate of infusion (and therefore the epinephrine dose) using continuous noninvasive monitoring of blood pressure, heart rate and function.",
"      <br/>",
"      <br/>",
"      <strong>",
"       As noted above, epinephrine is commercially available in several dilutions, and great care must be taken to use the correct dilution in order to avoid overdosing the patient",
"      </strong>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/71\">",
"       71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      <strong>",
"       The epinephrine dilution for intravenous infusion contains 0.1",
"       <span class=\"nowrap\">",
"        mg/mL",
"       </span>",
"       and may also be labeled 1:10,000.",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For adults, the initial dose for intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      infusion is 2 to 10 micrograms per minute, titrated to effect on blood pressure with continuous noninvasive monitoring [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For infants and children, the dose for intravenous infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      is 0.1 to 1 microgram per kilogram per minute, titrated to effect on blood pressure with continuous noninvasive monitoring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To reduce the risk of making a medication error, we suggest that centers have available a protocol that includes steps on how to prepare and administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    infusion. Examples of adult (",
"    <a class=\"graphic graphic_table graphicRef75682 \" href=\"mobipreview.htm?7/17/7454\">",
"     table 11",
"    </a>",
"    ) and pediatric infusions (",
"    <a class=\"graphic graphic_table graphicRef56049 \" href=\"mobipreview.htm?2/18/2350\">",
"     table 12",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66791 \" href=\"mobipreview.htm?39/39/40573\">",
"     table 13",
"    </a>",
"    ) are provided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series have implicated the failure to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    early in the course of treatment as a consistent finding in anaphylaxis deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14,23-28,76\">",
"     14,23-28,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 13 fatal and near fatal food-induced anaphylactic reactions in children and adolescents, six of the seven patients (86 percent) who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      within 30 minutes of symptom onset, survived. In contrast, only two of the six patients (33 percent) who received epinephrine one hour or more after symptom onset, survived [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of anaphylactic deaths occurring from 1992 to 1998, only 20 percent of 24 patients were given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      at any point in their treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the fatality series described previously, only 14 percent of the 164 patients dying from anaphylaxis received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      before respiratory or cardiac arrest, although 62 percent of the 164 patients eventually received it before demise [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, anaphylaxis occurring during evaluation of venom immunotherapy has been investigated prospectively. In one study, 68 patients with a history of anaphylaxis to insect stings were randomly assigned to venom immunotherapy or placebo immunotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/57\">",
"     57",
"    </a>",
"    ]. Following this, all were stung in a controlled, monitored setting and treated if needed with a standardized protocol of high flow oxygen,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    infusion, and normal saline rapid infusion. Nineteen of the 21 patients in the placebo group developed anaphylaxis and received epinephrine. Symptoms responded within five minutes in all but one patient. In nine patients, an initial attempt to stop the epinephrine infusion was followed by a return of symptoms, which subsided again once the epinephrine infusion was restarted.",
"   </p>",
"   <p>",
"    Finally, there is extensive clinical experience among allergy practitioners with giving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    to treat anaphylaxis occurring in response to immunotherapy. This is a unique situation, because allergy clinic staff observe patients closely for the symptoms and signs of anaphylaxis and reactions are detected at very early stages. Over the past few decades, consensus has been reached that even mild systemic reactions are best treated immediately with epinephrine, as this appears to prevent progression to more severe symptoms more effectively than any other available therapies. As a result, successive guidelines for treatment of immunotherapy reactions have called for epinephrine to be given as soon as a systemic reaction of",
"    <strong>",
"     any",
"    </strong>",
"    severity is detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/77\">",
"     77",
"    </a>",
"    ]. In studies in which all or most patients who developed anaphylaxis after allergen immunotherapy were treated promptly with epinephrine injections, symptoms were mild and no additional injections of epinephrine were given, even in the 10 to 23 percent of reactions that were biphasic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Situations requiring caution",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are",
"    <strong>",
"     NO",
"    </strong>",
"    absolute contraindications to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    use in anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22,64,66-70\">",
"     18-22,64,66-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subgroups of patients might theoretically be at higher risk for adverse effects during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    therapy. Formal risk-benefit analyses are not possible.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with cardiovascular diseases: reluctance to administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      due to fear of adverse cardiac effects should be countered by the awareness that the heart is a target organ in anaphylaxis. In the healthy human heart, mast cells are present throughout the myocardium and in the intima of coronary arteries. In patients with coronary artery disease, mast cells are found in atherosclerotic lesions and contribute to atherogenesis. Anaphylaxis can unmask subclinical coronary artery disease, and myocardial infarction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arrhythmias can occur during anaphylaxis, even if epinephrine is not injected [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/39,78\">",
"       39,78",
"      </a>",
"      ]. Moreover, anaphylaxis itself can cause vasospasm, arrhythmias, and myocardial infarction in patients, including children, with healthy hearts as confirmed by normal electrocardiograms, echocardiography, and other studies after resolution of anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients receiving monoamine oxidase inhibitors (which block",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      metabolism), or tricyclic antidepressants (which prolong epinephrine duration of action).",
"     </li>",
"     <li>",
"      Patients with certain preexisting conditions, such as recent intracranial surgery, aortic aneurysm, uncontrolled hyperthyroidism or hypertension, or other conditions that might place them at higher risk for adverse effects related to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Patients receiving stimulant medications (eg, amphetamines or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/60/39881?source=see_link\">",
"       methylphenidate",
"      </a>",
"      used in the treatment of attention deficit hyperactivity disorder) or abusing cocaine that might place them at higher risk for adverse effects from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To reiterate, there are no absolute contraindications to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in the treatment of anaphylaxis. The risk of death or serious disability from hypoxic- ischemic encephalopathy due to inadequately treated anaphylaxis usually outweighs other concerns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22,64,66-70\">",
"     18-22,64,66-70",
"    </a>",
"    ]. Existing evidence clearly favors the benefit of epinephrine administration in anaphylaxis. Sound clinical judgment is essential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Glucagon for patients taking beta-blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving beta-blockers may be resistant to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and can develop refractory hypotension and bradycardia. In this situation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/32/25093?source=see_link\">",
"     glucagon",
"    </a>",
"    should be administered because it has inotropic and chronotropic effects that are not mediated through beta-receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/80\">",
"     80",
"    </a>",
"    ]. A dose of 1 to 5 mg in adults (in children, 20 to 30 micrograms per kilogram to a maximum of 1 mg) administered intravenously over 5 minutes is recommended. This dose may be repeated or followed by an infusion of 5 to 15 micrograms per minute. Rapid administration of glucagon can induce vomiting; therefore, protection of the airway, for example, by placement in the lateral recumbent position, is important in drowsy or obtunded patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Adjunctive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive therapies for the treatment of anaphylaxis include antihistamines, bronchodilators, glucocorticoids, and other vasopressors in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     H1 antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     Epinephrine",
"    </a>",
"    is first-line treatment for anaphylaxis and there is no known equivalent substitute. A systematic review of the literature has failed to retrieve any randomized controlled trials that meet current standards and support the use of H1 antihistamines in anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite this, H1 antihistamines are the most commonly administered medications in the treatment of anaphylaxis. This suggests overreliance on these agents, which should be considered adjunctive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    for the purpose of relieving itching and hives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/81-84\">",
"     81-84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H1 antihistamines relieve itch and hives. These medications DO NOT relieve upper or lower airway obstruction, hypotension or shock, and in standard doses do not inhibit mediator release from mast cells and basophils. It is probable that the improvement in noncutaneous symptoms that is sometimes attributed to antihistamine treatment occurs instead because of endogenous production of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      and other compensatory mediators, including other catecholamines, angiotensin II, and endothelin I [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17\">",
"       17",
"      </a>",
"      ]. In addition, the onset of action of antihistamines, even",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      given by injection, is too slow to provide any immediate benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For parenteral treatment, only first-generation agents are available:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For adults: consider",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      25 to 50 mg intravenously; may be repeated up to a maximum daily dose of 400 mg per 24 hours.",
"     </li>",
"     <li>",
"      For children weighing less than 40 kg: consider",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      1 mg per kg (maximum 40 mg) intravenously, which may be repeated up to a maximum daily dose of 5 mg per kg or 200 mg per 24 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For oral treatment, second-generation H1 antihistamines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/34/36390?source=see_link\">",
"     cetirizine",
"    </a>",
"    ) offer certain advantages over first-generation agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/52/24390?source=see_link\">",
"     chlorpheniramine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/24/391?source=see_link\">",
"     hydroxyzine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    ). Second-generation H1 antihistamines are less likely to impair cognition or psychomotor performance (eg, the ability to drive safely), or to cause sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/65,69,86\">",
"     65,69,86",
"    </a>",
"    ]. Orally-administered cetirizine acts within one hour. However, second-generation H1 antihistamines are not available in parenteral formulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     H2 antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is minimal evidence to support the use of H2 antihistamines in conjunction with H1 antihistamines in the emergency treatment of anaphylaxis. Most guidelines do not include these medications.",
"   </p>",
"   <p>",
"    If used,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (50 mg in adults) (12.5 to 50 mg [1 mg per kilogram] in children), may be diluted in 5 percent dextrose to a total volume of 20 mL and injected intravenously over five minutes. Rapid infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    can cause hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Bronchodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the treatment of bronchospasm not responsive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , inhaled bronchodilators, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    should be administered by",
"    <span class=\"nowrap\">",
"     nebulizer/compressor",
"    </span>",
"    as needed. They are adjunctive treatment to epinephrine because they do not prevent or relieve mucosal edema in the upper airway or shock, for which the alpha-1 adrenergic effects of epinephrine are required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18-22\">",
"     18-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of action of glucocorticoids takes several hours; therefore, these medications do not relieve the initial symptoms and signs of anaphylaxis. The rationale for giving them is to prevent the biphasic or protracted reactions that occur in up to 23 percent of adults with anaphylaxis, and up to 11 percent of children with anaphylaxis. A systematic review of the literature failed to retrieve any randomized controlled trials in anaphylaxis that confirmed the effectiveness of glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/31,87\">",
"     31,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If given, a dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    of 1 to 2 mg per kilogram per day is sufficient. If glucocorticoid treatment is instituted, it can be stopped after three days without a taper, since all biphasic reactions reported to date have occurred within 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Time course'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Refractory anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Admission to an intensive care unit should occur without delay. There are no published prospective studies on the optimal management of refractory anaphylaxis.",
"   </p>",
"   <p>",
"    One theory about the pathogenesis of refractory anaphylaxis proposes that the clinical manifestations may become refractory to further catecholamine administration, perhaps due to saturation or desensitization of adrenergic receptors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/88\">",
"     88",
"    </a>",
"    ]. The use of nonadrenergic vasopressors, such as vasopressin, in the management of anaphylaxis refractory to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    in adults is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=see_link&amp;anchor=H25#H25\">",
"     \"Use of vasopressors and inotropes\", section on 'Vasopressin and analogs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anaphylactic shock displays features of both distributive (vasodilatory) and hypovolemic shock. The management of severe forms of these types of shock is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=see_link\">",
"     \"Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=see_link\">",
"     \"Hypovolemic shock in children: Initial evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=see_link&amp;anchor=H11#H11\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Vasopressors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     TREATMENT ERRORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important errors in the treatment of anaphylaxis include failure to administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    promptly, and delay in epinephrine injection due to overreliance on antihistamines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    , and glucocorticoids. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Adjunctive agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      should be administered as soon as possible once anaphylaxis is recognized. Delayed administration has been implicated in contributing to fatalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14,23-28,76\">",
"       14,23-28,76",
"      </a>",
"      ]. As noted above, a study of 13 fatal or near-fatal food-induced anaphylactic reactions in children reported that six of the seven children who survived received epinephrine within 30 minutes of ingesting the allergen, whereas only two of the six children who died received epinephrine within the first hour [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      H1 antihistamines are useful for relieving itching and urticaria, as mentioned previously. They do NOT relieve stridor, shortness of breath, wheezing, gastrointestinal symptoms and signs, hypotension or shock, and should not be substituted for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18,19,22,65,86\">",
"       18,19,22,65,86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bronchodilator treatment with nebulized",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      should be given in individuals with severe bronchospasm, as an adjunctive treatment to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      . However, albuterol does NOT prevent or relieve upper airway edema, hypotension or shock and should not be substituted for epinephrine in the treatment of anaphylaxis.",
"     </li>",
"     <li>",
"      Glucocorticoids theoretically reduce the late phase response. They do not relieve the initial symptoms of anaphylaxis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     CARE UPON RESOLUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;To reduce the risk of recurrence, patients who have been successfully treated for anaphylaxis subsequently require confirmation of the anaphylaxis trigger, as well as anaphylaxis education. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=see_link\">",
"     \"Anaphylaxis: Confirming the diagnosis and determining the trigger(s)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=see_link\">",
"     \"Long-term management of patients with anaphylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the optimal observation period for a patient who has been successfully treated for anaphylaxis in a healthcare facility. We suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with moderate anaphylaxis who do not respond promptly to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , and all patients with severe anaphylaxis, should be admitted to an observation unit or to a hospital.",
"     </li>",
"     <li>",
"      For patients with anaphylaxis that resolved promptly and completely with treatment, we suggest a minimum observation period of a few hours, and prefer a period of 8 to 10 hours, if possible. We also suggest that if patients are sent home after only a few hours, they should be trained to use an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector and should actually be supplied with one, rather than simply handed a prescription for one. As noted previously, up to 23 percent of adults may experience a biphasic reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Biphasic anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Discharge care",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients who have experienced anaphylaxis should be sent home with an anaphylaxis emergency action plan, one or more",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjectors, a plan for arranging further evaluation, and printed information about anaphylaxis and its treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Anaphylaxis emergency action plan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discharge, patients should be given a written personalized anaphylaxis emergency action plan that lists the common symptoms and signs of anaphylaxis and contains information about prompt self-injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Epinephrine autoinjector",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, patients should be supplied with an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    autoinjector directly. Instructions in the proper use of epinephrine autoinjectors should be reviewed verbally and they should be given a DVD",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    written material and directed to a manufacturer's website video providing relevant information. (See",
"    <a class=\"local\" href=\"#H44\">",
"     'Information for patients'",
"    </a>",
"    below.) If this is not possible, they should be instructed in how to use an epinephrine autoinjector correctly, provided with a prescription for it, and advised to fill the prescription immediately. In one survey, 28 percent of patients who did not inject epinephrine during anaphylaxis reported that they had never received a prescription for an autoinjector [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Counseling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mnemonic \"SAFE\" was developed to remind clinicians of the four basic action steps suggested for patients with anaphylaxis who have been treated and are subsequently leaving the emergency department or hospital [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/90\">",
"     90",
"    </a>",
"    ]. The SAFE counseling is outlined below and has been incorporated into printable patient information materials. (See",
"    <a class=\"local\" href=\"#H44\">",
"     'Information for patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Seek support",
"      </strong>",
"      &mdash; Advise the patient that:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      They have experienced anaphylaxis or \"killer allergy,\" which is a life-threatening condition.",
"     </li>",
"     <li>",
"      Symptoms of the current episode may recur up to three days after the initial onset of symptoms.",
"     </li>",
"     <li>",
"      They should self-inject",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      , and call emergency medical services or get to the nearest emergency facility at the first sign of recurrence of symptoms.",
"     </li>",
"     <li>",
"      They are at risk for repeat episodes of anaphylaxis in the future.",
"     </li>",
"     <li>",
"      Refer the patient to resources. (See",
"      <a class=\"local\" href=\"#H44\">",
"       'Information for patients'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Allergen identification and avoidance",
"      </strong>",
"      &mdash; Before the patient is discharged, an effort should be made to identify his or her anaphylaxis trigger using the history and in vitro testing (measurement of specific IgE to the allergen identified in the history). If the patient has received volume resuscitation, IgE levels might be falsely absent or undetectable due to the potential dilutional effects on circulating IgE, and it might be necessary to recheck the levels four to six weeks after the anaphylactic episode.",
"     </li>",
"     <li>",
"      Emphasize the importance of subsequent allergy skin testing to confirm the trigger, so that it can be successfully avoided in the future.",
"     </li>",
"     <li>",
"      <strong>",
"       Follow-up with specialty care",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Advise the patient to follow-up with his or her primary care clinician and obtain a referral to an allergist or to seek consultation directly with an allergist for testing and ongoing management.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      <strong>",
"       for emergencies",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Provide the patient with an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector or with a prescription for self-injectable epinephrine, as well as verbal plus",
"      <span class=\"nowrap\">",
"       DVD/written",
"      </span>",
"      instructions for use.",
"     </li>",
"     <li>",
"      Explain the importance of carrying the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector at all times.",
"     </li>",
"     <li>",
"      Advise the patient to make sure that family and friends are aware of the risks of anaphylaxis, the triggers, and how to administer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      . The correct injection technique is important to avoid unintentional injection into fingers, thumbs, or other body parts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with anaphylaxis will experience recurrent episodes unless long-term risk reduction measures are implemented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Specifically, the trigger for the anaphylactic episode should be verified. In addition, anaphylaxis education is required in order to help patients successfully avoid their confirmed trigger(s), and self-inject",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    promptly and confidently in the event of a recurrent anaphylactic episode. For these reasons, patients with anaphylaxis benefit from referral to an allergy specialist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=see_link\">",
"       \"Patient information: Anaphylaxis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=see_link\">",
"       \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=see_link\">",
"       \"Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=see_link\">",
"       \"Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other sources of accurate patient information, accessible through the Internet, include the American Academy of Allergy, Asthma and Immunology (",
"    <a class=\"external\" href=\"file://www.aaaai.org\">",
"     www.aaaai.org",
"    </a>",
"    ) and the American College of Allergy, Asthma and Immunology (",
"    <a class=\"external\" href=\"file://www.acaai.org/\">",
"     www.acaai.org",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/29/35290/abstract/90,92\">",
"     90,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definition and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are three clinical criteria for the diagnosis of anaphylaxis, which reflect the different ways in which anaphylaxis may present (",
"      <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"       table 1",
"      </a>",
"      ). Anaphylaxis is highly likely when any",
"      <strong>",
"       ONE",
"      </strong>",
"      of the three criteria is fulfilled. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Diagnostic criteria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Recognition is not always easy, because anaphylaxis can mimic many other disorders and can be variable in its presentation. Anaphylaxis may present with various combinations of as many as 40 potential symptoms and signs (",
"      <a class=\"graphic graphic_table graphicRef66333 \" href=\"mobipreview.htm?20/36/21068\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients and healthcare professionals commonly fail to recognize and diagnose anaphylaxis in its early stages, when it is most responsive to treatment. In particular, there is a reluctance to diagnose anaphylaxis in the absence of hypotension, even though this sign is not required for the diagnosis and occurs late or not at all in a food-induced anaphylactic episode. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Pitfalls in making the diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis most often results from an IgE-mediated allergic reaction. Common triggers include foods, insect stings, and medications. There is a rapidly expanding list of novel",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      unusual triggers (",
"      <a class=\"graphic graphic_table graphicRef70667 \" href=\"mobipreview.htm?29/0/29708\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Triggers and mechanisms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of anaphylaxis may or may not be confirmed by measurement of elevated concentrations of plasma histamine or serum or plasma total tryptase. Elevations in these mediators are transient (",
"      <a class=\"graphic graphic_table graphicRef72041 \" href=\"mobipreview.htm?21/8/21644\">",
"       table 6",
"      </a>",
"      ). Serum tryptase is seldom elevated in food-triggered anaphylaxis or in normotensive patients with anaphylaxis. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Laboratory tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt recognition and treatment are critical in anaphylaxis. In fatal anaphylaxis, median times to cardiorespiratory arrest are 5 minutes in iatrogenic anaphylaxis, 15 minutes in stinging insect venom-induced anaphylaxis, and 30 minutes in food-induced anaphylaxis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Time course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial management is summarized in a rapid overview table for adults (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 8",
"      </a>",
"      ) and children (",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 9",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Immediate management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       Epinephrine",
"      </a>",
"      is lifesaving in anaphylaxis. It should be injected as early as possible in the episode in order to prevent progression of symptoms and signs. There are no absolute contraindications to its use, and it is the treatment of choice for anaphylaxis",
"      <strong>",
"       of any severity",
"      </strong>",
"      . We recommend epinephrine for patients with apparently mild symptoms and signs (eg, a few hives and mild wheezing) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ) and for patients with moderate to severe symptoms and signs (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The route of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      administration depends upon the presenting symptoms. For patients who are",
"      <strong>",
"       not",
"      </strong>",
"      profoundly hypotensive or in shock or cardiorespiratory arrest, intramuscular (IM) injection into the mid-anterolateral thigh as the initial route of administration is advised, in preference to subcutaneous administration:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For adults, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      is 0.3 mg to 0.5 mg, injected intramuscularly into the mid-anterolateral thigh. This",
"      <strong>",
"      </strong>",
"      treatment may be repeated at 5 to 15 minute intervals.",
"     </li>",
"     <li>",
"      For infants and children, the dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      is 0.01 mg per kilogram up to 0.5 mg per dose, injected intramuscularly into the mid-anterolateral thigh. This treatment may be repeated at 5 to 15 minute intervals.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      is indicated for patients with profound hypotension or symptoms and signs suggestive of impending shock (dizziness, incontinence of urine or stool) or those who do not respond to an initial intramuscular injection of epinephrine and fluid resuscitation. For these patients we suggest that epinephrine be administered by continuous slow intravenous infusion rather than by intermittent IV bolus (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Epinephrine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Massive fluid shifts can occur in anaphylaxis, and all patients with orthostasis, hypotension, or incomplete response to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      should receive large volume fluid resuscitation with normal saline. Normotensive patients should receive normal saline to maintain venous access in case their status deteriorates. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Intravenous fluids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supplemental oxygen should be administered.",
"     </li>",
"     <li>",
"      Patients successfully treated for anaphylaxis should be discharged with a personalized written anaphylaxis emergency action plan (",
"      <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"       form 1",
"      </a>",
"      ), an",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      autoinjector, written information about anaphylaxis and its treatment, and a plan for further evaluation. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Care upon resolution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H44\">",
"       'Information for patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is critical that patients be evaluated further to confirm the trigger, as specific avoidance measures are useful in reducing the risk of recurrence. Additionally, for some allergens, immunomodulation is also available to reduce the risk. (See",
"      <a class=\"local\" href=\"#H37\">",
"       'Care upon resolution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H43\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/1\">",
"      Lieberman P, Camargo CA Jr, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/2\">",
"      Decker WW, Campbell RL, Manivannan V, et al. The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol 2008; 122:1161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/3\">",
"      Lin RY, Anderson AS, Shah SN, Nurruzzaman F. Increasing anaphylaxis hospitalizations in the first 2 decades of life: New York State, 1990 -2006. Ann Allergy Asthma Immunol 2008; 101:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/4\">",
"      Poulos LM, Waters AM, Correll PK, et al. Trends in hospitalizations for anaphylaxis, angioedema, and urticaria in Australia, 1993-1994 to 2004-2005. J Allergy Clin Immunol 2007; 120:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/5\">",
"      Sheikh A, Hippisley-Cox J, Newton J, Fenty J. Trends in national incidence, lifetime prevalence and adrenaline prescribing for anaphylaxis in England. J R Soc Med 2008; 101:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/6\">",
"      Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol 2009; 123:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/7\">",
"      Ewan PW, Dugu&eacute; P, Mirakian R, et al. BSACI guidelines for the investigation of suspected anaphylaxis during general anaesthesia. Clin Exp Allergy 2010; 40:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/8\">",
"      Chacko T, Ledford D. Peri-anesthetic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/9\">",
"      Harboe T, Benson MD, Oi H, et al. Cardiopulmonary distress during obstetrical anaesthesia: attempts to diagnose amniotic fluid embolism in a case series of suspected allergic anaphylaxis. Acta Anaesthesiol Scand 2006; 50:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/10\">",
"      Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ. Haemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006; 61:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/11\">",
"      Oswalt ML, Kemp SF. Anaphylaxis: office management and prevention. Immunol Allergy Clin North Am 2007; 27:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/12\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/13\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Bock SA, et al. Symposium on the definition and management of anaphylaxis: summary report. J Allergy Clin Immunol 2005; 115:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/14\">",
"      Pumphrey RS. Lessons for management of anaphylaxis from a study of fatal reactions. Clin Exp Allergy 2000; 30:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/15\">",
"      Simons FE. Anaphylaxis. J Allergy Clin Immunol 2010; 125:S161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/16\">",
"      Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/17\">",
"      Simons FE. Anaphylaxis, killer allergy: long-term management in the community. J Allergy Clin Immunol 2006; 117:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/18\">",
"      Lieberman P, Nicklas RA, Oppenheimer J, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol 2010; 126:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/19\">",
"      Simons FE, Ardusso LR, Bil&ograve; MB, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol 2011; 127:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/20\">",
"      Soar J, Pumphrey R, Cant A, et al. Emergency treatment of anaphylactic reactions--guidelines for healthcare providers. Resuscitation 2008; 77:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/21\">",
"      Brown SG, Mullins RJ, Gold MS. Anaphylaxis: diagnosis and management. Med J Aust 2006; 185:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/22\">",
"      Muraro A, Roberts G, Clark A, et al. The management of anaphylaxis in childhood: position paper of the European academy of allergology and clinical immunology. Allergy 2007; 62:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/23\">",
"      Sampson HA, Mendelson L, Rosen JP. Fatal and near-fatal anaphylactic reactions to food in children and adolescents. N Engl J Med 1992; 327:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/24\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. J Allergy Clin Immunol 2001; 107:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/25\">",
"      Bock SA, Mu&ntilde;oz-Furlong A, Sampson HA. Further fatalities caused by anaphylactic reactions to food, 2001-2006. J Allergy Clin Immunol 2007; 119:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/26\">",
"      Pumphrey R. Anaphylaxis: can we tell who is at risk of a fatal reaction? Curr Opin Allergy Clin Immunol 2004; 4:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/27\">",
"      Pumphrey RS, Gowland MH. Further fatal allergic reactions to food in the United Kingdom, 1999-2006. J Allergy Clin Immunol 2007; 119:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/28\">",
"      Greenberger PA, Rotskoff BD, Lifschultz B. Fatal anaphylaxis: postmortem findings and associated comorbid diseases. Ann Allergy Asthma Immunol 2007; 98:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/29\">",
"      Shen Y, Li L, Grant J, et al. Anaphylactic deaths in Maryland (United States) and Shanghai (China): a review of forensic autopsy cases from 2004 to 2006. Forensic Sci Int 2009; 186:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/30\">",
"      Yilmaz R, Yuksekbas O, Erkol Z, et al. Postmortem findings after anaphylactic reactions to drugs in Turkey. Am J Forensic Med Pathol 2009; 30:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/31\">",
"      Tole JW, Lieberman P. Biphasic anaphylaxis: review of incidence, clinical predictors, and observation recommendations. Immunol Allergy Clin North Am 2007; 27:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/32\">",
"      Scranton SE, Gonzalez EG, Waibel KH. Incidence and characteristics of biphasic reactions after allergen immunotherapy. J Allergy Clin Immunol 2009; 123:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/33\">",
"      Simons FE. Anaphylaxis in infants: can recognition and management be improved? J Allergy Clin Immunol 2007; 120:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/34\">",
"      Chaudhuri K, Gonzales J, Jesurun CA, et al. Anaphylactic shock in pregnancy: a case study and review of the literature. Int J Obstet Anesth 2008; 17:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/35\">",
"      Simons FE, Frew AJ, Ansotegui IJ, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol 2007; 120:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/36\">",
"      Gonz&aacute;lez-P&eacute;rez A, Aponte Z, Vidaurre CF, Rodr&iacute;guez LA. Anaphylaxis epidemiology in patients with and patients without asthma: a United Kingdom database review. J Allergy Clin Immunol 2010; 125:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/37\">",
"      Iribarren C, Tolstykh IV, Miller MK, Eisner MD. Asthma and the prospective risk of anaphylactic shock and other allergy diagnoses in a large integrated health care delivery system. Ann Allergy Asthma Immunol 2010; 104:371.",
"     </a>",
"    </li>",
"    <li>",
"     Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Goodman and Gilman's the pharmacological basis of therapeutics, 11th ed, Brunton LL (Ed), McGraw-Hill, New York 2006. p.215.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/39\">",
"      Triggiani M, Patella V, Staiano RI, et al. Allergy and the cardiovascular system. Clin Exp Immunol 2008; 153 Suppl 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/40\">",
"      Watson A. Alpha adrenergic blockers and adrenaline. A mysterious collapse. Aust Fam Physician 1998; 27:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/41\">",
"      Ru&euml;ff F, Przybilla B, Bil&oacute; MB, et al. Predictors of severe systemic anaphylactic reactions in patients with Hymenoptera venom allergy: importance of baseline serum tryptase-a study of the European Academy of Allergology and Clinical Immunology Interest Group on Insect Venom Hypersensitivity. J Allergy Clin Immunol 2009; 124:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/42\">",
"      Mueller UR. Cardiovascular disease and anaphylaxis. Curr Opin Allergy Clin Immunol 2007; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/43\">",
"      Lin RY, Schwartz LB, Curry A, et al. Histamine and tryptase levels in patients with acute allergic reactions: An emergency department-based study. J Allergy Clin Immunol 2000; 106:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/44\">",
"      Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/45\">",
"      Komarow HD, Hu Z, Brittain E, et al. Serum tryptase levels in atopic and nonatopic children. J Allergy Clin Immunol 2009; 124:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/46\">",
"      Summers CW, Pumphrey RS, Woods CN, et al. Factors predicting anaphylaxis to peanuts and tree nuts in patients referred to a specialist center. J Allergy Clin Immunol 2008; 121:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/47\">",
"      Vadas P, Gold M, Perelman B, et al. Platelet-activating factor, PAF acetylhydrolase, and severe anaphylaxis. N Engl J Med 2008; 358:28.",
"     </a>",
"    </li>",
"    <li>",
"     Lieberman PL. Anaphylaxis. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF Jr, Bochner BS, Busse WW, et al (Eds), St. Louis 2009. p.1027.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/49\">",
"      Izikson L, English JC 3rd, Zirwas MJ. The flushing patient: differential diagnosis, workup, and treatment. J Am Acad Dermatol 2006; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/50\">",
"      Erem C, Kocak M, Onder Ersoz H, et al. Epinephrine-secreting cystic pheochromocytoma presenting with an incidental adrenal mass: a case report and a review of the literature. Endocrine 2005; 28:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/51\">",
"      Ueda T, Oka N, Matsumoto A, et al. Pheochromocytoma presenting as recurrent hypotension and syncope. Intern Med 2005; 44:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/52\">",
"      Becker K, Southwick K, Reardon J, et al. Histamine poisoning associated with eating tuna burgers. JAMA 2001; 285:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/53\">",
"      Daschner A, Alonso-G&oacute;mez A, Caba&ntilde;as R, et al. Gastroallergic anisakiasis: borderline between food allergy and parasitic disease-clinical and allergologic evaluation of 20 patients with confirmed acute parasitism by Anisakis simplex. J Allergy Clin Immunol 2000; 105:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/54\">",
"      Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008; 359:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/55\">",
"      Greenberger PA. Idiopathic anaphylaxis. Immunol Allergy Clin North Am 2007; 27:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/56\">",
"      Brown SG. Cardiovascular aspects of anaphylaxis: implications for treatment and diagnosis. Curr Opin Allergy Clin Immunol 2005; 5:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/57\">",
"      Brown SG, Blackman KE, Stenlake V, Heddle RJ. Insect sting anaphylaxis; prospective evaluation of treatment with intravenous adrenaline and volume resuscitation. Emerg Med J 2004; 21:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/58\">",
"      Simons FE. First-aid treatment of anaphylaxis to food: focus on epinephrine. J Allergy Clin Immunol 2004; 113:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/59\">",
"      Simons FE, Gu X, Simons KJ. Epinephrine absorption in adults: intramuscular versus subcutaneous injection. J Allergy Clin Immunol 2001; 108:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/60\">",
"      Simons FE, Roberts JR, Gu X, Simons KJ. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/61\">",
"      Pumphrey RS. Fatal posture in anaphylactic shock. J Allergy Clin Immunol 2003; 112:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/62\">",
"      Brown SG. The pathophysiology of shock in anaphylaxis. Immunol Allergy Clin North Am 2007; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/63\">",
"      Brown SG. Anaphylaxis: clinical concepts and research priorities. Emerg Med Australas 2006; 18:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/64\">",
"      Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol 2010; 10:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/65\">",
"      Sheikh A, Ten Broek V, Brown SG, Simons FE. H1-antihistamines for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2007; 62:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/66\">",
"      Sheikh A, Shehata YA, Brown SG, Simons FE. Adrenaline for the treatment of anaphylaxis: cochrane systematic review. Allergy 2009; 64:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/67\">",
"      Simons FE. Emergency treatment of anaphylaxis. BMJ 2008; 336:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/68\">",
"      McLean-Tooke AP, Bethune CA, Fay AC, Spickett GP. Adrenaline in the treatment of anaphylaxis: what is the evidence? BMJ 2003; 327:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/69\">",
"      Simons FE. Pharmacologic treatment of anaphylaxis: can the evidence base be strengthened? Curr Opin Allergy Clin Immunol 2010; 10:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/70\">",
"      Kemp SF, Lockey RF, Simons FE, World Allergy Organization ad hoc Committee on Epinephrine in Anaphylaxis. Epinephrine: the drug of choice for anaphylaxis. A statement of the World Allergy Organization. Allergy 2008; 63:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/71\">",
"      Kanwar M, Irvin CB, Frank JJ, et al. Confusion about epinephrine dosing leading to iatrogenic overdose: a life-threatening problem with a potential solution. Ann Emerg Med 2010; 55:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/72\">",
"      Hegenbarth MA, American Academy of Pediatrics Committee on Drugs. Preparing for pediatric emergencies: drugs to consider. Pediatrics 2008; 121:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/73\">",
"      Song TT, Nelson MR, Chang JH, et al. Adequacy of the epinephrine autoinjector needle length in delivering epinephrine to the intramuscular tissues. Ann Allergy Asthma Immunol 2005; 94:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/74\">",
"      Stecher D, Bulloch B, Sales J, et al. Epinephrine auto-injectors: is needle length adequate for delivery of epinephrine intramuscularly? Pediatrics 2009; 124:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/75\">",
"      Wheeler DW, Carter JJ, Murray LJ, et al. The effect of drug concentration expression on epinephrine dosing errors: a randomized trial. Ann Intern Med 2008; 148:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/76\">",
"      Anchor J, Settipane RA. Appropriate use of epinephrine in anaphylaxis. Am J Emerg Med 2004; 22:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/77\">",
"      Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/78\">",
"      Ridella M, Bagdure S, Nugent K, Cevik C. Kounis syndrome following beta-lactam antibiotic use: review of literature. Inflamm Allergy Drug Targets 2009; 8:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/79\">",
"      Biteker M, Duran NE, Biteker FS, et al. Allergic myocardial infarction in childhood: Kounis syndrome. Eur J Pediatr 2010; 169:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/80\">",
"      Thomas M, Crawford I. Best evidence topic report. Glucagon infusion in refractory anaphylactic shock in patients on beta-blockers. Emerg Med J 2005; 22:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/81\">",
"      Clark S, Bock SA, Gaeta TJ, et al. Multicenter study of emergency department visits for food allergies. J Allergy Clin Immunol 2004; 113:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/82\">",
"      Clark S, Long AA, Gaeta TJ, Camargo CA Jr. Multicenter study of emergency department visits for insect sting allergies. J Allergy Clin Immunol 2005; 116:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/83\">",
"      Gaeta TJ, Clark S, Pelletier AJ, Camargo CA. National study of US emergency department visits for acute allergic reactions, 1993 to 2004. Ann Allergy Asthma Immunol 2007; 98:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/84\">",
"      Banerji A, Long AA, Camargo CA Jr. Diphenhydramine versus nonsedating antihistamines for acute allergic reactions: a literature review. Allergy Asthma Proc 2007; 28:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/85\">",
"      Jones DH, Romero FA, Casale TB. Time-dependent inhibition of histamine-induced cutaneous responses by oral and intramuscular diphenhydramine and oral fexofenadine. Ann Allergy Asthma Immunol 2008; 100:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/86\">",
"      Simons FE. Advances in H1-antihistamines. N Engl J Med 2004; 351:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/87\">",
"      Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010; 65:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/88\">",
"      Dewachter P, Mouton-Faivre C, Emala CW. Anaphylaxis and anesthesia: controversies and new insights. Anesthesiology 2009; 111:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/89\">",
"      Simons FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol 2009; 124:301.",
"     </a>",
"    </li>",
"    <li>",
"     The American College of Allergy, Asthma and Immunology. www.acaai.org (Accessed on August 13, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/29/35290/abstract/91\">",
"      Simons FE, Edwards ES, Read EJ Jr, et al. Voluntarily reported unintentional injections from epinephrine auto-injectors. J Allergy Clin Immunol 2010; 125:419.",
"     </a>",
"    </li>",
"    <li>",
"     The American Academy of Allergy, Asthma and Immunology. www.aaaai.org (Accessed on August 13, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 392 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-CBA3D06F7A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35290=[""].join("\n");
var outline_f34_29_35290=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H45\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diagnostic criteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Criterion 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Criterion 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Criterion 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Time course",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Biphasic anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Pitfalls in making the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TRIGGERS AND MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTRIBUTORY FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Comorbidities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Concurrent medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LABORATORY TESTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      IMMEDIATE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Airway management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Intravenous fluids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PHARMACOLOGIC TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Epinephrine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Therapeutic actions and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Situations requiring caution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Glucagon for patients taking beta-blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Adjunctive agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - H1 antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - H2 antihistamines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Bronchodilators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Refractory anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      TREATMENT ERRORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      CARE UPON RESOLUTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Discharge care",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Anaphylaxis emergency action plan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Epinephrine autoinjector",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Counseling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/392\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/392|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/392|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 1\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/36/21068\" title=\"table 2\">",
"      Symptoms and signs of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?10/11/10427\" title=\"table 3\">",
"      Comorbidities and medications affecting recognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/0/29708\" title=\"table 4\">",
"      Anaphylaxis triggers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/39/36476\" title=\"table 5\">",
"      Comorbidities and medications affecting severity and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/8/21644\" title=\"table 6\">",
"      Tryptase and histamine collection instructions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/61/41948\" title=\"table 7\">",
"      Differential diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16813\" title=\"table 8\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 9\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/4/32844\" title=\"table 10\">",
"      Epinepherine actions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/17/7454\" title=\"table 11\">",
"      Example of epinephrine infusion - adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/18/2350\" title=\"table 12\">",
"      Example of epinephrine infusion - pediatric 10 kg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/39/40573\" title=\"table 13\">",
"      Example of epinephrine infusion - pediatric 20 kg",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7610?source=related_link\">",
"      Anaphylaxis in pregnant and breastfeeding women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/11/9401?source=related_link\">",
"      Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/24/19847?source=related_link\">",
"      Biphasic and protracted anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/62/38888?source=related_link\">",
"      Differential diagnosis of anaphylaxis in children and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/13/1241?source=related_link\">",
"      Fatal anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/59/41912?source=related_link\">",
"      Hypovolemic shock in children: Initial evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/44/5833?source=related_link\">",
"      Long-term management of patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/20/6470?source=related_link\">",
"      Maintenance fluid therapy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18778?source=related_link\">",
"      Pathophysiology of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/30/33250?source=related_link\">",
"      Patient information: Anaphylaxis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/57/15250?source=related_link\">",
"      Patient information: Anaphylaxis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?40/14/41186?source=related_link\">",
"      Patient information: Anaphylaxis treatment and prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42809?source=related_link\">",
"      Perioperative anaphylaxis: Clinical manifestations, etiology, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/6/10346?source=related_link\">",
"      Systemic inflammatory response syndrome (SIRS) and sepsis in children: Definitions, epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33625?source=related_link\">",
"      Unique aspects of anaphylaxis in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/35/40505?source=related_link\">",
"      Use of vasopressors and inotropes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_29_35291="ANCA accuracy in GN in adults";
var content_f34_29_35291=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ANCA results for pauci-immune crescentic glomerulonephritis in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical presentation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of PI-CGN",
"       </td>",
"       <td class=\"subtitle1\">",
"        PPV for PI-CGN",
"       </td>",
"       <td class=\"subtitle1\">",
"        NPV for PI-CGN",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rapidly progressive glomerulonephritis*",
"       </td>",
"       <td>",
"        47 percent (106/224)",
"       </td>",
"       <td>",
"        98 percent",
"       </td>",
"       <td>",
"        80 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine &gt;3 mg/dL",
"       </td>",
"       <td>",
"        21 percent (181/862)",
"       </td>",
"       <td>",
"        92 percent",
"       </td>",
"       <td>",
"        93 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine 1.5-3 mg/dL",
"       </td>",
"       <td>",
"        7 percent (51/685)",
"       </td>",
"       <td>",
"        77 percent",
"       </td>",
"       <td>",
"        98 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematuria, proteinuria, and creatinine &lt;1.5 mg/dL",
"       </td>",
"       <td>",
"        2 percent (13/768)",
"       </td>",
"       <td>",
"        47 percent",
"       </td>",
"       <td>",
"        99 percent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated positive predictive values (PPV) and negative predictive values (NPV) of ANCA results for pauci-immune crescentic glomerulonephritis (PI-CGN) in adults (&gt;18 years old) with different clinical presentations using an assay approach (that has a 72.5 percent sensitivity and a 98.4 percent specificity).",
"    <div class=\"footnotes\">",
"     * This clinical presentation presumed from renal biopsy showing &gt;50 percent of glomeruli with crescents.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Jennette, JC, Wilkman, AS, Falk, RJ, Kidney Int 1998; 53:796.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35291=[""].join("\n");
var outline_f34_29_35291=null;
var title_f34_29_35292="Causes of congenital hypothyroidism";
var content_f34_29_35292=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major causes of congenital hypothyroidism, approximate incidence, and serum thyroid function test results",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Cause",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum free T4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum T4",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serum TSH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Primary hypothyroidism",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        1:2000 to 1:4000",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other_start\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Thyroid dysgenesis: ectopia, aplasia, or hypoplasia",
"       </td>",
"       <td class=\"sublist_other\">",
"        85 percent of cases",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Inborn errors of thyroxine synthesis (dyshormonogenesis)",
"       </td>",
"       <td class=\"sublist_other\">",
"        15 percent of cases",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central hypothyroidism",
"       </td>",
"       <td>",
"        1:25,000-1:100,000",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        Normal or &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"5\">",
"        Transient hypothyroidism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Europe - iodine deficiency",
"       </td>",
"       <td class=\"sublist_other\">",
"        1:100",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr; then normalizes",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr; then normalizes",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr; then normalizes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - North America - iodide excess and other causes",
"       </td>",
"       <td class=\"sublist_other\">",
"        1:50,000",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr; then normalizes",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr; then normalizes",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr; then normalizes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Maternal antibody-mediated hypothyroidism",
"       </td>",
"       <td class=\"sublist_other\">",
"        1:25,000-1:100,000",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &darr;",
"       </td>",
"       <td class=\"sublist_other\">",
"        &uarr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroxine-binding globulin deficiency (causes low serum T4 concentrations but not hypothyroidism)",
"       </td>",
"       <td>",
"        1:4300",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35292=[""].join("\n");
var outline_f34_29_35292=null;
var title_f34_29_35293="Contents: Mast cell disorders";
var content_f34_29_35293=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?43/1/44061\">",
"       Allergy and Immunology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Mast cell disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Mast cell disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?6/1/6170\">",
"           Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/13/18650\">",
"           Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/28/20937\">",
"           Mast cell activation disorders",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?34/6/34921\">",
"           Mast cell derived mediators",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?43/22/44393\">",
"           Mast cells: Development, identification, and physiologic roles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?20/28/20936\">",
"           Mast cells: Surface receptors and signal transduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/50/41767\">",
"           Treatment and prognosis of cutaneous mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?38/56/39817\">",
"           Treatment and prognosis of systemic mastocytosis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-3A607ACD9E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f34_29_35293=[""].join("\n");
var outline_f34_29_35293=null;
var title_f34_29_35294="Teen births US";
var content_f34_29_35294=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Birth rates for teenagers by race and Hispanic origin: United States, 1991, 2005, 2007, and 2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 284px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AI/AN: American Indian or Alaska Native; API: Asian or Pacific Islander",
"     <br>",
"      * Non-Hispanic.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Martin JA, Hamilton BE, Ventura SJ, et al. Births: Final data for 2009. Nat Vital Stat Rep 2011; 60:1.",
"     <a href=\"file://www.cdc.gov/nchs/births.htm\" target=\"_blank\">",
"      www.cdc.gov/nchs/births.htm",
"     </a>",
"     (Accessed on January 09, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35294=[""].join("\n");
var outline_f34_29_35294=null;
var title_f34_29_35295="Radio-opaque marking thoracotomy tube";
var content_f34_29_35295=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F79934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F79934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radio-opaque marking on thoracoatomy tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radio-opaque marker is seen in blue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Friedberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_29_35295=[""].join("\n");
var outline_f34_29_35295=null;
